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Statins are a class of drug that inhibits cholesterol biosynthesis, and are used to treat 
patients with high serum cholesterol levels. They exert this function by 
competitively binding to the enzyme 3-hydroxy-3-methylglutaryl-CoenzymeA 
reductase (HMGR), which catalyses the formation of mevalonate, a rate-limiting step 
in cholesterol biosynthesis. In addition, statins have what are called “pleiotropic 
effects”, which include the reduction of inflammation, immunomodulation, and anti-
microbial effects. Statins can also improve survival of patients with sepsis and 
pneumonia. Cystic fibrosis (CF) is the most common recessive inherited disease in 
the Caucasian population, which is characterised by factors including, but not limited 
to, excessive lung inflammation and increased susceptibility to infection. Therefore, 
the overall objective of this study was to examine the effects of statins on CF-
associated bacterial pathogens and the host response. 
In this work, the prevalence of HMGR was examined in respiratory pathogens, and 
several CF-associated pathogens were found to possess homologues of this enzyme. 
HMGR homology was analysed in Staphylococcus aureus, Burkholderia 
cenocepacia and Streptococcus pneumoniae, and the HMGR of B. cenocepacia was 
found to have significant conservation to that of Pseudomonas mevalonii, which is 
the most widely-characterised bacterial HMGR. However, in silico analysis revealed 
that, unlike S. aureus and S. pneumoniae, B. cenocepacia did not possess 
homologues of other mevalonate pathway proteins, and that the HMGR of B. 
cenocepacia appeared to be involved in an alternative metabolic pathway. The effect 
of simvastatin was subsequently tested on the growth and virulence of S. aureus, B. 
cenocepacia and S. pneumoniae. Simvastatin inhibited the growth of all 3 species in 
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a dose-dependent manner. In addition, statin treatment also attenuated biofilm 
formation of all 3 species, and reduced in vitro motility of S. aureus. Interestingly, 
simvastatin also increased the potency of the aminoglycoside antibiotic gentamicin 
against B. cenocepacia. 
The impact of statins was subsequently tested on the predominant CF-associated 
pathogen Pseudomonas aeruginosa, which does not possess a HMGR homologue. 
Mevastatin, lovastatin and simvastatin did not influence the growth of this species. 
However, sub-inhibitory statin concentrations reduced the swarming motility and 
biofilm formation of P. aeruginosa.  The influence of statins was also examined on 
Type 3 toxin secretion, quorum sensing and chemotaxis, and no statin effect was 
observed on any of these phenotypes. Statins did not appear to have a characteristic 
effect on the P. aeruginosa transcriptome. However, a mutant library screen revealed 
that the effect of statins on P. aeruginosa biofilm was mediated through the PvrR 
regulator and the Cup fimbrial biosynthesis genes. Furthermore, proteomic analysis 
demonstrated that 6 proteins were reproducibly induced by simvastatin in the P. 
aeruginosa swarming cells. 
The effect of statins on the regulation of the host-P. aeruginosa immune response 
was also investigated. Statin treatment increased expression of the pro-inflammatory 
cytokines IL-8 and CCL20 in lung epithelial cells, but did not attenuate P. 
aeruginosa-mediated inflammatory gene induction. In fact, simvastatin and P. 
aeruginosa caused a synergistic effect on CCL20 expression. The expression of the 
transcriptional regulators KLF2 and KLF6 was also increased by statins and P. 
aeruginosa, with the induction of KLF6 by simvastatin proving to be a novel effect. 
Interestingly, both statins and P. aeruginosa were capable of inducing alternative 
splicing of KLF6. P. aeruginosa was found to induce KLF6 alternative splicing by 
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way of the type 3 secreted toxin ExoS. In addition, a mechanistic role was elucidated 
for KLF6 in the lung, as it was determined that statin-mediated induction of this 
protein was responsible for the induction of the host response genes CCL20 and 
iNOS. Moreover, statin treatment caused a slight increase in infection-related 
cytotoxicity, and increased bacterial adhesion to cells.  
Taken together, these data demonstrate that statins can reduce the virulence of CF-
associated bacterial pathogens and alter host response effectors. Furthermore, novel 











One of the major undisputed clinical breakthroughs of the 20
th
 century is the 
discovery of the statin family of drugs. These compounds are renowned for their 
ability to lower cholesterol levels, and are used to treat approximately 40 million 
individuals with high cholesterol worldwide. Since the discovery of mevastatin as a 
metabolic product of Penicillium citrinum in 1976 (1, 2) a total of 9 statins have been 
characterised (Figure 1), 7 of which are approved by the FDA to treat patients with 
high cholesterol. Most of these are synthetic, although lovastatin occurs naturally as 
a metabolic product of Aspergillus terreus (3). Structurally, statins are characterised 
by the presence of a conserved lactone ring (4). This structure is present in a 
hydrolysed (active) form in all statins except for mevastatin, lovastatin and 
simvastatin, where the lactone ring is hydrolysed in the liver (5).  
Statins can be divided into 2 broad classes (Figure 1). Type 1 statins are lipophilic, 
and possess a butaryl side chain – they are said to structurally resemble mevastatin 
(4). Lovastatin, pravastatin and simvastatin are type 1 statins. Type 2 statins are 
classically lipophobic, and are distinguished from type 1 by the replacement of the 
butaryl side chain with a fluorophenol group and typically larger side chains than 
type 1 statins (4). Atorvastatin, cerivastatin, fluvastatin, pitavastatin and rosuvastatin 





Figure 1: Chemical structures of the statins. Type 1 statins are characterised by a 
conserved lactone ring (highlighted in blue), a decalin structure (not highlighted) and a 
butaryl side chain (highlighted in red), which is different in each statin. The type 2 statins 
differ from type 1 statins due to the replacement of the butaryl side chain with a flurophenyl 
group (highlighted in orange), and although the lactone ring structure is conserved in all 
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statins, the decalin group of Type 1 statins is replaced by a longer distinct side chain. Statins 
marked with an asterisk (*) are licenced to treat high cholesterol. Adapted from Rozman & 




1.2. Isoprenoid metabolism 
1.2.1. Statins and the mevalonate pathway 
Statins exert their cholesterol inhibitory effect by binding to the active site of 3-
hydroxy-3-methylglutaryl-CoenzymeA reductase (HMGR), which is a rate-limiting 
enzyme in cholesterol biosynthesis (4). The reaction that statins inhibit is as follows: 
HMG-CoA + 2 NADP(H) + 2 H+ = Mevalonate + CoASH + 2 NAD(P)+ 
HMGR is an integral part of the mevalonate pathway of isoprenoid biosynthesis. 
Isoprenoids are lipid compounds, which are essential for cell signalling and 
structure. Mevalonate dependent-isoprenoid biosynthesis is detailed in Figure 2A. In 
humans, 3-hydroxy-3-methylglutaryl-CoenzymeA (HMG-CoA) is synthesised from 
acetoacetate and acetyl-coA by the enzyme HMG-CoA synthase. HMG-CoA is then 
converted to mevalonate by HMGR, and it is this event that is inhibited by statins 
(Figure 2B). Mevalonate undergoes 2 phosphorylation events – firstly by mevalonate 
kinase, producing mevalonate-5-phosphate, and secondly by mevalonate 
phosphokinase, resulting in the production of mevalonate-pyrophosphate. 
Mevalonate-pyrophosphate is then converted to the isoprenoid intermediate 
compound isopentenyl-pyrophosphate (IPP) by mevalonate-pyrophosphate 
decarboxylase, thus commencing isoprenoid metabolism. IPP is converted to 
dimethylallyl pyrophosphate (DMAPP) by IPP-isomerase. Farnesyl-pyrophosphate 
(FPP)-synthase converts DMAPP to FPP, which is subsequently used by 
geranylgeranyl-pyrophosphate (GGPP)-synthase to produce GGPP.  
FPP and GGPP are key intermediate compounds for 2 reasons. Firstly, they are used 
by the enzyme squalene synthase to produce the sterol squalene, which is one of the 
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compounds used to synthesize cholesterol. Secondly, FPP and GGPP are also 
responsible for the prenylation and activation of the Rho GTPase family of proteins 
(7) and when mevalonate synthesis is inhibited, the corresponding decrease in FPP 
and GGPP leads to a decrease in Rho GTPase activity. Rho GTPases control a 
number of cellular functions, including maintenance of the actin cytoskeleton, 
apoptosis and gene expression. They do this by acting as a “molecular switch”, as 
they cycle between GDP-bound (inactive) and GTP-bound (active) states (8). 
Furthermore, as well as inhibiting cholesterol biosynthesis by reducing mevalonate 
production, statin treatment also increases levels of the low density lipoprotein 




Figure 2: Statins and the mevalonate pathway. (A) In hepatocytes, HMGR binds its 
substrate HMG-CoA and converts it to mevalonate. This leads to the production of 
cholesterol via several intermediate compounds, including FPP and GGPP, which are 
involved in the prenylation and activation of Rho GTPases. (B) Where statins are present, 
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they competitively bind the active site of HMGR, thus inhibiting the production of 




1.2.2. Isoprenoid production in bacteria – the mevalonate-independent pathway 
Several bacterial species undergo HMGR-dependent isoprenoid metabolism. The 
first bacterial HMGR to be characterised was that of the industrial strain 
Pseudomonas mevalonii in 1989 (9). The HMGR of P. mevalonii only possesses 2 
regions of significant similarity to mammalian HMGR (9), but it has since been 
found to have 3 domains that are essential for its catalytic capacity (10). It has since 
been discovered that statins and statin analogues can bind to and inhibit the function 
of P. mevalonii HMGR (11), thus making it the archetypal form of this enzyme for 
studies carried out in other bacterial species. 
Several other bacterial species are now known to possess functional HMGR 
analogues, including staphylococci, streptococci, enterococci and Listeria 
monocytogenes (12–15). However, many bacteria do not possess a mevalonate 
pathway. Instead, these organisms undergo isoprenoid biosynthesis by the 2-C-
methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate (MEP/DOXP) or 
mevalonate-independent pathway (16) (outlined in Figure 3). This pathway shares 
common isoprenoid end products – DMAPP and IPP – with the mevalonate 
pathway, but different metabolites are used in the course of their synthesis. 1-Deoxy-
D-xylulose 5-phosphate synthase (DOXP synthase) produces DOXP from pyruvate 
and glyceraldehyde-3-phosphate. DOXP reductase then converts DOXP to 2-C-
methylerythritol 4-phosphate (MEP), which is then converted to 4-diphosphocytidyl-
2-C-methylerythritol (CDP-ME) by CDP-ME synthase. CDP-ME is subsequently 
phosphorylated by CDP-ME kinase to form methylerythritol cyclodiphosphate 
(MEcPP), which is subsequently deoxygenated by (E)-4-Hydroxy-3-methyl-but-2-
enyl pyrophosphate synthase (HMB-PP synthase). The resultant compound, HMB-
10 
 
PP, compound is reduced to the isoprenoid intermediate compounds DMAPP and 





Figure 3: The MEP/DOXP pathway of isoprenoid biosynthesis. DOXP is reduced to 
MEP. CDP-MEP is synthesised from MEP, and 2 phosphorylation events lead to the 
formation of MEcPP and HMB-PP. This compound is then reduced to the isoprenoid 




1.3. Pleiotropic effects of statins 
As well as the inhibition of cholesterol, statins have also been found to have a 
number of cholesterol-independent, so-called “pleiotropic” effects. These include 
anti-inflammatory effects and immunomodulatory effects on host cell gene 
expression, but a growing number of studies are demonstrating that statins can also 
influence growth and behaviour of bacterial pathogens, independent of the host 
response. 
 
1.3.1. Anti-microbial effects of statins 
Statins have been found to directly inhibit the growth of both Gram positive and 
Gram negative bacterial species which cause a wide range of infections. The growth 
of the Gram positive nosocomial pathogens Staphylococcus aureus and 
Streptococcus pneumoniae has been inhibited by atorvastatin, rosuvastatin and 
simvastatin (17–20), with 1 study observing a bactericidal effect of simvastatin on S. 
pneumoniae (18). The growth of S. aureus is also inhibited by fluvastatin (17). Both 
type 1 (simvastatin) and type 2 (atorvastatin, fluvastatin and rosuvastatin) statins 
have also demonstrated a bacteriostatic effect against other Gram positive cocci, 
notably Streptococcus pyogenes, Staphylococcus epidermidis and enterococci (17, 
19, 20).  
Both type 1 and type 2 statins have also been found to reduce the growth of several 
clinically important species Gram negative species.  The growth of the nosocomial 
respiratory pathogens Pseudomonas aeruginosa, Acinetobacter baumanii and 
Klebsiella pneumoniae is reduced by atorvastatin, rosuvastatin and simvastatin (19, 
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20), while simvastatin is bacteriocidal against Moraxella catarrhalis, another 
causative agent of pulmonary infections (18). It was recently reported that 
atorvastatin, rosuvastatin and simvastatin have bacteriostatic effects against 
organisms that cause a range of infections, including Citrobacter freundii, 
Escherichia coli, Enterobacter aerogenes, Haemophilus influenzae and Proteus 
mirabilis (19), although another study found similar simvastatin concentrations to be 
ineffective against H. influenzae (18), suggesting that strain-specificity may be an 
issue. Furthermore, simvastatin and lovastatin are bactericidal against the spirochete 
Borrelia burgdorferi (the causative agent of Lyme disease) (21).  
The minimum inhibitory concentration (MIC) required to inhibit bacterial growth 
varies based on the type of statin used. Taken together, current data suggests that 
simvastatin and atorvastatin generally appear to be more effective against S. aureus, 
S. pneumoniae and enterococci than other statins (17–20). The particular bacterial 
strain employed also seems to be significant. For instance, 3 distinct simvastatin 
MICs were reported against S. aureus clinical isolates from the U. K. and Jordan as 
well as typed reference strains (17, 19). One common factor is that all efficacious 
statin concentrations are much higher than the typical levels observed in plasma – for 
instance, the maximum plasma concentrations for simvastatin (10-20 µg/L) and 
lovastatin (20-34 µg/L) (22) are much lower than the in vitro MIC values observed 
to date.  
Promisingly, statins can inhibit the growth of antibiotic-resistant species such as 
methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) 
(17, 19, 20). Given this information, it has been hypothesised that non- or sub-
inhibitory doses of statins could be used in combination with antibiotics to increase 
efficacy of treatment. Current information in this area is conflicting. A synergistic 
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effect has been reported between penicillin and simvastatin against pneumococcal 
growth (18) and statins have also been found to increase the potency of anti-malarial 
agents (23). However, a recent study, which examined the effects of several 
combination of 6 antibiotics and 5 statins on 4 clinically important Gram negative 
strains – P. aeruginosa, A. baumanii, E. coli and K. pneumoniae – found that statins 
neither increase nor decrease the susceptibilty of any of these bacteria to any of the 
antibiotics tested (24).  
  
1.3.2. Effect of statins on in vitro and in vivo infection models 
Several studies have reported the attenuation of both in vitro and in vivo bacterial 
virulence by statin treatment. An in-depth in vitro study carried out using S. 
pneumoniae demonstrated that sub-inhibitory concentrations of simvastatin and 
lovastatin do not influence secretion of the pneumolysin toxin (25). However, the 
same study analysed the effect of simvastatin on gene expression of S. pneumoniae, 
and found that 24 genes were significantly up-regulated, while 6 genes were 
significantly decreased. Altered genes mostly fell into the ABC transporter category 
and did not have clear roles in infection and host interaction. 
Statins can reduce the growth and essential internalisation of obligate intercellular 
bacterial pathogens. Simvastatin and cerivastatin decrease the levels of the 
intracellular respiratory bacterium Chlamydiae pneumoniae in mouse lung cells and 
macrophages respectively (26, 27). Furthermore, lovastatin reduces both the 
intracellular growth of the respiratory pathogen Coxiella burnetti (which causes Q 
fever) (28), and plaque formation by the causative agent of Rocky mountain spotted 
fever, Rickettsia conorii (29). The influence of statins on intracellular growth and 
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internalisation is not limited to obligate intracellular organisms. A recent study 
involving macrophages demonstrated that simvastatin treatment reduces the ability 
of the foodborne pathogen Listeria monocytogenes to grow inside mouse and 
primary macrophages, without influencing phagocytosis (30). The intracellular 
growth of another foodborne bacteria, Salmonella Typhimurium, is reduced by 
lovastatin treatment of murine macrophages, leading to improved infection outcome 
(31). Furthermore, mevastatin completely inhibits the internalisation of Group B 
streptococcus into HeLa cells (32), and attenuates the invasion of E. coli into bladder 
epithelial cells (33). Finally, simvastatin can reduce invasion of S. aureus into 
vascular epithelial cells (34) and also reduces the translocation of P. aeruginosa 
across the kidney apical epithelial barrier, although it does not influence its invasive 
potential (35).  
One key mechanism behind the attenuation of bacterial internalisation appears to be 
the statin-mediated inhibition of lipid raft formation. Lipid rafts are glycoprotein 
domains present in the cell membrane, which are formed as a result of cholesterol 
spontaneously interacting with sphingoglycolipids. Bacteria can manipulate lipid 
rafts in order to invade cells and induce apoptosis (36). However, statins are known 
to inhibit the formation of lipid rafts due to inhibition of cholesterol biosynthesis 
(37). It appears that that the effects of statins on L. monocytogenes and R. conorii 
may be resultant of the inhibition of lipid raft formation by statins (29, 30). 
Statin treatment also appears to increase bacterial killing in host cells. Simvastatin 
has been found to significantly increase killing of S. aureus in a mouse model of 
pneumonia (38), and reduce S. aureus recovery from mouse peritoneal and lung cell 
(39). Mevastatin significantly reduces the amount of S. aureus recovered from 
intracellular infection of human neutrophils and mouse macrophages (39), and also 
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reduces the CFU counts of S. pneumoniae and S. Typhimurium recovered from 
mouse macrophages (31, 40).  
As well as inhibiting bacteria, statins also have protective effects on cells during 
infection. Firstly, statins can reduce the impact of bacterial toxins on host cells. In a 
study which utilised S. aureus α-toxin, leukocyte recruitment in mice was attenuated 
by simvastatin treatment (41). Lovastatin can improve the survival of mice which 
were exposed to another S. aureus toxin, enterotoxin B (42). Simvastatin attenuates 
the cytotoxicity exerted by S. pneumoniae pneumolysin in both human endothelial 
cells and in mouse lungs, leading to improved survival (25). Furthermore, the 
cytotoxicity of Bacillus anthracis lethal toxin against macrophages is reduced by 
fluvastatin, mevastatin, and simvastatin (43). The regulation of the inflammatory 
response by statins can also have protective effects. Statin treatment reduces the 
expression of inflammatory mediators in macrophages infected with C. pneumoniae, 
leading to decreased infective potential (44). The inflammatory response in LPS-
treated mice is also reduced by cerivastatin treatment, leading to improved survival 
(45). Furthermore, simvastatin treatment can reduce both lung injury and the 
production of pro-inflammatory chemokines in a mouse sepsis model (46). 
      
1.3.3. Effects of statins on the inflammatory and innate immune responses 
When a healthy human host encounters infection by a microbial pathogen, the 
inflammatory and innate immune responses are activated in order to eradicate the 
threat. Host cells can perceive the presence of bacterial and viral pathogens by the 
Toll-like receptor (TLR) family of sensor proteins. Each member of this family 
recognises a specific ligand termed a “pathogen-associated molecular pattern” 
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(PAMP) such as lipopolysaccharide (LPS) (TLR4) (47) and flagellin (TLR5) (48). 
The binding of a particular PAMP to its respective TLR causes the activation of the 
MyD88 signalling cascade, resulting in the activation of the master regulator of 
inflammation (and indeed numerous other processes), NFκB (49). Activated NFκB is 
composed of 5 protein subunits – p50, p52, p65 (relA), relB, and relC – and this 
complex translocates to the nucleus, where it activates the transcription of pro-
inflammatory cytokines and chemokines (49, 50). This mechanism is described in 





Figure 4: TLR-mediated pro-inflammatory signalling in response to bacterial 
infections.  TLR4 and TLR5 recognise and bind to LPS and flagellin, respectively. MyD88 
interacts with the intercellular component of TLRs and recruits the IL-1 receptor (IL-1R)-
associated kinase family members IRAK1/2 and IRAK4. IRAK1/2 phosphorylates TNF 
receptor associated factor 6 (TRAF6), which ubiquinates TAB2/3, allowing transforming 
growth factor-activated protein kinase 1 (TAK1) to ubiquinate NFκB essential modifier 
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(NEMO). This activates IKKα and IKKβ, which phosphorylate IκK, causing it to be 
ubiquinated and degraded. This results in the formation of NFκB from its 5 subunits. NFκB 
translocates to the nucleus where it activates the expression of pro-inflammatory modulators. 
Statins have been found to inhibit MyD88-dependent signalling, NFκB complex assembly 





Statins can attenuate the activation of the innate immune and inflammatory 
responses in a number of tissue types. They exert these properties by inducing anti-
inflammatory regulators and effectors, and by repressing pro-inflammatory 
signalling and the production of cytokines. Statins can induce expression of the anti-
inflammatory enzymes endothelial nitric oxide synthase (eNOS) (51) and 
thrombomodulin (52), leading to a reduction in vascular inflammation and 
coagulation-mediated inflammation. Additionally, statins can activate expression of 
anti-inflammatory transcriptional regulators such as Kruppel-like Factor 2 (KLF2) 
(53–55), conferring a general anti-inflammatory state on the cell. The effects of 
KLF2 are discussed in more detail in 4.2.1. Another anti-inflammatory transcription 
factor, peroxisome proliferator-activated receptor γ (PPARγ) was also found to be 
activated by statin treatment of monocytes (56).  
Statins may also act as inhibitors of pro-inflammatory mediators, and have several 
mechanisms by which they reduce these targets. Firstly, statins act by inhibiting the 
expression of the pro-inflammatory transcriptional regulator NFκB (57–59). They do 
this by inhibiting mevalonate-dependent protein prenylation, which in turn reduces 
activation of NFκB by the pro-inflammatory cytokine tumour necrosis factor-α 
(TNFα) and the hormone angiotensin II in lymphocytes and vascular and mesangial 
cells (58–60). Statins also impact NFκB by inhibiting the translocation of its p65 
subunit from the cytoplasm to the nucleus (61). In addition, the induction of the anti-
inflammatory regulator PPARγ by statins reduces TNFα production, which in turn 
attenuates NFκB activity (56). 
Statins inhibit the production of the pro-inflammatory cytokine Interleukin-8 (IL-8) 
by stimulated ex vivo blood cells (62), endothelial cells (63), granulocytes (64) and 
rat and rabbit airway cells (65, 66). The reduction of IL-8 by statins attenuates 
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neutrophil infiltration into stimulated lung cells (66) and chemotactic migration by 
granulocytes (64). The statin-mediated reduction of IL-8 production by primary 
bronchial epithelial cells is channelled through inhibition of IL-17, another pro-
inflammatory cytokine (67). Statins can also regulate the activation of macrophages. 
The differentiation of LPS-stimulated monocytes into macrophages is inhibited by 
mevastatin (68), whereas lovastatin reduces migration and phagocytic activity of 
differentiated rabbit alveolar macrophages (65). These effects can be associated with 
the impact of statins on pro-inflammatory cytokines. For instance, statins inhibit the 
production of Chemokine (C-C motif) ligand 20 (CCL20) by keratinocytes (69) and 
endothelial cells (70), and also reduce the migration of T cells towards CCL20 (69). 
Like IL-8, the effect of statins on CCL20 is mediated through the inhibition of IL-17 
(70), and inhibition of TNFα by statins also causes a reduction in CCL20 production 
by fibroblasts (71). As well as inhibiting pro-inflammatory cytokine production, 
statins can also inhibit both the chemotactic migration of leukocytes towards IL-8 
(72) and the release of free radicals (the so-called “respiratory burst”) from 
leukocytes (64, 73). Furthermore, statins also inhibit neutrophil recruitment and 
migration in the lung (46). 
  
1.3.4. Improvement of patient morbidity and mortality by statins 
Increasing interest has been shown in using the pleiotropic effects of statins in order 
to combat multi-system microbial infections, such as sepsis and pneumonia. Sepsis is 
an infection-induced whole body inflammatory state, and as statins act in an anti-
inflammatory manner, it has been proposed that statins could be used to both prevent 
and treat sepsis (74). An early study in this field noted that individuals who had 
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undergone statin therapy prior to the onset of bacterial infection have a reduced risk 
of developing severe sepsis (75). Furthermore, a clinical review found evidence to 
suggest that not only do statins reduce morbidity and mortality associated with 
sepsis, but they also have the potential to be used as therapeutic agents for the 
management of sepsis (76). In accordance with the effects seen on sepsis, patients 
with bacteriaemia who have undergone prior statin treatment have a decreased risk 
of mortality (77). Another study of bacteriaemic patients also observed a decreased 
mortality rate in patients who had prior statin exposure, and also observed an inverse 
correlation between the length of statin treatment and risk of mortality (78).  
The use of statins has also been associated with a reduced risk of morbidity and 
mortality resulting from pneumonia. A retrospective study of patients in the U. K. 
found that prior statin treatment reduces pneumonia-associated mortality, and the 
risk of developing pneumonia (79). Prior statin treatment also reduced mortality rates 
in patients in the U. S. A. with community-acquired pneumonia (80). Furthermore, 
data from the Justification for the Use of Statin in Prevention: An Intervention Trial 
Evaluating Rosuvastatin (JUPITER) trial, which was initially undertaken to 
determine whether rosuvastatin could reduce the risk of cardiac disease in people 
without hyperlidemia (81) were retrospectively analysed in 2012. This analysis 
suggested that rosuvastatin treatment may decrease the occurrence of pneumonia 
(82).  
Some conflicting evidence has also been reported regarding statins and infections. A 
prospective cohort study which examined adults in 6 Canadian hospitals concluded 
that prior statin treatment does not yield reduced mortality from pneumonia, or a 
reduced risk of developing the condition (83). Additionally, retrospective analysis of 
the JUPITER trial data demonstrated that statin treatment has no impact on the risk 
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of developing sepsis (82). Therefore, while several studies have shown extremely 
promising potential for the use of statins to treat sepsis and pneumonia, further 





2.1. Respiratory Tract Infections 
Despite the discovery of anti-microbial compounds throughout much of the last 
century, respiratory tract infections (RTIs) caused by bacteria, fungi and viruses are 
still a significant cause of morbidity and mortality in the modern world. According 
to the most recent World Health Organisation (WHO) estimates, over 3.5 million 
people died as a result of RTIs in 2008 alone, meaning that RTIs accounted for 6.2 % 
of all deaths worldwide (84). Bacterial RTIs can be caused by many different 
microorganisms. In the developing world, the predominant causes of bacterial RTIs 
are organisms like Mycobacterium tuberculosis, Bordetella pertussis, and 
pneumonia caused by Haemophilus influenzae and Streptococcus pneumoniae. 
However, in regions where vaccinations are routinely carried out against such 
organisms – such as Europe and North America – the most common causes of 
bacterial RTIs are opportunistic and nosocomial species. This correlates with the 
increased prevalence of RTIs in young, elderly and immunocompromised individuals 
compared to other members of the general population in these regions. Bacterial 
pneumonia and chronic obstructive pulmonary disease (COPD) and their associated 
complications are a major cause of death in the developed world. However, a 
number of genetic conditions with dysfunctional respiratory tract components are 
exacerbated by bacterial RTIs. One example of this is the genetic condition cystic 
fibrosis. 
  
2.2. RTIs and Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder, which occurs due to 
a mutation in the gene that encodes the cystic fibrosis transmembrane conductance 
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regulator (CFTR). The term “cystic fibrosis” was devised by Dorothy Hansine 
Anderson in 1938, who described the symptoms of CF disease in the lungs, pancreas 
and gastrointestinal tract (85). The European incidence of CF is 1:2000-3000 and it 
is more common amongst Caucasians than any other ethnic group (86). Ireland has 
the highest rate of CF in the world – over 1200 individuals in Ireland have CF, 
giving it an incidence of 1:1353 (87). Furthermore, 1/19 individuals in Ireland are 
heterozygous carriers of the defective cftr gene, and this again is higher than the EU 
average of 1/25 (88). The risk of CF in Ireland is so severe in comparison to other 
regions that pre-natal screening was introduced in 2009.  
Five different classes of cftr mutations have been documented (reviewed in (89)), 
with a  frameshift mutation known as Δ508 being the most commonly-documented 
cftr mutation. This 3 base pair (bp) deletion is found in approximately 70 % of CF 
patients and is characterised by a missing phenylalanine residue at position 508 in 
the CFTR protein (90), causing it to be degraded by ubiquination (91). Another cftr 
mutation which is of particular interest in Ireland is the G551D mutation, in which 
the glycine residue at position 551 in CFTR is replaced by aspartic acid (92). G551D 
has become known as the Celtic mutation, due to Irish CF patients reportedly having 
the highest incidence of this mutation in the world (93).  
In individuals without CF, CFTR functions as a chloride ion channel which secretes 
Cl
- 
out of cells (Figure 5). This inhibits the neighbouring epithelial Na
+ 
channel 
(ENaC), of which the function is the absorption of Na
+ 
into cells. The inhibition of 
ENaC results in the presence of Na
+ 
in the airways, which causes water to leave 
epithelial cells by osmosis. This water plays a vital role as it keeps the respiratory 
mucus layer and epithelia apart, ensuring that beating of cilia occurs in order to 
effectively trap inhaled pathogens. In CF patients, the lack of functional CFTR leads 
26 
 
to deregulation of ENaC, causing excess Na
+
 to be absorbed by epithelial cells. This 
leads to increased amounts of water being drawn into the cells. In terms of CF lung 
disease, the lack of water in the airway results in adhesion of mucus to epithelial 
cells, and a higher concentration of mucus which prevents the beating of cilia, thus 
leading to increased risk of RTIs. However, CF patients also suffer from pancreatic 
and gastro-intestinal disease as a result of defective CFTR, leading to the 
development of conditions including gastro-oesophageal reflux, diabetes, and 






Figure 5: Mechanism of CFTR function in CF cells. The CFTR and ENaC channels are 
located adjacent to each other in the cell membrane. In CF, mutated CFTR does not export 
Cl- ions (green circles) out of the cell. The accumulation of Cl- in the cell causes the import 
of Na+ (yellow circles) via the ENaC channel. This leads to water entering the cell via 
osmosis, resulting in increased viscosity of pulmonary mucus, which is then colonised by 




2.3. Epidemiology of CF associated pathogens – the CF microbiome 
Bacteria and fungi are able to effectively colonise the CF lung due to the 
concentrated mucus of CF patients, which provides a nutrient-rich environment 
where the bacteria can grow and evade the host immune response. People with CF 
are now known to possess a distinct microbial community composed of opportunistic 
and nosocomial pathogens – termed the “CF microbiome” – within their lungs. 
Traditionally, the members of this community were identified from bronchoalveolar 
lavage fluid (BALF) using culture based methods (Figure 6A). However, more 
recently, 16S ribosomal DNA (rDNA) or rRNA sequencing has allowed for the 
identification of unculturable organisms within the CF lung (Figure 6B) (94). 
Children with CF are commonly colonised with Staphylococcus aureus, 
Pseudomonas aeruginosa and Haemophilus influenzae (95). However, S. aureus is 
the dominant species in the lungs of paediatric CF patients (96). Neonatal screening 
has detected S. aureus in up to 76 % of patients (97) and this species is found in over 
60 % of CF patients aged between 6 and 17 years old (96). Even though S. aureus is 
no longer dominant in adult CF patients, it remains a major component of the CF 
microbiome, infecting approximately 50 % of adults with CF (98). The maximum 
prevalence of H. influenzae is 32 % in CF patients aged between 2 and 5 years, after 
which its prevalence decreases to below 10 % of adult CF patients (96). The Gram 
positive species Streptococcus pneumoniae is also found in paediatric CF patients 
and is reportedly dominant in the lungs of infant CF patients (99). The official 
incidence of S. pneumoniae in CF patients is unknown, although it has been reported 
that approximately 5.5-6.9 % of people with CF are colonised with this organism 
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(100). In addition, over 61 % of CF patients were found to possess antibodies to S. 
pneumoniae (101).  
The Gram negative species Pseudomonas aeruginosa remains the predominant 
microorganism in the lungs of adult CF patients, chronically infecting approximately 
70-80 % of people with this disease (98). In addition, P. aeruginosa infection is 
correlated with the decline of lung function in CF patients (102). Colonisation with 
P. aeruginosa begins as a series of intermittent acute infections which eventually 
becomes a chronic infection (96). P. aeruginosa is also present in paediatric CF 
patients, but at a lower abundance than S. aureus (96). The mechanism by which P. 
aeruginosa out-competes S. aureus in adult CF patients remains unclear. 
Burkholderia cepacia complex (Bcc) is another significant Gram negative CF-
associated pathogen which causes chronic infections. Bcc is known to be composed 
of at least 17 Burkholderia species (103, 104). Bcc strains have been recovered from 
approximately 10 % of adult CF patients (105). B. multivorans and B. cenocepacia 
are the most common Bcc species found in CF patients, causing approximately 85-
97 % of all CF-related infections (106). However, the most prevalent Bcc species 
varies between CF patients in different regions – for instance, B. multivorans is now 
the most common Bcc species found in the UK, but B. cenocepacia is the most 
frequently-occurring species in the USA and Canada (105). CF patients are also at 
risk of chronic infection with non-tuberculous Mycobacterium species, which infect 
between 2 and 28 % of CF patients (96). As well as chronic infections, CF patients 
also experience transient infections from bacteria such as Stenotrophomonas 
maltophilia, which infects between 4 % and 12.4 % of CF patients (96), and 
Acinetobacter species (96).  
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The advent of sequence-based methods has allowed for the identification of 
unculturable and novel strains in the CF microbiome (Figure 6B). Analysis of 
ribosomal RNA (rRNA) in BALF from children with CF allowed for the 
identification of non-typical and non-culturable CF-associated bacteria, including 
novel α-Proteobacteria and Lysobacter species (107). rRNA sequencing has also 
uncovered Neisseria and Leptotrichia species, as well as Fusobacteria sequences, 
which were undetectable using culture-based methods (108). Furthermore, 
pyrosequencing of 16S ribosomal DNA (rDNA) from sputum samples has 
demonstrated the presence of non-canonical CF-associated bacteria, including 
Gemella, Prevotella and Veillonella (96). Sequencing developments have resulted in 
improved taxonomical classification of CF isolates. Sequencing and PCR-based 
analysis of 16S rDNA from clinical isolates which were originally classified as 
Burkholderia or Ralstonia led to the discovery and classification of the genus 
Pandoraea (96, 109). The methodology used in this area is consistently evolving and 
becoming more specific. For instance, a recently-described novel deep sequencing 
method revealed greater species specificity of unculturable samples and reduced 





Figure 6: Bacterial ecology of the CF lung. (A) Bacteria which have been isolated from 
CF patients using culture-based methods. (B) Species which have been identified using 




3.1. Virulence of Pseudomonas aeruginosa – the predominant CF-associated 
pathogen 
P. aeruginosa is a Gram negative, rod-shaped bacterial species, which is free-living 
and naturally occurs ubiquitously in the environment. This bacterium is classed as an 
opportunistic and nosocomial pathogen, and in addition to RTIs can also cause 
corneal and wound infections. P. aeruginosa is not only the most prevalent CF-
associated organism, but is arguably the most widely-characterised too, as the 
genomes of 13 P. aeruginosa strains have been sequenced to date (111). This makes 
P. aeruginosa an ideal model organism to study the mechanisms by which infections 
occur. P. aeruginosa has a number of behavioural traits, termed “virulence factors”, 
which facilitate its colonisation and long term survival in several different and often 
hostile host environments, including the lungs of people with CF. These factors and 
their regulation are detailed in Figure 7. Several of these factors are of interest in this 






Figure 7: Regulation of P. aeruginosa virulence. P. aeruginosa possesses numerous 
virulence factors which are required for both acute and chronic infections. These factors are 
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regulated by a plethora of transcriptional and post-translational pathways. Many virulence 
factors share a regulatory pathway, or are inversely regulated by the same pathway. From 
Balasubramanian et al., 2013 (112).  
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3.2. Type III Toxin Secretion 
A key virulence trait of P. aeruginosa is toxin secretion by way of a Type III 
secretion system (TTSS), and this virulence mechanism is crucial during the early 
acute phase of P. aeruginosa infection (113, 114). P. aeruginosa produces 4 type III 
exotoxins – ExoS, T, U and Y. ExoS and ExoT are bi-functional proteins, which 
contain an N-terminal GTPase-activation (GAP) domain, and C-terminal ADP-
ribosyltransferase activity (115–118). ExoU is a phospholipase (119), while ExoY 
possesses adenylate cyclase activity (120). Both ExoS and ExoU are primarily 
responsible for actin depolymerisation and cytotoxicity (121, 122). These proteins 
are mutually exclusive amongst P. aeruginosa strains, and strains which possess 
ExoU are generally more virulent and cytotoxic than strains which possess ExoS 
(121). Although ExoT also possesses GAP activity, it has been found to induce actin 
depolymerisation without causing cell death (123). ExoY causes cyclic-AMP-
mediated actin depolymerisation, but does not appear to influence cell death (120, 
124).  
The TTSS is activated when P. aeruginosa binds to host cell receptors. This induces 
the formation of a needle complex, which penetrates the host cell membrane and 
injects toxins into the cytoplasm (113). Host cell contact activates the ExsCDE 
regulatory cascade, which induces the transcription factor ExsA (113, 125, 126). 
ExsCDE is also activated under conditions of low calcium (Ca
2+
) (125, 126). Low 
Ca
2+
 also induces synthesis of cyclic AMP (cAMP), which complexes with the Vfr 
transcription factor, leading to Vfr-mediated TTSS activation (126). The direct 
expression of all TTSS toxins and secretion apparatus is regulated by ExsA (125, 
126). However, the transcriptional regulation of ExsA-mediated TTSS induction is 
extremely multifaceted (Figure 8). 
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The production of TTSS effectors by P. aeruginosa is positively regulated by the 
small RNA-binding protein RsmA (127). RsmA is in turn regulated by the small 
RNAs RsmY and RsmZ, which bind to RsmA, thus inhibiting its activity (128–132). 
The transcription of RsmY and RsmZ is directly regulated by the GacA regulatory 
protein (133), which is activated by its cognate sensor kinase GacS (134). GacA also 
interacts with the LadS and RetS sensors (135). RetS positively regulates the 
expression of the TTSS, while LadS has the opposite effect (125). However, RetS 
also indirectly induces TTSS by reducing intracellular levels of the signalling 
compound cyclic-di-GMP (c-di-GMP) in a RsmY/Z-dependent manner (136). The 
AlgR regulator also manipulates RsmY/Z expression in order to inhibit TTSS 
expression (137). Furthermore, the long chain fatty acid sensor PsrA can also 
regulate TTSS, as ligand binding to PsrA represses TTSS by inhibiting expression of 
exsC (138). TTSS expression can also be regulated by several environmental stress 
factors. For instance, we determined that limiting O2 induces the GltS/R sensor-
regulator system, which activates the Anr regulator, leading to induction of another 
regulator, NarL, which induces TTSS via modulation of RsmAYZ (139, 140). TTSS 
is also inhibited by metabolic cues such as long chain fatty acids and tryptophan, and 




Figure 8: Regulation of the P. aeruginosa TTSS. Expression of TTSS effectors is 
transcriptionally regulated by a number of conditions and proteins. However, ExsA is 
indisputably required for the expression of TTSS-related genes. Adapted from Yahr & 
Wolfgang, 2006 (126).  
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3.3. Quorum sensing 
Quorum sensing (QS) is a mechanism of intercellular bacterial communication, 
which is mediated through distinct molecular signals. P. aeruginosa QS is modulated 
via 2 key groups of chemical compounds, homoserine lactones (HSLs) and 
quinolones, and 3 QS systems. The regulation of these systems is detailed in Figure 
9. One key system of HSL-mediated QS regulation in P. aeruginosa is the LasI/R 2 
component sensor/regulator system. LasI is responsible for the synthesis of the HSL 
N-3-oxo-dodecanoyl-L-homoserine lactone (3OC12-HSL), which is recognised by 
the receptor LasR (141–143). Once the number of bacteria in culture passes a certain 
threshold, 3OC12-HSL binds to LasR, leading to the abundant activation of genes 
involved in a number of processes, including the activation of 2 other P. aeruginosa 
QS systems – the 2 component RhlI/R system, and 2-heptyl-3,4-dihydroxyquinolone 
(Pseudomonas quinolone signal; PQS). RhlI synthesises another HSL, N-butaryl-
homoserine lactone (C4-HSL), which binds to RhlR, the regulator of the RhlI/R 2 
component system (144–146). The production of C4-HSL is also positively regulated 
by GacA and RsmY/Z (131).  
PQS is one of approximately 50 quinolone-based QS molecules that P. aeruginosa 
possesses, and it and its precursor 4-hydroxy-2-heptylquinoline (HHQ) regulate the 
expression of virulence factors including motility, biofilm formation and antibiotic 
resistance. PQS and HHQ are produced by the pqsABCDE, phnAB and pqsH genes 
(147, 148) during the late stationary phase of infection (149). pqsABCDE and phnAB 
are regulated by the PqsR transcription factor (147, 150). Interestingly, some cross-
regulation exists between the P. aeruginosa QS systems. PQS can induce RhlI to the 
same extent as C4-HSL (149). Furthermore, pqsR transcription is positively regulated 
by LasR and inhibited by RhlR (150). In addition to the LasI/R, RhlI/R and PQS 
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systems, a putative third QS regulator – QscR – has been identified in P. aeruginosa 
(151). This regulator can bind 3OC12-HSL (152) and can consequently inhibit LasI 
and RhlR (153). 
The QS systems of P. aeruginosa collectively regulate virulence, causing a 
coordinated shift from acute to chronic infection phenotypes. HSL signalling is 
integral to P. aeruginosa virulence as it regulates myriad virulence factors, including 
production of Exotoxin A, elastase and lipase, and motility (154). Most importantly, 
HSL-mediated QS induces biofilm formation, arguably the most significant 
virulence factor of chronic P. aeruginosa infections (155). Las-mediated QS is 
required for initial attachment, while RhlI/R are implicated in maturation of biofilms 
(156). LasI is also essential for the formation of structurally-correct biofilms (157), 
and LasR is required for the production of microcolonies (158). Furthermore, LasI 
and RhlI are required for release of LPS and extracellular DNA (eDNA) during 
stationary phase, which are crucial for biofilm formation (159). Other virulence 
factors are also influenced by QS. The TTSS is inhibited by RhlI/R-mediated QS 
(160), and PQS inhibits the secretion of TTSS effectors in a concentration-dependent 
manner (161). The P. aeruginosa Type VI secretion system (Figure 7) is also 
modulated by LasI/R and RhlI/R-mediated QS – 2 Type VI-associated gene clusters 
(HSI-II and HSI-III) are increased by LasI/R and RhlI/R, while the remaining cluster 
(HSI-I) is decreased by Las QS (162). Furthermore, all 3 QS systems inhibit flagella-
associated motility (163, 164). In addition, RhlR directly regulates the production of 
P. aeruginosa rhamnolipid surfactant compounds, and PQS signalling is also 
essential for production of these compounds (165).  
 As QS regulates such a wide array of virulence factors, it has become a target in the 
development of novel antimicrobials. Several inhibitory mechanisms of QS – termed 
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“Quorum Quenching” (QQ) – have been identified. Firstly, QQ can be accomplished 
using compounds that mimic QS molecules. Algae, plants and fungi produce 
compounds which resemble AHLs (166). Secondly, many bacteria possess enzymes 
which degrade or modify QS molecules, such as the PvdQ acylase of P. aeruginosa, 
which catalyses the degradation of AHLs by hydrolysis of the peptide bond between 
the acyl chain and the homoserine lactone nucleus (167, 168). Degradation and 
modification of QS compounds renders them unrecognisable, leading to reduced 





Figure 9: Regulation of quorum sensing in P. aeruginosa. OdDHL (3OC12-HSL) is 
produced by LasI and binds to LasR, inducing virulence factors. Activation of LasI/R 
signalling induces expression of the RhlI/R system and its signalling molecule BHL (C4-
HSL). LasI/R signalling also stimulates the production of PQS, which positively regulates 
RhlR via interacting with the PqsR regulator. The orphan regulator QscR can inhibit both 




Bacterial motility is a key factor in both initiation of infection and the switch from 
the acute to chronic phase of infection. Three types of in vitro motility – swimming, 
swarming and twitching – have been observed in P. aeruginosa. Each of these 
phenotypes is controlled by an extracellular appendage of the bacterial cell wall. 
Swimming motility is controlled by the flagellum, and bacteria form a circular 
colony on plates (170). Twitching motility is characterised as bacterial adherence to 
and movement across a surface, and is mediated through Type IV pili (171). 
Swarming motility requires the co-expression of pili and flagella (172) and is 
characterised by the formation of snowflake-like pattern of tendrils on semisolid 
agar. However, each type of P. aeruginosa motility is also dependent upon several 
other factors, including chemotaxis, nutrient availability and QS. 
Swarming is an extremely multi-faceted phenotype. Over 200 P. aeruginosa genes 
with roles in a wide array of functions, including metabolism, transport and 
secretion, have been found to play a role in swarming (173). The regulation of this 
behaviour is similarly disparate, and is mediated through several regulatory and QS-
associated pathways. Both LasI/R and RhlI/R are required for full swarming motility 
(172). RsmA and HHQ promote swarming motility (130, 174), while it is inhibited 
by PQS (163) and the signalling molecule c-di-GMP (175). The latter effect is 
regulated by amino acid-mediated induction of c-di-GMP, which promotes biofilm 
formation (176). Because swarming is regulated by both LasI/R and RhlI/R, which 
are involved in attachment and biofilm maturation (156), it is thought that swarming 
motility is associated with the switch from acute to chronic infection. This 
hypothesis is supported by the observation that the gene expression and morphology 
of cells in the swarm centre are biofilm-like, while cells at the swarm tip are 
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planktonic and primarily express genes involved in nutrient acquisition and 
metabolism (172, 177). In addition, rhamnolipids are not only required for swarming 
motility, but also regulate the manner in which the bacteria move (178), highlighting 
the importance of RhlI/R in swarming motility. Inorganic phosphate deficiency has 
been correlated with inhibition of swarming (as well as swimming and twitching) 
(179) while swarming motility is inhibited by ammonium and excess iron (180).  
Swimming motility is regulated in a less complex manner than swarming, and is 
dependent upon the expression of the flagellum (172). This phenotype is associated 
with chemotaxis, and is mediated through the che genes, which regulate the direction 
of the flagellum (181, 182), and the Mot proteins, which form the flagellar motor 
(183). In addition, it also appears to be inhibited by LasR- and RhlR-mediated QS, as 
swimming is enhanced in the absence of LasR and RhlR (164). In contrast to 
swarming, swimming does not require rhamnolipids (178), but does require 
inorganic phosphate (179), and is also increased by tryptophan (184). 
Twitching motility is linked with biofilm formation (discussed in 3.5.)(185). It is a 
significant virulence factor, as it is required for the adhesion of P. aeruginosa to host 
surfaces (186). Twitching is regulated by the FimS/AlgR sensor-regulator system, 
and also requires the transcription factor AlgU, demonstrating that production of the 
exopolysaccharide alginate is associated with twitching motility (187). In addition, 
twitching, like TTSS, is positively regulated by the RetS sensor (188) and, in 
contrast to swarming, is increased by c-di-GMP (189). Under optimal nutrient 
conditions, twitching occurs independently of LasI/R- and RhlI/R-mediated QS 
(190), but interestingly is PqsR-dependent (163). However, under limiting iron, P. 
aeruginosa requires RhlI expression to carry out twitching motility (191). Other 
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nutritional requirements of twitching include inorganic phosphate (179) and carbon 
catabolite repression (192).  
 
3.5. Biofilm production 
The key trait which allows bacteria to chronically colonise the mucus of CF patients 
is biofilm formation. This phenomenon generally occurs in phases (described in 
(193) and in Figure 10). Firstly, bacteria reversibly attach to biotic or abiotic surfaces 
(Figure 10A). Initial attachment is linked to the motility of P. aeruginosa, which can 
utilise flagella and type IV pili to attach to surfaces (185). Attachment is also 
reciprocally associated with swarming motility – an attachment-deficient mutant has 
been found to display increased swarming motility (194). The switch from motile to 
sessile bacteria is mediated through c-di-GMP, which promotes aggregation and 
attachment of P. aeruginosa (195). Attachment becomes irreversible when Las-
mediated QS is activated (156). Interestingly, under anaerobic conditions, such as 
those encountered in the thick mucus of the CF lung, biofilms can develop as a 
structure called a microcolony, where bacteria do not attach directly to a surface, but 
instead adhere to themselves and material within sputum (196, 197). LasR is also  
required for microcolony formation (158).  
Once irreversibly attached to a surface, the bacteria enter a sessile state, termed 
maturation (193). Two phases of maturation – maturation-1 and -2 – have been 
proposed based on differences in gene expression at different intervals in in vitro 
mature biofilms (156). Maturation-1 is regulated by Rhl QS (156). In this phase, the 
density of the biofilm begins to thicken, as bacteria become surrounded by a tough 
extracellular matrix composed of extracellular DNA (eDNA), proteins and 
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exopolysaccharide. Inside this structure, bacteria are essentially protected from 
external stresses and become extremely resistant to most antibiotics. eDNA is known 
to be essential for the establishment of biofilms in P. aeruginosa (198). The main 
exopolysaccharide component produced by P. aeruginosa is alginate, which is 
associated with bacteria in a mucoid state (199) and is produced as a response to low 
oxygen/anaerobic environments (197, 200). Two other exopolysaccharides – the 
products of the pel and psl genes – are also essential for P. aeruginosa biofilm 
formation (201). The regulatory protein AlgR inhibits the transcription of  RhlI, 
meaning that it may promote development from maturation-1 into maturation-2 
(202).  This phase is characterised by maximum biofilm density, meaning that most 
of the cells within the biofilm are in a low oxygen or anaerobic environment (156). 
The final stage of biofilm formation is dispersal (Figure 10B), whereby the structure 
ruptures and the bacteria become disseminated to distal infection sites. This occurs 
as a result of changes in the external environment – P. aeruginosa chemotaxis 
transducer proteins have been found to regulate nutrient-induced dispersal (203). c-
di-GMP is also associated with biofilm dispersal. Phosphodiesterases which degrade 
c-di-GMP, such as DipA and PvrR, have been found to induce biofilm dispersal 
(204–206). In addition, the production of cis-2-decenoic acid by the DspI protein has 




Figure 10: Biofilm formation by P. aeruginosa. (A) Planktonic cells attach to a surface 
and form a monolayer. The production of Type IV pili leads to microcolony formation. 
3OC12-HSL mediates the development into a mature biofilm (maturation-1 and 2).  (B) 
Mature biofilms can disperse by either internal stimulation from bacterial signalling or by 
physical stress from the external environment. From Bjarnsholt et al., 2013 (193).   
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4. Regulation of host cell gene expression by P. aeruginosa 
4.1. Induction of inflammation by P. aeruginosa 
Infection of host cells by P. aeruginosa triggers the activation of genes involved in 
inflammation, immunity and cell death. Increased inflammation is a major cause for 
concern in CF patients, as the chronic inflammation caused by P. aeruginosa and 
other colonising organisms leads to impaired pulmonary function and permanent 
damage (89). P. aeruginosa-mediated inflammation is activated via a number of 
pathways, notably by the Toll-Like Receptors TLR4 and TLR5 (described in 1.4.3).  
The pro-inflammatory chemokine IL-8 (also known as CXCL8) is a key and widely-
characterised target protein of P. aeruginosa infection (208). IL-8 is a 99 amino acid 
(aa) protein whose genetic locus is located on Chromosome 4 in humans. It is 
produced by several tissue types including airway epithelial cells (209) and alveolar 
macrophages (210) with the purpose of attracting neutrophils to the site of infection 
(209). IL-8 expression is induced by TLR4 and TLR5 signalling (47, 211) in 
response to the LPS and flagellin of numerous Gram negative species, including 
Salmonella and E. coli (47). However, IL-8 is aberrantly produced in the CF lung by 
an altered neutrophil response, and is a contributory factor to the chronic 
inflammation and lung damage experienced by CF patients (212–215). CF-specific 
P. aeruginosa-mediated IL-8 activation was first reported by Schuster and 
colleagues (216). In addition, TLR/MyD88 signalling is known to induce NFκB-
mediated IL-8 expression in CF cells (217). IL-8 is chronically up-regulated in 
people with CF (218), and this is known to be a consequence of increased NFκB 
expression. The induction of inflammation by P. aeruginosa also causes 
deregulation of the macrophage response, as the pro-inflammatory cytokine 
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Chemokine (C-C motif) ligand 20 (CCL20) is upregulated by P. aeruginosa via 
TLR5 signalling (219, 220). This 95 aa protein (also known as Macrophage 
Inflammatory Protein-3; MIP3α) is also induced by LPS-stimulated TLR4 signalling 
(221) and is produced by several tissues, including but not limited to, airway 
epithelial cells (222), mast cells (219) neutrophils (223) and macrophages (224). 
CCL20 is chemoattractant to dendritic cells (225), T cells (226) and peripheral blood 
mononuclear cells (227), and stimulates monocyte differentiation into macrophages 
(228). 
P. aeruginosa colonisation also interferes with eukaryotic signalling systems in CF. 
Two signalling molecules of interest in this study are nitric oxide (NO) and 
ceramide. NO is a free radical compound which is produced in the lung by inducible 
nitric oxide synthase (iNOS) (229). NO contributes to the immune and inflammatory 
responses, as it is produced by phagocytes for respiratory burst-mediated bacterial 
killing (230). NO production is decreased in the CF lung, increasing the 
susceptibility to P. aeruginosa infection (231). Ceramide is a sphingolipid which is 
synthesised by the acid sphingomyelinase protein (ASM) (232). P. aeruginosa 
induces ASM activity in the lung, leading to increased ceramide production (233) 
and this contributes to the chronic inflammation experienced by CF patients (234). 
The mechanism by which ceramide increases inflammation is unclear; however, 
ceramide accumulation is correlated with an increased presence of macrophages and 
neutrophils in the lungs of cftr-deficient mice (234) 
The CF inflammasome is under study with regard to developing novel treatment 
strategies for people with CF. Recently, decoy molecules which mimic NFκB were 
found to bind to the promoters and reduce the expression of several pro-
inflammatory genes, including IL-8 (235). Screening is also underway to identify 
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potential novel anti-inflammatory therapies such as the plant compound corilagin, 
which has been found to reduce expression and secretion of IL-8 (236).  
 
4.2. Kruppel-like factors – a detailed example of a P. aeruginosa host cell target 
Kruppel-like factors (KLFs) are a family of DNA-binding transcription factors which 
are characterised by the presence of 3 highly conserved Cys2His2 zinc fingers of size 
82 aa (237). To date, 17 members of the KLF family have been characterised. KLFs 
bind to similar GT-box (5’-GGGGCGGGG-3’) or CACCC motifs in DNA in order 
to exert their function (238). KLFs regulate many diverse and important functions, 
including apoptosis, development, inflammation and proliferation (239). Therefore, 
it is reasonable to expect that they are prime targets in bacterial-host cell interactions. 
The family members KLF2 and KLF6 are of particular interest in this study, as they 
have been found to be induced in CF-affected tracheal epithelia by P. aeruginosa 






Figure 11: Protein structure of KLF2 and KLF6. Both proteins possess an N-terminal 
activation domain (blue). In addition, KLF2 possesses a transrepression domain (pink) 
between aa 110 and 267. The 3 characteristic C2H2 zinc fingers are conserved in both KLF2 




4.2.1. KLF2  
KLF2 is a 354 aa protein and is expressed in the lungs, the endothelial lining of 
blood vessels and lymphocytes (242), and is composed of an N-terminal activation 
domain between amino acids 1 and 110 and an inhibitory domain between amino 
acids 110 and 267 (243). KLF2 has mainly been characterised as an anti-
inflammatory transcription factor (241). As previously described, KLF2 is induced 
by statins in endothelial cells and macrophages (53–55), and interestingly, KLF2 can 
act as a repressor of inflammation by regulating similar processes to statins. It binds 
to and inhibits the promoter of p65, which is a subunit of NFκB (244). The primary 
mechanism of KLF2 induction is the binding of the MEF2 transcription factor to the 
KLF2 promoter (245). Interestingly, p65 is known to inhibit KLF2 promoter activity 
by forming a trimeric complex with MEF2 and HDAC4 (245). KLF2 also inhibits 
the promoter activity of AP-1, another pro-inflammatory regulator (244), and has 
been found to reduce the p65 and TNFα-mediated induction of pro-inflammatory 
adhesion molecules (246). Furthermore, it has been proposed that KLF2 plays a role 
in the CF lung. KLF2 can inhibit IL-8 release in an in vitro model of neutrophil-
mediated inflammation, and has also been found to be absent in tissue from patients 
with severe respiratory inflammation, thus suggesting that IL-8 in chronic 
inflammation is modulated by KLF2 (247).  
As well as inhibiting promoters of inflammation, like statins KLF2 promotes the 
expression of anti-inflammatory proteins. For example, eNOS expression is strongly 
induced by KLF2, and this confers an anti-inflammatory phenotype on endothelial 
cells (246). Additionally, KLF2 can induce thrombomodulin in endothelium, leading 
to a decrease in blood clotting (248). In fact, the induction of both eNOS and 
thrombomodulin by statins are mediated through KLF2 (53).  
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Given KLF2’s regulatory role in inflammation and immunity, it is not surprising that 
it is influenced by bacterial infection. We identified that the P. aeruginosa ExoS 
toxin is responsible for transcriptional induction of KLF2 in cftr
–
 tracheal epithelia 
(240), but other bacterial species have also been found to induce KLF2 (249).
 
The 
Gram negative gastro-intestinal pathogen Yersinia enterocolitica induces KLF2 
expression in HeLa cells (250) and mouse macrophages (251, 252) and this 
expression is dependent on presence of the cysteine protease YopT (251). KLF2 
induction is not limited to Gram negative toxins  – the Clostridium botulinum C3 
toxin can induce KLF2 expression in vascular endothelial cells (54). Furthermore, 
Moreilhon et al. demonstrated that S. aureus induces KLF2 in tracheal gland cells, 
although this effect is not linked to the production of a particular virulence factor, as 
both live bacteria and supernatant could increase KLF2 to a similar extent (253). 
KLF2 expression subsequently appears to influence the impact of bacterial 
infections. KLF2 was found to reduce P. aeruginosa-mediated NFκB activation in 
primary airway cells (247). It has been hypothesised that bacterial toxins induce 
KLF2 by inhibiting the downstream effects of RhoA, and this was suggested to be an 
immunosuppressive mechanism to prevent the damaging over-activation of the 
inflammatory response (254). Another report appears to confirm this hypothesis, as it 
showed that KLF2 deficiency causes unregulated activation of inflammatory 
components such as IL-17 and TNFα, resulting in increased bactericidal activity in 






4.2.2. KLF6  
KLF6 is a ubiquitously expressed 283 aa protein, which contains a serine- and 
proline–rich N-terminal activation domain (256). It is also known as core promoter 
element-binding protein (COPEB), GC-rich site binding factor (GBF) and zinc 
finger 9 (ZF9) (257–259). The main known function of KLF6 is regulation of cell 
proliferation and apoptosis. KLF6 halts cell growth by positively inducing the 
cyclin-dependent kinase p21, which has a strong inhibitory effect on cell 
proliferation (260). KLF6 induces apoptosis via a TGF-β-dependent mechanism 
(261). Due to the regulatory effects of KLF6 on apoptosis and proliferation, it has 
been described as a tumour suppressor gene. Loss of heterozygosity (LOH), 
promoter hypermethylation and alternative splicing of KLF6 have all been 
implicated in several types of cancers. KLF6 inactivation by LOH has been 
identified in tumours from patients with prostate (262), colorectal (263), lung (264) 
and ovarian (265) cancers. Moreover, silencing of KLF6 expression due to promoter 
hypermethylation has been implicated in oesphageal squamous cell (266) and 
hepatocellular (267) carcinomas. 
Despite its role as a tumour suppressor, it appears that KLF6 may have a role in 
inflammation and immunity. KLF6 indirectly induces CCL20 by inhibiting PPARγ 
in kidney cells (268), and may also induce TNFα (269). Another target of KLF6 is 
acid ceramidase (270), a protein which regulates the degradation of ceramide. Taken 
together, these reports suggest that KLF6 may increase inflammation. Furthermore, 
KLF6 has been induced by oxidative stress in a hepatocellular carcinoma cell line 
(269), and contributes to the production of NO by directly inducing expression of 
iNOS in kidney cells (271).  
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Intriguingly, given its potential role as an inflammatory regulator, KLF6 is induced 
during bacterial and viral infections. KLF6 expression is induced in CF tracheal 
epithelia by the P. aeruginosa toxins ExoS and ExoY (240). Furthermore, KLF6 was 
also found to be induced in mouse macrophages by S. aureus toxins (253) and in 
HeLa cells by Y. enterocolitica (250). The induction of iNOS by KLF6 also 
promotes apoptosis of cells infected with influenza A (272) and respiratory syncytial 
virus (273). Therefore, although KLF6 is not yet fully characterised as a regulator of 
infection, it is clear that it has a function in the immune response. 
  
4.2.3. Alternative splicing and KLF6  
As previously stated, KLF6 is 283 aa in size, and is coded by an mRNA of 4679 base 
pairs (bp). However, KLF6 is also regulated by alternative splicing. Alternative 
splicing is a process whereby an mRNA transcript of a gene can be spliced across a 
number of sites, generating 2 or more alternative RNA and protein products from the 
same transcript. Approximately 70 % of human genes are routinely regulated by 
alternative splicing, but this process can also occur abberantly, and as such is 
implicated in inflammatory disorders and cancer. KLF6 alternative splicing falls into 
the abberant category.  
KLF6 is spliced into 3 splice variants, and these are termed KLF6-SV1, KLF6-SV2 
and KLF6-SV3, with respective mRNA transcript lengths of 4525, 4553 and 4555 
bp) (274). These transcripts share the proline- and serine-rich N-terminal domain 
with full-length KLF6 (also known as wild type KLF6 [wtKLF6]), but, due to the 
deletion of nucleotides, the C-terminal zinc finger is either altered or not present in 
the splice variants (274). The structures of the KLF6 splice variants are detailed in 
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Figure 12. SV1, the shortest transcript, does not possess any zinc fingers, but instead 
contains a unique C-terminal sequence due to out of frame splicing. The first of the 3 
zinc fingers is absent from SV2, and SV3 contains the first zinc finger, but due to 
out-of-frame splicing the second and third zinc fingers are replaced by a novel C-
terminus sequence (274). 
With regard to mechanism, KLF6 alternative splicing is mediated through the 
splicing enhancer proteins ASF/SF2, which promotes dominant splicing of wtKLF6 
(275) and SRp40, which causes increased expression of the variants relative to the 
wild type (274). Increased expression of Ras, and activation of downstream proteins 
also increases production of splice variants (275). Furthermore, inheritance of 
IVSΔA, a particular KLF6 allele corresponding to a single nucleotide polymorphism 
upstream of exon 2, is linked to increased production of splice variants, as well as a 
reduction in p21 induction (274).  
As the splice variants lack the 3 conserved zinc fingers of the KLF family, they are 
unable to exert the same anti-proliferative effects as wtKLF6, and are consequently 
implicated in several types of cancers, with SV1 being most commonly observed. 
SV1 has been seen to be increased in prostate (274), liver (275), lung (276) and 
ovarian cancers (265), and overexpression of SV1 has been linked to decreased p21, 
and increased expression of the anti-apoptotic protein Bcl-2 (274, 277). At first, SV1 
was thought to be primarily localised in the cytoplasm (274) but it was demonstrated 
that SV1 can move between the nucleus and cytoplasm (278), and can bind the pro-
apoptotic protein NOXA, targeting it for degradation (279). Interestingly, SV1 may 
ablate KLF6 activity, as it has been found to bind KLF6, consequently inhibiting its 
ability to activate p21 and accelerating its cytoplasmic degradation (280). 
Furthermore, SV1 may also have a role in inflammation, as it is induced by oxidative 
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stress (269). However, unlike wtKLF6, SV1 may have an anti-inflammatory role, as 
it was found to reduce TNFα promoter activation (269). 
SV2 has been shown to be localised in the cytoplasm (274), and has been implicated 
in liver (281), ovarian (265) and prostate (274) cancers. Like SV1, overexpression of 
SV2 is known to decrease wtKLF6-mediated induction of p21 (274). To date, no 
additional information is known regarding SV3, and there is no current evidence to 
suggest that this transcript is translated to a protein. 
With regard to infection, a clear context has not yet been established for KLF6 splice 
variants. One report demonstrated that both wtKLF6 and SV2 are increased to a 
similar extent in human lung cells by 3OC12-HSL from P. aeruginosa (282). 
However, the transcriptional induction of wtKLF6 by bacterial toxins suggests that 
KLF6 splice variants may be induced during infections. Bacteria have been found to 
alter alternative splicing of human genes, either by causing simultaneous expression 
of more than 1 variant, or by promoting dominant transcription of one transcript 
variant over any others. Invasion of both Salmonella Typhimurium and Y. 
enterocolitica increases alternative splicing of the HLA-B27 gene – which is 
implicated in immunity and reactive arthritis – into a pro-arthritic soluble form 
(283). Furthermore, Mycobacterium tuberculosis can induce alternative splicing of 
the β1 subunit of IL-12 (il12rb1), producing a novel isoform which is linked to 





Figure 12: Structure of the KLF6 splice variants. wtKLF6 possess an N-terminal 
activation domain, a nuclear localisation signal (NLS) and 3 zinc fingers (blue). The N-
terminal domain is conserved in all splice variants, but they differ from the wt and each 
other at the C-terminus. SV3 possesses the NLS, 1 zinc finger, and a novel 12 aa domain 
which arises from out-of-frame splicing (green). The first zinc finger and NLS are absent 
from SV2, while the SV1 C-terminus is composed of a 25 aa domain resulting from out-of-




5.1. Statins, RTIs and cystic fibrosis: Objectives of this study 
Given the anti-inflammatory and anti-microbial effects of statins, it is possible that 
these compounds may play a role in attenuating bacterial virulence and morbidity 
associated with CF. Therefore, the aim of this research was to examine the effects of 
statins on the causative agents of CF-associated respiratory tract infections. In 
Chapter 2, this first part of this analysis entailed examining the prevalence of the 
mevalonate pathway in RTI-associated bacteria, and examining the effects of statins 
on these bacteria. Chapter 3 involved studying the effects of statins on in vitro 
virulence behaviour and transcriptomic and translational expression of Pseudomonas 
aeruginosa. Chapter 4 was undertaken to examine the mechanisms by which statins 
influenced P. aeruginosa infection, by examining specific infection-related target 
genes, including elucidating the role of KLF6 splice variants in P. aeruginosa 
infection. In summary, the effects of statins on both the host and the pathogen were 
examined, to determine whether these compounds could be used as therapeutic 




1.  Endo A, Kuroda M, Tanzawa K. 1976. Competitive inhibition of 3-
hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B 
fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72:323–
326. 
2.  Endo A, Kuroda M, Tsujita Y. 1976. ML-236A, ML-236B, and ML-236C, 
new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. 
Antibiot. (Tokyo). 29:1346–1348. 
3.  Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, 
Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, 
Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, 
Liesch J, Springer J. 1980. Mevinolin: a highly potent competitive inhibitor 
of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering 
agent. Proc. Natl. Acad. Sci. U. S. A. 77:3957–3961. 
4.  Istvan ES, Deisenhofer J. 2001. Structural mechanism for statin inhibition of 
HMG-CoA reductase. Science 292:1160–1164. 
5.  Hamelin BA, Turgeon J. 1998. Hydrophilicity/lipophilicity: relevance for 
the pharmacology and clinical effects of HMG-CoA reductase inhibitors. 
Trends Pharmacol. Sci. 19:26–37. 
6.  Rozman D, Monostory K. 2010. Perspectives of the non-statin 
hypolipidemic agents. Pharmacol. Ther. 127:19–40. 
7.  Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. 
Nature 343:425–430. 
8.  Mackay DJ, Hall A. 1998. Rho GTPases. J. Biol. Chem. 273:20685–20688. 
9.  Beach MJ, Rodwell VW. 1989. Cloning, sequencing, and overexpression of 
mvaA, which encodes Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl 
coenzyme A reductase. J. Bacteriol. 171:2994–3001. 
10.  Hedl M, Tabernero L, Stauffacher C V, Rodwell VW. 2004. Class II 3-
hydroxy-3-methylglutaryl coenzyme A reductases. J. Bacteriol. 186:1927–
1932. 
11.  Hedl M, Rodwell VW. 2004. Inhibition of the class II HMG-CoA reductase 
of Pseudomonas mevalonii. Protein Sci. 13:1693–1697. 
12.  Hedl M, Sutherlin A, Wilding EI, Mazzulla M, Mcdevitt D, Lane P, Ii 
JWB, Lehnbeuter KR, Stauffacher C V, Gwynn MN, Rodwell VW. 2002. 
Enterococcus faecalis acetoacetyl-coenzyme A thiolase/3-hydroxy-3-
methylglutaryl-coenzyme A reductase, a dual-function protein of isopentenyl 
diphosphate biosynthesis. J. Bacteriol. 184:2116–2122. 
60 
 
13.  Theivagt AE, Amanti EN, Beresford NJ, Tabernero L, Friesen JA. 2006. 
Characterization of an HMG-CoA reductase from Listeria monocytogenes that 
exhibits dual coenzyme specificity. Biochem. 45:14397–14406. 
14.  Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham 
KA, Iordanescu S, So CY, Rosenberg M, Gwynn MN. 2000. Identification, 
evolution, and essentiality of the mevalonate pathway for isopentenyl 
diphosphate biosynthesis in gram-positive cocci. J. Bacteriol. 182:4319–4327. 
15.  Wilding EI, Kim DY, Bryant AP, Gwynn MN, Lunsford RD, McDevitt D, 
Myers JE, Rosenberg M, Sylvester D, Stauffacher C V, Rodwell VW. 
2000. Essentiality, expression, and characterization of the class II 3-hydroxy-
3-methylglutaryl coenzyme A reductase of Staphylococcus aureus. J. 
Bacteriol. 182:5147–5152. 
16.  Heuston S, Begley M, Gahan CGM, Hill C. 2012. Isoprenoid biosynthesis 
in bacterial pathogens. Microbiology 158:1389–1401. 
17.  Jerwood S, Cohen J. 2008. Unexpected antimicrobial effect of statins. J. 
Antimicrob. Chemother. 61:362–364. 
18.  Bergman P, Linde C, Putsep K, Pohanka A, Normark S, Henriques-
Normark B, Andersson J, Bjorkhem-Bergman L. 2011. Studies on the 
Antibacterial Effects of Statins - In Vitro and In Vivo. PLoS One 6:e24394. 
19.  Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z. 2012. 
Antibacterial activity of statins: a comparative study of atorvastatin, 
simvastatin, and rosuvastatin. Ann. Clin. Microbiol. Antimicrob. 
11:doi:10.1186/1476–0711–11–13. 
20.  Welsh A-M, Kruger P, Faoagali J. 2009. Antimicrobial action of 
atorvastatin and rosuvastatin. Pathology 41:689–691. 
21.  Van Laar TA, Lin YH, Miller CL, Karna SL, Chambers JP, Seshu J. 
2012. Effect of levels of acetate on the mevalonate pathway of Borrelia 
burgdorferi. PLoS One 7:e38171. 
22.  Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. 1999. 
New insights into the pharmacodynamic and pharmacokinetic properties of 
statins. Pharmacol. Ther. 84:413–428. 
23.  Bienvenu A-L, Picot S. 2008. Statins alone are ineffective in cerebral malaria 
but potentiate artesunate. Antimicrob. Agents Chemother. 52:4203–4204. 
24.  Farmer AR, Murray CK, Mende K, Akers KS, Zera WC, Beckius ML, 
Yun HC. 2013. Effect of HMG-CoA reductase inhibitors on antimicrobial 
susceptibilities for gram-negative rods. J. Basic Microbiol. 53:336–339. 
25.  Rosch JW, Boyd AR, Hinojosa E, Pestina T, Hu Y, Persons DA, Orihuela 
CJ, Tuomanen EI. 2010. Statins protect against fulminant pneumococcal 
61 
 
infection and cytolysin toxicity in a mouse model of sickle cell disease. J. 
Clin. Invest. 120:627–635. 
26.  Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, Maass M. 
2003. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces 
Chlamydia pneumoniae-induced cell interaction and activation. Circulation 
108:261–265. 
27.  Erkkilä L, Jauhiainen M, Laitinen K, Haasio K, Tiirola T, Saikku P, 
Leinonen M. 2005. Effect of simvastatin, an established lipid-lowering drug, 
on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob. Agents 
Chemother. 49:3959–3962. 
28.  Botelho-Nevers E, Espinosa L, Raoult D, Rolain J-M. 2008. Lovastatin, but 
not pravastatin, limits in vitro infection due to Coxiella burnetii. J. 
Antimicrob. Chemother. 62:845–847. 
29.  Botelho-Nevers E, Rolain JM, Espinosa L, Raoult D. 2008. Statins limit 
Rickettsia conorii infection in cells. Int. J. Antimicrob. Agents 32:344–348. 
30.  Parihar SP, Guler R, Lang DM, Suzuki H, Marais AD, Brombacher F. 
2013. Simvastatin Enhances Protection against Listeria monocytogenes 
Infection in Mice by Counteracting Listeria-Induced Phagosomal Escape. 
PLoS One 8:e75490. 
31.  Catron DM, Lange Y, Borensztajn J, Sylvester MD, Jones BD, Haldar K. 
2004. Salmonella enterica serovar Typhimurium requires nonsterol precursors 
of the cholesterol biosynthetic pathway for intracellular proliferation. Infect. 
Immun. 72:1036–1042. 
32.  Burnham CA, Shokoples SE, Tyrrell GJ. 2007. Rac1, RhoA, and Cdc42 
participate in HeLa cell invasion by group B streptococcus. FEMS Microbiol. 
Lett. 272:8–14. 
33.  Martinez JJ, Hultgren SJ. 2002. Requirement of Rho-family GTPases in the 
invasion of Type 1-piliated uropathogenic Escherichia coli. Cell Microbiol. 
4:19–28. 
34.  Horn MP, Knecht SM, Rushing FL, Birdsong J, Siddall CP, Johnson CM, 
Abraham TN, Brown A, Volk CB, Gammon K, Bishop DL, McKillip JL, 
McDowell SA. 2008. Simvastatin inhibits Staphylococcus aureus host cell 
invasion through modulation of isoprenoid intermediates. J. Pharmacol. Exp. 
Ther. 326:135–143. 
35.  Shibata H, Nishitani N, Yaohara S, Arakaki N, Higuti T, Kawazoe K, 
Minakuchi K. 2012. Simvastatin represses translocation of Pseudomonas 




36.  Riethmüller J, Riehle A, Grassmé H, Gulbins E. 2006. Membrane rafts in 
host-pathogen interactions. Biochim. Biophys. Acta 1758:2139–2147. 
37.  Hansen GH, Niels-Christiansen LL, Thorsen E, Immerdal L, Danielsen 
EM. 2000. Cholesterol depletion of enterocytes. Effect on the Golgi complex 
and apical membrane trafficking. J. Biol. Chem. 275:5136–5142. 
38.  McDowell SA, Ma Y, Kusano R, Akinbi HT. 2011. Simvastatin is 
protective during Staphylococcus aureus pneumonia. Curr. Pharm. 
Biotechnol. 12:1455–1462. 
39.  Chow OA, von Kockritz-Blickwede M, Bright AT, Hensler ME, 
Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, 
Nizet V. 2010. Statins enhance formation of phagocyte extracellular traps. 
Cell. Host. Microbe 8:445–454. 
40.  Boyd AR, Hinojosa CA, Rodriguez PJ, Orihuela CJ. 2012. Impact of oral 
simvastatin therapy on acute lung injury in mice during pneumococcal 
pneumonia. BMC Microbiol. 12:doi: 10.1186/1471–2180–12–73. 
41.  Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, 
Sibelius U, Grandel U, Grimminger F, Seeger W, Meyer J, Darius H, 
Buerke M. 2002. Simvastatin inhibits inflammatory properties of 
Staphylococcus aureus alpha-toxin. Circulation 106:2104–2110. 
42.  Tilahun ME, Kwan A, Natarajan K, Quinn M, Tilahun AY, Xie C, 
Margulies DH, Osborne BA, Goldsby RA, Rajagopalan G. 2011. Chimeric 
anti-staphylococcal enterotoxin B antibodies and lovastatin act synergistically 
to provide in vivo protection against lethal doses of SEB. PLoS One 6:e27203. 
43.  deCathelineau AM, Bokoch GM. 2009. Inactivation of rho GTPases by 
statins attenuates anthrax lethal toxin activity. Infect. Immun. 77:348–359. 
44.  Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M, Katus H a. 
2000. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the 
inflammatory response of human nacrophages and endothelial cells infected 
with Chlamydia pneumoniae. Circulation 101:1760–1763. 
45.  Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. 2000. Cerivastatin 
improves survival of mice with lipopolysaccharide-induced sepsis. J. 
Pharmacol. Exp. Ther. 294:1043–1046. 
46.  Zhang S, Rahman M, Zhang S, Qi Z, Thorlacius H. 2011. Simvastatin 
antagonizes CD40L secretion, CXC chemokine formation, and pulmonary 
infiltration of neutrophils in abdominal sepsis. J. Leukoc. Biol. 89:735–742. 
47.  Tapping RI, Akashi S, Miyake K, Godowski PJ, Tobias PS. 2000. Toll-like 
receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia 
and Salmonella lipopolysaccharides. J. Immunol. 165:5780–5787. 
63 
 
48.  Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng 
JK, Akira S, Underhill DM, Aderem A. 2001. The innate immune response 
to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099–
1103. 
49.  Mogensen TH. 2009. Pathogen recognition and inflammatory signaling in 
innate immune defenses. Clin. Microbiol. Rev. 22:240–273. 
50.  Liew FY, Xu D, Brint EK, O’Neill LAJ. 2005. Negative regulation of toll-
like receptor-mediated immune responses. Nat. Rev. Immunol. 5:446–458. 
51.  Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-
Pascuala R, Hernández G, Díaz C, Lamas S. 1998. Effects of the 3-
hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and 
simvastatin, on the expression of endothelin-1 and endothelial nitric oxide 
synthase in vascular endothelial cells. J. Clin. Invest. 101:2711–2719. 
52.  Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori 
I. 2003. Pitavastatin-induced thrombomodulin expression by endothelial cells 
acts via inhibition of small G proteins of the Rho family. Arter. Thromb. 
Vasc. Biol. 23:512–517. 
53.  Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone Jr. MA, 
Garcia-Cardena G. 2005. Statins exert endothelial atheroprotective effects 
via the KLF2 transcription factor. J. Biol. Chem. 280:26714–26719. 
54.  Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, Banerjee P, 
Kumar A, Jain MK. 2005. Kruppel-like factor 2 as a novel mediator of statin 
effects in endothelial cells. Circulation 112:720–726. 
55.  Tuomisto TT, Lumivuori H, Kansanen E, Hakkinen SK, Turunen MP, 
van Thienen J V, Horrevoets AJ, Levonen AL, Yla-Herttuala S. 2008. 
Simvastatin has an anti-inflammatory effect on macrophages via upregulation 
of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc. 
Res. 78:175–184. 
56.  Grip O, Janciauskiene S, Lindgren S. 2002. Atorvastatin activates PPAR-
gamma and attenuates the inflammatory response in human monocytes. 
Inflamm. Res. 51:58–62. 
57.  Guijarro C, Kim Y, Schoonover CM, Massy ZA, O’Donnell MP, Kasiske 
BL, Keane WF, Kashtan CE. 1996. Lovastatin inhibits lipopolysaccharide-
induced NF-kappaB activation in human mesangial cells. Nephrol. Dial. 
Transplant. 11:990–996. 
58.  Law RE, Stimmel JB, Damore MA, Carter C, Clarke S, Wall R. 1992. 
Lipopolysaccharide-induced NF-kappa B activation in mouse 70Z/3 pre-B 
lymphocytes is inhibited by mevinolin and 5’-methylthioadenosine: roles of 




59.  Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández 
G, Egido J. 1999. Atorvastatin reduces NF-kappaB activation and chemokine 
expression in vascular smooth muscle cells and mononuclear cells. 
Atherosclerosis 147:253–261. 
60.  Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, 
Díaz C, Hernández G, Egido J. 1998. HMG-CoA reductase inhibition by 
atorvastatin reduces neointimal inflammation in a rabbit model of 
atherosclerosis. J. Am. Coll. Cardiol. 32:2057–2064. 
61.  Sochanowicz B, Szumiel I, Gradzka I. 1999. Nuclear translocation of the 
p65 subunit of NF-kappaB in L5178Y sublines differing in antioxidant 
defense. Radiat. Environ. Biophys. 38:125–131. 
62.  Jouneau S, Bonizec M, Belleguic C, Desrues B, Brinchault G, Galaine J, 
Gangneux JP, Martin-Chouly C. 2011. Anti-inflammatory effect of 
fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and 
Aspergillus fumigatus antigens in cystic fibrosis. PLoS One 6:e22655. 
63.  Zineh I, Luo X, Welder GJ, Debella AE, Wessel TR, Arant CB, Schofield 
RS, Chegini N. 2006. Modulatory effects of atorvastatin on endothelial cell-
derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 
26:333–340. 
64.  Guasti L, Marino F, Cosentino M, Cimpanelli M, Maio RC, Klersy C, 
Crespi C, Restelli D, Simoni C, Franzetti I, Gaudio G, Marnini P, Grandi 
AM, Lecchini S, Venco A. 2006. Simvastatin treatment modifies 
polymorphonuclear leukocyte function in high-risk individuals: a longitudinal 
study. J. Hypertens. 24:2423–2430. 
65.  Miyata R, Bai N, Vincent R, Sin DD, Van Eeden SF. 2013. Statins reduce 
ambient particulate matter-induced lung inflammation by promoting the 
clearance of particulate matter, < 10 μm from lung tissues. Chest 143:452–
460. 
66.  Ou X-M, Wang B-D, Wen F-Q, Feng Y-L, Huang X-Y, Xiao J. 2008. 
Simvastatin attenuates lipopolysaccharide-induced airway mucus 
hypersecretion in rats. Chin. Med. J. (Engl). 121:1680–1687. 
67.  Murphy DM, Forrest IA, Corris PA, Johnson GE, Small T, Jones D, 
Fisher AJ, Egan JJ, Cawston TE, Ward C, Lordan JL. 2008. Simvastatin 
attenuates release of neutrophilic and remodeling factors from primary 
bronchial epithelial cells derived from stable lung transplant recipients. Am. J. 
Physiol. Lung Cell. Mol. Physiol. 294:L592–599. 
68.  Vamvakopoulos JE, Green C. 2003. HMG-CoA reductase inhibition aborts 
functional differentiation and triggers apoptosis in cultured primary human 
monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC 
Cardiovasc. Disord. 3:doi:10.1186/1471–2261–3–6. 
65 
 
69.  Kim T-G, Byamba D, Wu WH, Lee M-G. 2011. Statins inhibit chemotactic 
interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis 
treatment. Exp. Dermatol. 20:855–857. 
70.  Hot A, Lavocat F, Lenief V, Miossec P. 2013. Simvastatin inhibits the pro-
inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial 
cells. Ann. Rheum. Dis. 72:754–760. 
71.  Kok S-H, Lin L-D, Hou K-L, Hong C-Y, Chang C-C, Hsiao M, Wang J-
H, Lai EH-H, Lin S-K. 2013. Simvastatin inhibits cysteine-rich protein 61 
expression in rheumatoid arthritis synovial fibroblasts through the regulation 
of sirtuin-1/FoxO3a signaling. Arthritis Rheum. 65:639–649. 
72.  Kaneider NC, Reinisch CM, Dunzendorfer S, Meierhofer C, Djanani A, 
Wiedermann CJ. 2001. Induction of apoptosis and inhibition of migration of 
inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 158:23–
33. 
73.  Bokoch GM, Prossnitz V. 1992. Isoprenoid metabolism is required for 
stimulation of the respiratory burst oxidase of HL-60 cells. J. Clin. Invest. 
89:402–408. 
74.  Mermis JD, Simpson SQ. 2012. HMG-CoA reductase inhibitors for 
prevention and treatment of severe sepsis. Curr. Infect. Dis. Rep. 14:484–492. 
75.  Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger 
M, Zeller L, Danon A. 2004. Prior statin therapy is associated with a 
decreased rate of severe sepsis. Circulation 110:880–885. 
76.  Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P, Maltezos E. 
2011. Statins in prevention and treatment of severe sepsis and septic shock. 
Eur. J. Intern. Med. 22:125–133. 
77.  Liappis AP, Kan VL, Rochester CG, Simon GL. 2001. The effect of statins 
on mortality in patients with bacteremia. Clin. Infect. Dis. 33:1352–1357. 
78.  Nseir W, Mograbi J, Khateeb J, Abu-Elheja O, Bishara J, Jihad B, Assy 
N. 2012. The impact of prior long-term versus short-term statin use on the 
mortality of bacteraemic patients. Infection 40:41–48. 
79.  Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. 2007. Statins and 
the risk of pneumonia: a population-based, nested case-control study. 
Pharmacotherapy 27:325–332. 
80.  Mortensen EM, Restrepo MI, Anzueto A, Pugh J. 2005. The effect of prior 
statin use on 30-day mortality for patients hospitalized with community-
acquired pneumonia. Respir. Res. 6:doi:10.1186/1465–9921–6–82. 
81.  Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein 
JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard 
66 
 
BG, Shepherd J, Willerson JT, Glynn RJ. 2008. Rosuvastatin to prevent 
vascular events in men and women with elevated C-reactive protein. N. Engl. 
J. Med. 359:2195–2207. 
82.  Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. 
2012. The effect of rosuvastatin on incident pneumonia: results from the 
JUPITER trial. CMAJ 184:E367–372. 
83.  Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. 2006. 
Statins and outcomes in patients admitted to hospital with community 
acquired pneumonia: population based prospective cohort study. BMJ 
333:999. 
84.  WHO | Disease and injury regional estimates, 2004-2008. 
85.  Andersen DH. 1938. Cystic fibrosis of the pancreas and its relation to celiac 
disease. A clincial and pathologic study. Arch. Pediatr. Adolesc. Med. 
56:344–399. 
86.  Bobadilla JL, Macek M, Fine JP, Farrell PM. 2002. Cystic fibrosis: a 
worldwide analysis of CFTR mutations--correlation with incidence data and 
application to screening. Hum. Mutat. 19:575–606. 
87.  Farrell P, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. 2007. 
Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and 
costs. Ir. Med. J. 100:557–560. 
88.  Farrell PM. 2008. The prevalence of cystic fibrosis in the European Union. J. 
Cyst. Fibros. 7:450–453. 
89.  Buchanan PJ, Ernst RK, Elborn JS, Schock B. 2009. Role of CFTR, 
Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung 
inflammation. Biochem. Soc. Trans. 37:863–867. 
90.  Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, 
Chakravarti A, Buchwald M, Tsui LC. 1989. Identification of the cystic 
fibrosis gene: genetic analysis. Science 245:1073–1080. 
91.  Ward CL, Omura S, Kopito RR. 1995. Degradation of CFTR by the 
ubiquitin-proteasome pathway. Cell 83:121–127. 
92.  Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui LC, 
Antonarakis SE, Kazazian HH. 1990. A cluster of cystic fibrosis mutations 
in the first nucleotide-binding fold of the cystic fibrosis conductance regulator 
protein. Nature 346:366–369. 
93.  Cashman SM, Patino A, Delgado MG, Byrne L, Denham B, De Arce M. 
1995. The Irish cystic fibrosis database. J. Med. Genet. 32:972–975. 
67 
 
94.  Lynch S V, Bruce KD. 2013. The cystic fibrosis airway microbiome. Cold 
Spring Harb. Perspect. Med. 3:a009738. 
95.  Saiman L. 2004. Microbiology of early CF lung disease. Paediatr. Respir. 
Rev. 5 Suppl A:S367–369. 
96.  Lipuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. 
Clin. Microbiol. Rev. 23:299–323. 
97.  Souza HA, Nogueira KS, Matos AP, Vieira RP, Riedi CA, Rosário NA, 
Telles FQ, Costa LMD. 2006. Early microbial colonization of cystic fibrosis 
patients identified by neonatal screening, with emphasis on Staphylococcus 
aureus. J. Pediatr. (Rio. J). 82:377–382. 
98.  Millar FA, Simmonds NJ, Hodson ME. 2009. Trends in pathogens 
colonising the respiratory tract of adult patients with cystic fibrosis, 1985-
2005. J. Cyst. Fibros. 8:386–391. 
99.  Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, 
Housman ML, Moore JH, Guill MF, Morrison HG, Sogin ML, Hampton 
TH, Karagas MR, Palumbo PE, Foster JA, Hibberd PL, O’Toole GA. 
2012. Serial analysis of the gut and respiratory microbiome in cystic fibrosis 
in infancy: interaction between intestinal and respiratory tracts and impact of 
nutritional exposures. MBio 3:e00251–12. 
100.  Del Campo R, Morosini M-I, de la Pedrosa EG-G, Fenoll A, Muñoz-
Almagro C, Máiz L, Baquero F, Cantón R. 2005. Population structure, 
antimicrobial resistance, and mutation frequencies of Streptococcus 
pneumoniae isolates from cystic fibrosis patients. J. Clin. Microbiol. 43:2207–
2214. 
101.  Lahiri T, Waltz DA. 2001. Preimmunization anti-pneumococcal antibody 
levels are protective in a majority of patients with cystic fibrosis. Pediatrics 
108:E62. 
102.  Pier GB. 2012. The challenges and promises of new therapies for cystic 
fibrosis. J. Exp. Med. 209:1235–1239. 
103.  Lipuma JJ. 2005. Update on the Burkholderia cepacia complex. Curr. Opin. 
Pulm. Med. 11:528–533. 
104.  Vandamme P, Dawyndt P. 2011. Classification and identification of the 
Burkholderia cepacia complex: Past, present and future. Syst. Appl. 
Microbiol. 34:87–95. 
105.  Gautam V, Singhal L, Ray P. 2011. Burkholderia cepacia complex: beyond 
pseudomonas and acinetobacter. Indian J. Med. Microbiol. 29:4–12. 
68 
 
106.  Drevinek P, Mahenthiralingam E. 2010. Burkholderia cenocepacia in cystic 
fibrosis: epidemiology and molecular mechanisms of virulence. Clin. 
Microbiol. Infect. 16:8218–8230. 
107.  Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari 
C, Kaess H, Deterding RR, Accurso FJ, Pace NR. 2007. Molecular 
identification of bacteria in bronchoalveolar lavage fluid from children with 
cystic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 104:20529–20533. 
108.  Sibley CD, Grinwis ME, Field TR, Eshaghurshan CS, Faria MM, Dowd 
SE, Parkins MD, Rabin HR, Surette MG. 2011. Culture enriched molecular 
profiling of the cystic fibrosis airway microbiome. PLoS One 6:e22702. 
109.  Coenye T, Liu L, Vandamme P, LiPuma JJ. 2001. Identification of 
Pandoraea species by 16S ribosomal DNA-based PCR assays. J. Clin. 
Microbiol. 39:4452–4455. 
110.  Salipante SJ, Sengupta DJ, Rosenthal C, Costa G, Spangler J, Sims EH, 
Jacobs MA, Miller SI, Hoogestraat DR, Cookson BT, McCoy C, Matsen 
FA, Shendure J, Lee CC, Harkins TT, Hoffman NG. 2013. Rapid 16S 
rRNA next-generation sequencing of polymicrobial clinical samples for 
diagnosis of complex bacterial infections. PLoS One 8:e65226. 
111.  Winsor GL, Lam DKW, Fleming L, Lo R, Whiteside MD, Yu NY, 
Hancock REW, Brinkman FSL. 2011. Pseudomonas Genome Database: 
improved comparative analysis and population genomics capability for 
Pseudomonas genomes. Nucleic Acids Res. 39:D596–600. 
112.  Balasubramanian D, Schneper L, Kumari H, Mathee K. 2013. A dynamic 
and intricate regulatory network determines Pseudomonas aeruginosa 
virulence. Nucleic Acids Res. 41:1–20. 
113.  Hauser AR. 2009. The type III secretion system of Pseudomonas aeruginosa: 
infection by injection. Nat. Rev. Microbiol. 7:654–665. 
114.  Lee VT, Smith RS, Tümmler B, Lory S. 2005. Activities of Pseudomonas 
aeruginosa effectors secreted by the Type III secretion system in vitro and 
during infection. Infect. Immun. 73:1695–1705. 
115.  Goehring UM, Schmidt G, Pederson KJ, Aktories K, Barbieri JT. 1999. 
The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a 
GTPase-activating protein for Rho GTPases. J. Biol. Chem. 274:36369–
36372. 
116.  Iglewski BH, Sadoff J, Bjorn MJ, Maxwell ES. 1978. Pseudomonas 
aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct 
from toxin A. Proc. Natl. Acad. Sci. U. S. A. 75:3211–3215. 
69 
 
117.  Krall R, Schmidt G, Aktories K, Barbieri JT. 2000. Pseudomonas 
aeruginosa ExoT is a Rho GTPase-activating protein. Infect. Immun. 
68:6066–6068. 
118.  Garrity-Ryan L, Kazmierczak B, Kowal R, Comolli J, Hauser A, Engel 
JN. 2000. The arginine finger domain of ExoT contributes to actin 
cytoskeleton disruption and inhibition of internalization of Pseudomonas 
aeruginosa by epithelial cells and macrophages. Infect. Immun. 68:7100–
7113. 
119.  Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, 
Finck-Barbancon V, Buchaklian A, Lei M, Long RM, Wiener-Kronish J, 
Sawa T. 2003. The mechanism of action of the Pseudomonas aeruginosa-
encoded type III cytotoxin, ExoU. EMBO J. 22:2959–2969. 
120.  Yahr TL, Vallis AJ, Hancock MK, Barbieri JT, Frank DW. 1998. ExoY, 
an adenylate cyclase secreted by the Pseudomonas aeruginosa type III 
system. Proc. Natl. Acad. Sci. U. S. A. 95:13899–13904. 
121.  Finck-Barbançon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, 
Fleiszig SM, Wu C, Mende-Mueller L, Frank DW. 1997. ExoU expression 
by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial 
injury. Mol. Microbiol. 25:547–557. 
122.  Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A. 1997. Intracellular 
targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent 
translocation induces phagocytosis resistance, cytotoxicity and disruption of 
actin microfilaments. Mol. Microbiol. 25:1125–1139. 
123.  Sundin C, Henriksson ML, Hallberg B, Forsberg A, Frithz-Lindsten E. 
2001. Exoenzyme T of Pseudomonas aeruginosa elicits cytotoxicity without 
interfering with Ras signal transduction. Cell. Microbiol. 3:237–246. 
124.  Vallis AJ, Finck-Barbançon V, Yahr TL, Frank DW. 1999. Biological 
effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells. 
Infect. Immun. 67:2040–2044. 
125.  Diaz MR, King JM, Yahr TL. 2011. Intrinsic and Extrinsic Regulation of 
Type III Secretion Gene Expression in Pseudomonas aeruginosa. Front. 
Microbiol. 2:doi: 10.3389/fmicb.2011.00089. 
126.  Yahr TL, Wolfgang MC. 2006. Transcriptional regulation of the 
Pseudomonas aeruginosa type III secretion system. Mol. Microbiol. 62:631–
640. 
127.  Mulcahy H, O’Callaghan J, O’Grady EP, Adams C, O’Gara F. 2006. The 
posttranscriptional regulator RsmA plays a role in the interaction between 
Pseudomonas aeruginosa and human airway epithelial cells by positively 
regulating the type III secretion system. Infect. Immun. 74:3012–3015. 
70 
 
128.  Burrowes E, Baysse C, Adams C, O’Gara F. 2006. Influence of the 
regulatory protein RsmA on cellular functions in Pseudomonas aeruginosa 
PAO1, as revealed by transcriptome analysis. Microbiology 152:405–418. 
129.  Burrowes E, Abbas A, O’Neill A, Adams C, O’Gara F. 2005. 
Characterisation of the regulatory RNA RsmB from Pseudomonas aeruginosa 
PAO1. Res. Microbiol. 156:7–16. 
130.  Heurlier K, Williams F, Heeb S, Dormond C, Pessi G, Singer D, Camara 
M, Williams P, Haas D. 2004. Positive control of swarming, rhamnolipid 
synthesis, and lipase production by the posttranscriptional RsmA/RsmZ 
system in Pseudomonas aeruginosa PAO1. J. Bacteriol. 186:2936–2945. 
131.  Kay E, Humair B, Dénervaud V, Riedel K, Spahr S, Eberl L, Valverde C, 
Haas D. 2006. Two GacA-dependent small RNAs modulate the quorum-
sensing response in Pseudomonas aeruginosa. J. Bacteriol. 188:6026–6033. 
132.  Pessi G, Williams F, Hindle Z, Heurlier K, Holden MT, Cámara M, Haas 
D, Williams P. 2001. The global posttranscriptional regulator RsmA 
modulates production of virulence determinants and N-acylhomoserine 
lactones in Pseudomonas aeruginosa. J. Bacteriol. 183:6676–6683. 
133.  Brencic A, McFarland KA, McManus HR, Castang S, Mogno I, Dove SL, 
Lory S. 2009. The GacS/GacA signal transduction system of Pseudomonas 
aeruginosa acts exclusively through its control over the transcription of the 
RsmY and RsmZ regulatory small RNAs. Mol. Microbiol. 73:434–445. 
134.  Chancey ST, Wood DW, Pierson, L. S. I. 1999. Two-Component 
Transcriptional Regulation of N-Acyl-Homoserine Lactone Production in 
Pseudomonas aureofaciens. Appl. Envir. Microbiol. 65:2294–2299. 
135.  Records AR, Gross DC. 2010. Sensor kinases RetS and LadS regulate 
Pseudomonas syringae type VI secretion and virulence factors. J. Bacteriol. 
192:3584–3596. 
136.  Moscoso JA, Mikkelsen H, Heeb S, Williams P, Filloux A. 2011. The 
Pseudomonas aeruginosa sensor RetS switches type III and type VI secretion 
via c-di-GMP signalling. Environ. Microbiol. 13:3128–3138. 
137.  Intile PJ, Diaz MR, Urbanowski ML, Wolfgang MC, Yahr TL. 2014. The 
AlgZR Two-Component System Recalibrates the RsmAYZ 
Posttranscriptional Regulatory System To Inhibit Expression of the 
Pseudomonas aeruginosa Type III Secretion System. J. Bacteriol. 196:357–
366. 
138.  Kang Y, Lunin V V, Skarina T, Savchenko A, Schurr MJ, Hoang TT. 
2009. The long-chain fatty acid sensor, PsrA, modulates the expression of 
rpoS and the type III secretion exsCEBA operon in Pseudomonas aeruginosa. 
Mol. Microbiol. 73:120–136. 
71 
 
139.  O’Callaghan J, Reen FJ, Adams C, Casey PG, Gahan CGM, O’Gara F. 
2012. A novel host-responsive sensor mediates virulence and type III 
secretion during Pseudomonas aeruginosa-host cell interactions. 
Microbiology 158:1057–1070. 
140.  O’Callaghan J, Reen FJ, Adams C, O’Gara F. 2011. Low oxygen induces 
the type III secretion system in Pseudomonas aeruginosa via modulation of 
the small RNAs rsmZ and rsmY. Microbiology 157:3417–3428. 
141.  Gambello MJ, Iglewski BH. 1991. Cloning and characterization of the 
Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase 
expression. J. Bacteriol. 173:3000–3009. 
142.  Passador L, Cook J, Gambello M, Rust L, Iglewski B. 1993. Expression of 
Pseudomonas aeruginosa virulence genes requires cell-to-cell 
communication. Science 260:1127–1130. 
143.  Pearson JP, Gray KM, Passador L, Tucker KD, Eberhard A, Iglewski 
BH, Greenberg EP. 1994. Structure of the autoinducer required for 
expression of Pseudomonas aeruginosa virulence genes. Proc. Natl. Acad. 
Sci. U. S. A. 91:197–201. 
144.  Ochsner UA, Reiser J. 1995. Autoinducer-mediated regulation of 
rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. Proc. Natl. 
Acad. Sci. U. S. A. 92:6424–6428. 
145.  Ochsner UA, Koch AK, Fiechter A, Reiser J. 1994. Isolation and 
characterization of a regulatory gene affecting rhamnolipid biosurfactant 
synthesis in Pseudomonas aeruginosa. J. Bacteriol. 176:2044–2054. 
146.  Pearson JP, Passador L, Iglewski BH, Greenberg EP. 1995. A second N-
acylhomoserine lactone signal produced by Pseudomons aeruginosa. Proc. 
Natl. Acad. Sci. U. S. A. 92:1490–1494. 
147.  Déziel E, Lépine F, Milot S, He J, Mindrinos MN, Tompkins RG, Rahme 
LG. 2004. Analysis of Pseudomonas aeruginosa 4-hydroxy-2-alkylquinolines 
(HAQs) reveals a role for 4-hydroxy-2-heptylquinoline in cell-to-cell 
communication. Proc. Natl. Acad. Sci. U. S. A. 101:1339–1344. 
148.  Gallagher LA, McKnight SL, Kuznetsova MS, Pesci EC, Manoil C. 2002. 
Functions Required for Extracellular Quinolone Signaling by Pseudomonas 
aeruginosa. J. Bacteriol. 184:6472–6480. 
149.  McKnight SL, Iglewski BH, Pesci EC. 2000. The Pseudomonas quinolone 
signal regulates rhl quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 
182:2702–2708. 
150.  Wade DS, Calfee MW, Rocha ER, Ling EA, Engstrom E, Coleman JP, 
Pesci EC. 2005. Regulation of Pseudomonas quinolone signal synthesis in 
Pseudomonas aeruginosa. J. Bacteriol. 187:4372–4380. 
72 
 
151.  Chugani SA, Whiteley M, Lee KM, D’Argenio D, Manoil C, Greenberg 
EP. 2001. QscR, a modulator of quorum-sensing signal synthesis and 
virulence in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 
98:2752–2757. 
152.  Oinuma K-I, Greenberg EP. 2011. Acyl-homoserine lactone binding to and 
stability of the orphan Pseudomonas aeruginosa quorum-sensing signal 
receptor QscR. J. Bacteriol. 193:421–428. 
153.  Mattmann ME, Blackwell HE. 2010. Small molecules that modulate 
quorum sensing and control virulence in Pseudomonas aeruginosa. J. Org. 
Chem. 75:6737–6746. 
154.  Juhas M, Eberl L, Tümmler B. 2005. Quorum sensing: the power of 
cooperation in the world of Pseudomonas. Environ. Microbiol. 7:459–471. 
155.  Shrout JD, Tolker-Nielsen T, Givskov M, Parsek MR. 2011. The 
contribution of cell-cell signaling and motility to bacterial biofilm formation. 
MRS Bull. 36:367–373. 
156.  Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. 2002. 
Pseudomonas aeruginosa displays multiple phenotypes during development 
as a biofilm. J. Bacteriol. 184:1140–1154. 
157.  Li Y-H, Tian X. 2012. Quorum sensing and bacterial social interactions in 
biofilms. Sensors (Basel). 12:2519–2538. 
158.  Sriramulu DD, Lunsdorf H, Lam JS, Romling U. 2005. Microcolony 
formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic 
fibrosis lung. J. Med. Microbiol. 54:667–676. 
159.  Nakamura S, Higashiyama Y, Izumikawa K, Seki M, Kakeya H, 
Yamamoto Y, Yanagihara K, Miyazaki Y, Mizuta Y, Kohno S. 2008. The 
roles of the quorum-sensing system in the release of extracellular DNA, 
lipopolysaccharide, and membrane vesicles from Pseudomonas aeruginosa. 
Jpn. J. Infect. Dis. 61:375–378. 
160.  Bleves S, Soscia C, Nogueira-Orlandi P, Lazdunski A, Filloux A. 2005. 
Quorum sensing negatively controls type III secretion regulon expression in 
Pseudomonas aeruginosa PAO1. J. Bacteriol. 187:3898–3902. 
161.  Singh G, Wu B, Baek MS, Camargo A, Nguyen A, Slusher NA, 
Srinivasan R, Wiener-Kronish JP, Lynch S V. 2010. Secretion of 
Pseudomonas aeruginosa type III cytotoxins is dependent on Pseudomonas 
quinolone signal concentration. Microb. Pathog. 49:196–203. 
162.  Tashiro Y, Yawata Y, Toyofuku M, Uchiyama H, Nomura N. 2013. 
Interspecies interaction between Pseudomonas aeruginosa and other 
microorganisms. Microbes Environ. 28:13–24. 
73 
 
163.  Guo Q, Kong W, Jin S, Chen L, Xu Y, Duan K. 2013. PqsR-dependent and 
PqsR-independent regulation of motility and biofilm formation by PQS in 
Pseudomonas aeruginosa PAO1. J. Basic Microbiol. doi: 
10.1002/jobm.201300091. 
164.  Nakagami G, Morohoshi T, Ikeda T, Ohta Y, Sagara H, Huang L, Nagase 
T, Sugama J, Sanada H. 2011. Contribution of quorum sensing to the 
virulence of Pseudomonas aeruginosa in pressure ulcer infection in rats. 
Wound Repair Regen. 19:214–222. 
165.  Reis RS, Pereira AG, Neves BC, Freire DMG. 2011. Gene regulation of 
rhamnolipid production in Pseudomonas aeruginosa - a review. Bioresour. 
Technol. 102:6377–6384. 
166.  Boyer M, Wisniewski-Dyé F. 2009. Cell-cell signalling in bacteria: not 
simply a matter of quorum. FEMS Microbiol. Ecol. 70:1–19. 
167.  Huang JJ, Han J-I, Zhang L-H, Leadbetter JR. 2003. Utilization of acyl-
homoserine lactone quorum signals for growth by a soil pseudomonad and 
Pseudomonas aeruginosa PAO1. Appl. Environ. Microbiol. 69:5941–5949. 
168.  Sio CF, Otten LG, Cool RH, Diggle SP, Braun PG, Bos R, Daykin M, 
Cámara M, Williams P, Quax WJ. 2006. Quorum quenching by an N-acyl-
homoserine lactone acylase from Pseudomonas aeruginosa PAO1. Infect. 
Immun. 74:1673–1682. 
169.  Hong K-W, Koh C-L, Sam C-K, Yin W-F, Chan K-G. 2012. Quorum 
quenching revisited--from signal decays to signalling confusion. Sensors 
(Basel). 12:4661–4696. 
170.  Schneider WR, Doetsch RN. 1974. Effect of Viscosity on Bacterial Motility. 
J. Bacteriol. 117:696–701. 
171.  Bradley DE. 1980. A function of Pseudomonas aeruginosa PAO polar pili: 
twitching motility. Can. J. Microbiol. 26:146–154. 
172.  Kohler T, Curty LK, Barja F, van Delden C, Pechere JC. 2000. Swarming 
of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and 
requires flagella and pili. J. Bacteriol. 182:5990–5996. 
173.  Yeung ATY, Torfs ECW, Jamshidi F, Bains M, Wiegand I, Hancock 
REW, Overhage J. 2009. Swarming of Pseudomonas aeruginosa is 
controlled by a broad spectrum of transcriptional regulators, including MetR. 
J. Bacteriol. 191:5592–5602. 
174.  Ha D-G, Merritt JH, Hampton TH, Hodgkinson JT, Janecek M, Spring 
DR, Welch M, O’Toole GA. 2011. 2-Heptyl-4-quinolone, a precursor of the 
Pseudomonas quinolone signal molecule, modulates swarming motility in 
Pseudomonas aeruginosa. J. Bacteriol. 193:6770–6780. 
74 
 
175.  Kuchma SL, Ballok AE, Merritt JH, Hammond JH, Lu W, Rabinowitz 
JD, O’Toole GA. 2010. Cyclic-di-GMP-mediated repression of swarming 
motility by Pseudomonas aeruginosa: the pilY1 gene and its impact on 
surface-associated behaviors. J. Bacteriol. 192:2950–2964. 
176.  Bernier SP, Ha D-G, Khan W, Merritt JH, O’Toole G a. 2011. Modulation 
of Pseudomonas aeruginosa surface-associated group behaviors by individual 
amino acids through c-di-GMP signaling. Res. Microbiol. 162:680–688. 
177.  Tremblay J, Déziel E. 2010. Gene expression in Pseudomonas aeruginosa 
swarming motility. BMC Genomics 11:doi: 10.1186/1471–2164–11–587. 
178.  Caiazza NC, Shanks RMQ, Toole GAO. 2005. Rhamnolipids Modulate 
Swarming Motility Patterns of Pseudomonas aeruginosa. J. Bacteriol. 
187:7351–7361. 
179.  Rashid MH, Kornberg A. 2000. Inorganic polyphosphate is needed for 
swimming, swarming, and twitching motilities of Pseudomonas aeruginosa. 
Proc. Natl. Acad. Sci. U. S. A. 97:4885–4890. 
180.  Déziel E, Lépine F, Milot S, Villemur R. 2003. rhlA is required for the 
production of a novel biosurfactant promoting swarming motility in 
Pseudomonas aeruginosa: 3-(3-hydroxyalkanoyloxy) alkanoic acids (HAAs), 
the precursors of rhamnolipids. Microbiology 149:2005–2013. 
181.  Ferrández A, Hawkins AC, Summerfield DT, Harwood CS. 2002. Cluster 
II che genes from Pseudomonas aeruginosa are required for an optimal 
chemotactic response. J. Bacteriol. 184:4374–4383. 
182.  Masduki A, Nakamura J, Ohga T, Umezaki R, Kato J, Ohtake H. 1995. 
Isolation and characterization of chemotaxis mutants and genes of 
Pseudomonas aeruginosa. J. Bacteriol. 177:948–952. 
183.  Doyle TB, Hawkins AC, McCarter LL. 2004. The complex flagellar torque 
generator of Pseudomonas aeruginosa. J. Bacteriol. 186:6341–6350. 
184.  Brandenburg KS, Rodriguez KJ, McAnulty JF, Murphy CJ, Abbott NL, 
Schurr MJ, Czuprynski CJ. 2013. Tryptophan inhibits biofilm formation by 
Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 57:1921–1925. 
185.  O’Toole GA, Kolter R. 1998. Flagellar and twitching motility are necessary 
for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30:295–
304. 
186.  Zolfaghar I, Evans DJ, Fleiszig SMJ. 2003. Twitching motility contributes 
to the role of pili in corneal infection caused by Pseudomonas aeruginosa. 
Infect. Immun. 71:5389–5393. 
75 
 
187.  Whitchurch CB, Alm RA, Mattick JS. 1996. The alginate regulator AlgR 
and an associated sensor FimS are required for twitching motility in 
Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 93:9839–9843. 
188.  Zolfaghar I, Angus AA, Kang PJ, To A, Evans DJ, Fleiszig SMJ. 2005. 
Mutation of retS, encoding a putative hybrid two-component regulatory 
protein in Pseudomonas aeruginosa, attenuates multiple virulence 
mechanisms. Microbes Infect. 7:1305–1316. 
189.  Jain R, Behrens A-J, Kaever V, Kazmierczak BI. 2012. Type IV pilus 
assembly in Pseudomonas aeruginosa over a broad range of cyclic di-GMP 
concentrations. J. Bacteriol. 194:4285–4294. 
190.  Beatson SA, Whitchurch CB, Semmler ABT, Mattick JS. 2002. Quorum 
sensing is not required for twitching motility in Pseudomonas aeruginosa. J. 
Bacteriol. 184:3598–3604. 
191.  Patriquin GM, Banin E, Gilmour C, Tuchman R, Greenberg EP, Poole 
K. 2008. Influence of quorum sensing and iron on twitching motility and 
biofilm formation in Pseudomonas aeruginosa. J. Bacteriol. 190:662–671. 
192.  O’Toole GA, Gibbs KA, Hager PW, Phibbs P V, Kolter R. 2000. The 
global carbon metabolism regulator Crc is a component of a signal 
transduction pathway required for biofilm development by Pseudomonas 
aeruginosa. J. Bacteriol. 182:425–431. 
193.  Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, 
Kühl M, Jensen PØ, Høiby N. 2013. The in vivo biofilm. Trends Microbiol. 
21:466–474. 
194.  Merritt JH, Brothers KM, Kuchma SL, O’Toole GA. 2007. SadC 
reciprocally influences biofilm formation and swarming motility via 
modulation of exopolysaccharide production and flagellar function. J. 
Bacteriol. 189:8154–8164. 
195.  Simm R, Morr M, Kader A, Nimtz M, Römling U. 2004. GGDEF and EAL 
domains inversely regulate cyclic di-GMP levels and transition from sessility 
to motility. Mol. Microbiol. 53:1123–1134. 
196.  Lam J, Chan R, Lam K, Costerton JW. 1980. Production of mucoid 
microcolonies by Pseudomonas aeruginosa within infected lungs in cystic 
fibrosis. Infect. Immun. 28:546–556. 
197.  Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, 
Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, 
Randell S, Boucher RC, Döring G. 2002. Effects of reduced mucus oxygen 
concentration in airway Pseudomonas infections of cystic fibrosis patients. J. 
Clin. Invest. 109:317–325. 
76 
 
198.  Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. 2002. 
Extracellular DNA required for bacterial biofilm formation. Science 
295:1487. 
199.  Fyfe JA, Govan JR. 1980. Alginate synthesis in mucoid Pseudomonas 
aeruginosa: a chromosomal locus involved in control. J. Gen. Microbiol. 
119:443–450. 
200.  Hassett DJ. 1996. Anaerobic production of alginate by Pseudomonas 
aeruginosa: alginate restricts diffusion of oxygen. J. Bacteriol. 178:7322–
7325. 
201.  Ryder C, Byrd M, Wozniak DJ. 2007. Role of polysaccharides in 
Pseudomonas aeruginosa biofilm development. Curr. Opin. Microbiol. 
10:644–648. 
202.  Morici LA, Carterson AJ, Wagner VE, Frisk A, Schurr JR, Höner zu 
Bentrup K, Hassett DJ, Iglewski BH, Sauer K, Schurr MJ. 2007. 
Pseudomonas aeruginosa AlgR represses the Rhl quorum-sensing system in a 
biofilm-specific manner. J. Bacteriol. 189:7752–7764. 
203.  Morgan R, Kohn S, Hwang S, Hassett DJ, Sauer K. 2006. BdlA, a 
Chemotaxis Regulator Essential for Biofilm Dispersion in Pseudomonas 
aeruginosa. J. Bacteriol. 188:7335–7343. 
204.  Mikkelsen H, Hui K, Barraud N, Filloux A. 2013. The pathogenicity island 
encoded PvrSR/RcsCB regulatory network controls biofilm formation and 
dispersal in Pseudomonas aeruginosa PA14. Mol. Microbiol. 89:450–463. 
205.  Mikkelsen H, Ball G, Giraud C, Filloux A. 2009. Expression of 
Pseudomonas aeruginosa CupD fimbrial genes is antagonistically controlled 
by RcsB and the EAL-containing PvrR response regulators. PLoS One 
4:e6018. 
206.  Roy AB, Petrova OE, Sauer K. 2012. The phosphodiesterase DipA 
(PA5017) is essential for Pseudomonas aeruginosa biofilm dispersion. J. 
Bacteriol. 194:2904–2915. 
207.  Amari DT, Marques CNH, Davies DG. 2013. The putative enoyl-coenzyme 
A hydratase DspI is required for production of the Pseudomonas aeruginosa 
biofilm dispersion autoinducer cis-2-decenoic acid. J. Bacteriol. 195:4600–
4610. 
208.  Massion PP, Inoue H, Richman-Eisenstat J, Grunberger D, Jorens PG, 
Housset B, Pittet JF, Wiener-Kronish JP, Nadel JA. 1994. Novel 
Pseudomonas product stimulates interleukin-8 production in airway epithelial 
cells in vitro. J. Clin. Invest. 93:26–32. 
209.  Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. 1992. 
Neutrophil elastase in respiratory epithelial lining fluid of individuals with 
77 
 
cystic fibrosis induces interleukin-8 gene expression in a human bronchial 
epithelial cell line. J. Clin. Invest. 89:1478–1484. 
210.  Becker S, Quay J, Soukup J. 1991. Cytokine (tumor necrosis factor, IL-6, 
and IL-8) production by respiratory syncytial virus-infected human alveolar 
macrophages. J. Immunol. 147:4307–4312. 
211.  Reed KA, Hobert ME, Kolenda CE, Sands KA, Rathman M, O’Connor 
M, Lyons S, Gewirtz AT, Sansonetti PJ, Madara JL. 2002. The Salmonella 
typhimurium flagellar basal body protein FliE is required for flagellin 
production and to induce a proinflammatory response in epithelial cells. J. 
Biol. Chem. 277:13346–13353. 
212.  Carrabino S, Carpani D, Livraghi A, Di Cicco M, Costantini D, Copreni 
E, Colombo C, Conese M. 2006. Dysregulated interleukin-8 secretion and 
NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J. Cyst. 
Fibros. 5:113–119. 
213.  Kim J-S, Okamoto K, Rubin BK. 2006. Pulmonary function is negatively 
correlated with sputum inflammatory markers and cough clearability in 
subjects with cystic fibrosis but not those with chronic bronchitis. Chest 
129:1148–1154. 
214.  Francoeur C, Denis M. 1995. Nitric oxide and interleukin-8 as inflammatory 
components of cystic fibrosis. Inflammation 19:587–598. 
215.  Richman-Eisenstat JB, Jorens PG, Hébert CA, Ueki I, Nadel JA. 1993. 
Interleukin-8: an important chemoattractant in sputum of patients with chronic 
inflammatory airway diseases. Am. J. Physiol. 264:L413–418. 
216.  Schuster A, Haarmann A, Wahn V. 1995. Cytokines in neutrophil-
dominated airway inflammation in patients with cystic fibrosis. Eur. Arch. 
Otorhinolaryngol. 252:S59–S60. 
217.  Greene CM, Carroll TP, Smith SGJ, Taggart CC, Devaney J, Griffin S, 
O’Neill SJ, McElvaney NG. 2005. TLR-induced inflammation in cystic 
fibrosis and non-cystic fibrosis airway epithelial cells. J. Immunol. 174:1638–
1646. 
218.  Muhlebach MS, Stewart PW, Leigh MW, Noah TL. 1999. Quantitation of 
inflammatory responses to bacteria in young cystic fibrosis and control 
patients. Am. J. Respir. Crit. Care Med. 160:186–191. 
219.  Lin T, Maher L, Gomi K. 2003. Selective early production of CCL20, or 
macrophage inflammatory protein 3α, by human mast cells in response to 
Pseudomonas aeruginosa. Infect. Immun. 71:365–373. 
220.  Parker D, Prince A. 2013. Epithelial uptake of flagella initiates 
proinflammatory signaling. PLoS One 8:e59932. 
78 
 
221.  Soboll G, Crane-Godreau MA, Lyimo MA, Wira CR. 2006. Effect of 
oestradiol on PAMP-mediated CCL20/MIP-3 alpha production by mouse 
uterine epithelial cells in culture. Immunology 118:185–194. 
222.  Starner TD, Barker CK, Jia HP, Kang Y, McCray PB. 2003. CCL20 is an 
inducible product of human airway epithelia with innate immune properties. 
Am. J. Respir. Cell Mol. Biol. 29:627–633. 
223.  Scapini P, Laudanna C, Pinardi C, Allavena P, Mantovani A, Sozzani S, 
Cassatella MA. 2001. Neutrophils produce biologically active macrophage 
inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. 
Eur. J. Immunol. 31:1981–1988. 
224.  Power CA, Church DJ, Meyer A, Alouani S, Proudfoot AEI, Clark-Lewis 
I, Sozzani S, Mantovani A, Wells TNC. 1997. Cloning and Characterization 
of a Specific Receptor for the Novel CC Chemokine MIP-3  from Lung 
Dendritic Cells. J. Exp. Med. 186:825–835. 
225.  Dieu M-C, Vanbervliet B, Vicari A, Bridon J-M, Oldham E, Ait-Yahia S, 
Briere F, Zlotnik A, Lebecque S, Caux C. 1998. Selective Recruitment of 
Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in 
Different Anatomic Sites. J. Exp. Med. 188:373–386. 
226.  Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM. 1999. 
CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells 
and determines responsiveness to macrophage inflammatory protein 3 alpha. 
J. Immunol. 162:186–194. 
227.  Hromas R, Gray PW, Chantry D, Godiska R, Krathwohl M, Fife K, Bell 
GI, Takeda J, Aronica S, Gordon M, Cooper S, Broxmeyer HE, Klemsz 
MJ. 1997. Cloning and Characterization of Exodus, a Novel beta -
Chemokine. Blood 89:3315–3322. 
228.  Hausmann M, Bataille F, Spoettl T, Schreiter K, Falk W, Schoelmerich J, 
Herfarth H, Rogler G. 2005. Physiological role of macrophage inflammatory 
protein-3 alpha induction during maturation of intestinal macrophages. J. 
Immunol. 175:1389–1398. 
229.  Alderton WK, Cooper CE, Knowles RG. 2001. Nitric oxide synthases: 
structure, function and inhibition. Biochem. J. 357:593–615. 
230.  Li H, Hu J, Xin W, Zhao B. 2000. Production and interaction of oxygen and 
nitric oxide free radicals in PMA stimulated macrophages during the 
respiratory burst. Redox Rep. 5:353–358. 
231.  Kelley TJ, Drumm ML. 1998. Inducible nitric oxide synthase expression is 




232.  Schneider PB, Kennedy EP. 1967. Sphingomyelinase in normal human 
spleens and in spleens from subjects with Niemann-Pick disease. J. Lipid Res. 
8:202–209. 
233.  Grassme H, Jendrossek V, Riehle A, von Kurthy G, Berger J, Schwarz H, 
Weller M, Kolesnick R, Gulbins E. 2003. Host defense against 
Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 
9:322–330. 
234.  Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De 
Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, 
Schmid KW, Weller M, Tummler B, Lang F, Grassme H, Doring G, 
Gulbins E. 2008. Ceramide accumulation mediates inflammation, cell death 
and infection susceptibility in cystic fibrosis. Nat. Med. 14:382–391. 
235.  Finotti A, Borgatti M, Bezzerri V, Nicolis E, Lampronti I, Dechecchi M, 
Mancini I, Cabrini G, Saviano M, Avitabile C, Romanelli A, Gambari R. 
2012. Effects of decoy molecules targeting NF-kappaB transcription factors in 
Cystic fibrosis IB3-1 cells: recruitment of NF-kappaB to the IL-8 gene 
promoter and transcription of the IL-8 gene. Artif. DNA. PNA XNA 3:97–
296. 
236.  Gambari R, Borgatti M, Lampronti I, Fabbri E, Brognara E, Bianchi N, 
Piccagli L, Yuen MC-W, Kan C-W, Hau DK-P, Fong W-F, Wong W-Y, 
Wong RS-M, Chui C-H. 2012. Corilagin is a potent inhibitor of NF-kappaB 
activity and downregulates TNF-alpha induced expression of IL-8 gene in 
cystic fibrosis IB3-1 cells. Int. Immunopharmacol. 13:308–315. 
237.  Bieker JJ. 2001. Kruppel-like factors: three fingers in many pies. J. Biol. 
Chem. 276:34355–34358. 
238.  Van Vliet J, Crofts LA, Quinlan KGR, Czolij R, Perkins AC, Crossley M. 
2006. Human KLF17 is a new member of the Sp/KLF family of transcription 
factors. Genomics 87:474–482. 
239.  McConnell BB, Yang VW. 2010. Mammalian Krüppel-like factors in health 
and diseases. Physiol. Rev. 90:1337–1381. 
240.  O’Grady EP, Mulcahy H, O’Callaghan J, Adams C, O’Gara F. 2006. 
Pseudomonas aeruginosa infection of airway epithelial cells modulates 
expression of Kruppel-like factors 2 and 6 via RsmA-mediated regulation of 
type III exoenzymes S and Y. Infect. Immun. 74:5893–5902. 
241.  Atkins GB, Jain MK. 2007. Role of Kruppel-like transcription factors in 
endothelial biology. Circ. Res. 100:1686–1695. 
242.  Suzuki T, Aizawa K, Matsumura T, Nagai R. 2005. Vascular implications 




243.  Conkright MD, Wani MA, Lingrel JB. 2001. Lung Kruppel-like factor 
contains an autoinhibitory domain that regulates its transcriptional activation 
by binding WWP1, an E3 ubiquitin ligase. J. Biol. Chem. 276:29299–29306. 
244.  Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, 
Majumder PK, Jain MK. 2006. Kruppel-like factor 2 (KLF2) regulates 
proinflammatory activation of monocytes. Proc. Natl. Acad. Sci. U. S. A. 
103:6653–6658. 
245.  Kumar A, Lin Z, SenBanerjee S, Jain MK. 2005. Tumor necrosis factor 
alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-
kappaB and histone deacetylases. Mol. Cell. Biol. 25:5893–5903. 
246.  SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, 
Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, 
Gimbrone Jr. MA, Garcia-Cardena G, Jain MK. 2004. KLF2 is a novel 
transcriptional regulator of endothelial proinflammatory activation. J. Exp. 
Med. 199:1305–1315. 
247.  Saavedra MT, Patterson AD, West J, Randell SH, Riches DW, Malcolm 
KC, Cool CD, Nick JA, Dinarello CA. 2008. Abrogation of anti-
inflammatory transcription factor LKLF in neutrophil-dominated airways. 
Am. J. Respir. Cell. Mol. Biol. 38:679–688. 
248.  Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan 
DE, Gimbrone MA, Balasubramanian V, García-Cardeña G, Jain MK. 
2005. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. 
Circ. Res. 96:e48–57. 
249.  O’Grady E, Mulcahy H, Adams C, Morrissey JP, O’Gara F. 2007. 
Manipulation of host Kruppel-like factor (KLF) function by exotoxins from 
diverse bacterial pathogens. Nat. Rev. Microbiol. 5:337–341. 
250.  Bohn E, Müller S, Lauber J, Geffers R, Speer N, Spieth C, Krejci J, 
Manncke B, Buer J, Zell A, Autenrieth IB. 2004. Gene expression patterns 
of epithelial cells modulated by pathogenicity factors of Yersinia 
enterocolitica. Cell. Microbiol. 6:129–141. 
251.  Hoffmann R, van Erp K, Trülzsch K, Heesemann J. 2004. Transcriptional 
responses of murine macrophages to infection with Yersinia enterocolitica. 
Cell. Microbiol. 6:377–390. 
252.  Sauvonnet N, Pradet-Balade B, Garcia-Sanz JA, Cornelis GR. 2002. 
Regulation of mRNA expression in macrophages after Yersinia enterocolitica 
infection. Role of different Yop effectors. J. Biol. Chem. 277:25133–25142. 
253.  Moreilhon C, Gras D, Hologne C, Bajolet O, Cottrez F, Magnone V, 
Merten M, Groux H, Puchelle E, Barbry P. 2005. Live Staphylococcus 
aureus and bacterial soluble factors induce different transcriptional responses 
in human airway cells. Physiol. Genomics 20:244–255. 
81 
 
254.  Dach K, Zovko J, Hogardt M, Koch I, van Erp K, Heesemann J, 
Hoffmann R. 2009. Bacterial toxins induce sustained mRNA expression of 
the silencing transcription factor klf2 via inactivation of RhoA and Rhophilin 
1. Infect. Immun. 77:5583–5592. 
255.  Mahabeleshwar GH, Kawanami D, Sharma N, Takami Y, Zhou G, Shi H, 
Nayak L, Jeyaraj D, Grealy R, White M, McManus R, Ryan T, Leahy P, 
Lin Z, Haldar SM, Atkins GB, Wong HR, Lingrel JB, Jain MK. 2011. 
The myeloid transcription factor KLF2 regulates the host response to 
polymicrobial infection and endotoxic shock. Immunity 34:715–728. 
256.  Koritschoner NP, Bocco JL, Panzetta-Dutari GM, Dumur CI, Flury A, 
Patrito LC. 1997. A novel human zinc finger protein that interacts with the 
core promoter element of a TATA box-less gene. J. Biol. Chem. 272:9573–
9580. 
257.  Inuzuka H, Wakao H, Masuho Y, Muramatsu MA, Tojo H, Nanbu-
Wakao R. 1999. cDNA cloning and expression analysis of mouse zf9, a 
Krüppel-like transcription factor gene that is induced by adipogenic hormonal 
stimulation in 3T3-L1 cells. Biochim. Biophys. Acta 1447:199–207. 
258.  Onyango P, Koritschoner NP, Patrito LC, Zenke M, Weith A. 1998. 
Assignment of the gene encoding the core promoter element binding protein 
(COPEB) to human chromosome 10p15 by somatic hybrid analysis and 
fluorescence in situ hybridization. Genomics 48:143–144. 
259.  Ratziu V, Lalazar A, Wong L, Dang Q, Collins C, Shaulian E, Jensen S, 
Friedman SL. 1998. Zf9, a Kruppel-like transcription factor up-regulated in 
vivo during early hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 95:9500–
9505. 
260.  Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, 
Tarocchi M, Friedman SL. 2007. In vivo regulation of p21 by the Kruppel-
like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular 
carcinoma. Oncogene 26:4428–4434. 
261.  Kojima S, Hayashi S, Shimokado K, Suzuki Y, Shimada J, Crippa MP, 
Friedman SL. 2000. Transcriptional activation of urokinase by the Kruppel-
like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial 
cells. Blood 95:1309–1316. 
262.  Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman a C, 
Glucksman MJ, Narla J, Eng FJ, Chan a M, Ferrari a C, Martignetti J a, 
Friedman SL. 2001. KLF6, a candidate tumor suppressor gene mutated in 
prostate cancer. Science 294:2563–2566. 
263.  Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, 
Harpaz N, Goldberg S, Tal-Kremer S. 2004. Kruppel-like factor 6 (KLF6) 




264.  Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, 
Hasegawa Y, Shimokata K, Sekido Y. 2004. Krüppel-like factor 6 is 
frequently down-regulated and induces apoptosis in non-small cell lung 
cancer cells. Cancer Res. 64:3838–3843. 
265.  DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, 
Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller 
RE, Martignetti JA. 2006. Roles of KLF6 and KLF6-SV1 in ovarian cancer 
progression and intraperitoneal dissemination. Clin. Cancer Res. 12:3730–
3739. 
266.  Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato 
F, Meltzer SJ, Sidransky D. 2002. Pharmacologic unmasking of 
epigenetically silenced tumor suppressor genes in esophageal squamous cell 
carcinoma. Cancer Cell 2:485–495. 
267.  Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, Miyazaki 
M, Ochiai T, Saisho H, Yokosuka O. 2006. Methylation status of genes 
upregulated by demethylating agent 5-aza-2’-deoxycytidine in hepatocellular 
carcinoma. Oncology 71:77–85. 
268.  Qi W, Holian J, Tan CY, Kelly DJ, Chen XM, Pollock CA. 2011. The roles 
of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-
gamma in the regulation of macrophage inflammatory protein-3alpha at early 
onset of diabetes. Int. J. Biochem. Cell. Biol. 43:383–392. 
269.  Urtasun R, Cubero FJ, Nieto N. 2012. Oxidative stress modulates KLF6Full 
and its splice variants. Alcohol. Clin. Exp. Res. 36:1851–1862. 
270.  Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH. 
2005. KLF6 is one transcription factor involved in regulating acid ceramidase 
gene expression. Biochim. Biophys. Acta 1732:82–87. 
271.  Warke VG, Nambiar MP, Krishnan S, Tenbrock K, Geller DA, 
Koritschoner NP, Atkins JL, Farber DL, Tsokos GC. 2003. 
Transcriptional activation of the human inducible nitric-oxide synthase 
promoter by Kruppel-like factor 6. J. Biol. Chem. 278:14812–14819. 
272.  Mgbemena V, Segovia JA, Chang T-H, Tsai S-Y, Cole GT, Hung C-Y, 
Bose S. 2012. Transactivation of inducible nitric oxide synthase gene by 
Kruppel-like factor 6 regulates apoptosis during influenza A virus infection. J. 
Immunol. 189:606–615. 
273.  Mgbemena V, Segovia J, Chang T-H, Bose S. 2013. KLF6 and iNOS 
regulates apoptosis during respiratory syncytial virus infection. Cell. 
Immunol. 283:1–7. 
274.  Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, 
Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen 
SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, 
83 
 
Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, 
Thibodeau SN, Friedman SL, Martignetti JA. 2005. A germline DNA 
polymorphism enhances alternative splicing of the KLF6 tumor suppressor 
gene and is associated with increased prostate cancer risk. Cancer Res. 
65:1213–1222. 
275.  Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, 
Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, 
Llovet JM, Friedman SL. 2008. Ras promotes growth by alternative 
splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular 
carcinoma. Gastroenterology 134:1521–1531. 
276.  Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo 
EA, Choudhri A, Narla G. 2009. Targeted reduction of KLF6-SV1 restores 
chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer 
66:292–297. 
277.  Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, 
Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, 
Rubin MA, Martignetti JA. 2008. KLF6-SV1 overexpression accelerates 
human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 
118:2711–2721. 
278.  Rodriguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA. 
2010. Nucleo-cytoplasmic localization domains regulate Kruppel-like factor 6 
(KLF6) protein stability and tumor suppressor function. PLoS One 5:e12639. 
279.  Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, 
Martignetti JA. 2009. KLF6-SV1 is a novel antiapoptotic protein that targets 
the BH3-only protein NOXA for degradation and whose inhibition extends 
survival in an ovarian cancer model. Cancer Res. 69:4733–4741. 
280.  Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, 
Hannivoort R, Narla G, M Llovet J, Thung SN, Friedman SL. 2012. 
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular 
carcinoma by coordinate KLF6 depletion and increased messenger RNA 
splicing. Hepatology 56:1361–1370. 
281.  Hanoun N, Bureau C, Diab T, Gayet O, Dusetti N, Selves J, Vinel JP, 
Buscail L, Cordelier P, Torrisani J. 2010. The SV2 variant of KLF6 is 
down-regulated in hepatocellular carcinoma and displays anti-proliferative 
and pro-apoptotic functions. J. Hepatol. 53:880–888. 
282.  Bryan A, Watters C, Koenig L, Youn E, Olmos A, Li G, Williams SC, 
Rumbaugh KP. 2010. Human transcriptome analysis reveals a potential role 
for active transport in the metabolism of Pseudomonas aeruginosa 
autoinducers. Microbes Infect. 12:1042–1050. 
84 
 
283.  Huang F, Yamaguchi A, Tsuchiya N, Ikawa T, Tamura N, Virtala MM, 
Granfors K, Yasaei P, Yu DT. 1997. Induction of alternative splicing of 
HLA-B27 by bacterial invasion. Arthritis Rheum. 40:694–703. 
284.  Robinson RT, Khader SA, Martino CA, Fountain JJ, Teixeira-Coelho M, 
Pearl JE, Smiley ST, Winslow GM, Woodland DL, Walter MJ, Conejo-
Garcia JR, Gubler U, Cooper AM. 2010. Mycobacterium tuberculosis 
infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform 
that enhances DC migration. J. Exp. Med. 207:591–605. 
285.  DiFeo A, Martignetti JA, Narla G. 2009. The role of KLF6 and its splice 











The mevalonate pathway is a metabolic pathway which feeds into cholesterol 
biosynthesis in mammals. This pathway is inhibited by a class of drug called statins, 
which bind to a rate-limiting enzyme within the pathway, 3-hydroxy-3-
methylglutaryl-CoenzymeA reductase (HMGR). Statins have also been found to 
have pleiotropic effects, including the inhibition of bacterial growth and improved 
survival of patients with pneumonia and sepsis. Based on this information, the 
prevalence of HMGR in respiratory bacterial pathogens was examined. Three cystic 
fibrosis-associated pathogens – Staphylococcus aureus, Streptococcus pneumoniae 
and Burkholderia cenocepacia – were found to possess HMGR homologues, but 
interestingly B. cenocepacia did not possess a mevalonate pathway. Bioinformatic 
analysis suggested that the HMGR of B. cenocepacia may have an alternative 
metabolic role. The impact of simvastatin on the growth and virulence of the selected 
species was subsequently examined. Simvastatin reduced the growth of all 3 species 
in a dose dependent manner. In addition, statin treatment inhibited the spreading 
motility of S. aureus, and the biofilm formation of all 3 species. Furthermore, 
simvastatin also potentiated the effect of the aminoglycoside antibiotic gentamicin 





Statins are a class of pharmaceuticals that reduces cholesterol biosynthesis, by 
inhibiting the rate-limiting 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) 
enzyme in the human mevalonate pathway, of which cholesterol is one of the 
synthetic end products (1). This inhibitory effect occurs via the competitive binding 
of statins to the active site of HMGR, blocking the binding of its substrate 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) (1). In addition to this inhibitory effect, 
statins have also been found to have a number of cholesterol-independent, 
pleiotropic effects. Two key pleiotropic effects are reduction of inflammation 
(reviewed in (2)), and inhibition of microbial growth. With regard to the latter 
phenomenon, over the course of the past decade statins have increasingly been found 
to reduce the in vitro growth of bacterial pathogens. The affected species include 
both Gram positive organisms such as Staphylococcus aureus (3), and Streptococcus 
pneumoniae (4), and the Gram negative bacteria Escherichia coli (5), Pseudomonas 
aeruginosa (5) and Moraxella catarrhalis (4). Statins may also influence bacterial 
virulence in infections. Shibata and colleagues demonstrated that simvastatin 
treatment can reduce the translocation of Pseudomonas aeruginosa across epithelial 
cell monolayers (6) and statins have also been found to attenuate the adhesion of 
Streptococcus pneumoniae to lung cells in an in vivo infection model (7). In addition, 
without influencing toxin production, statins can  reduce the cytotoxicity of Bacillus 
anthracis lethal toxin and the inflammatory effects of S. aureus toxins against host 
cells (8, 9). Furthermore, epidemiological data suggest that patients with prior statin 
treatment are less likely to develop conditions such as sepsis (10) and pneumonia 
(11, 12) compared to un-treated patients, and are also more likely to survive these 
conditions (11, 13). 
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Due to their anti-inflammatory and anti-microbial effects, it has been proposed that 
statins may have beneficial effects for patients with the recessive genetic disorder 
cystic fibrosis (CF). This disease is caused by a mutation that renders the CFTR Cl
-
 
transporter protein non-functional (14) and is characterised by impaired lung 
function as a result of viscous mucous production, leading to chronic inflammation 
and infection with opportunistic pathogens. Statins have previously been found to 
reduce both basal and LPS-induced production of the pro-inflammatory cytokine 
Interleukin 8 (IL-8) in blood cells from CF patients (15). Furthermore, Chen et al. 
demonstrated that statins can reduce mucin production and pro-inflammatory 
cytokine production in an in vivo airway model (16). The potential advantages of 
statin treatment for CF patients are so promising that in 2010, researchers at the 
University of British Columbia proposed plans for a randomised clinical trial to test 
the efficacy of statin treatment of CF patients (17), although this trial was later 
withdrawn due to lack of funding. 
To date, the mechanisms by which statins inhibit bacterial growth are not yet clear, 
although it was proposed by Wilding and colleagues that the HMGR of S. aureus 
(MvaA) is essential for the growth of this organism, thus implying that statins may 
inhibit bacterial growth due to their interaction with this enzyme (18). HMGR 
enzymes are common in mammalian species, and are present in mice, dogs and 
primates amongst other species; these are termed Class I HMGR. However, there is 
also a second category of HMGR enzymes which is present only in prokaryotic 
species, termed Class II HMGR. The first Class II HMGR to be identified was that 
of the environmental bacterium Pseudomonas mevalonii (19), and homologues of 
this enzyme were subsequently identified in Staphylococcus aureus (18), 
Streptococcus pneumoniae (20) and Enterococcus faecalis (21). The distinction of 
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Class I and Class II HMGR was proposed by Bochar et al., based on protein 
sequence dissimilarities between eukaryotic HMGR and prokaryotic HMGR (22), 
and this distinction is also based upon the coenzyme specificity (either NADH, 
NAD(P)H or NADPH) required for the reaction to occur (reviewed in (23)). 
Although statins are classically seen as inhibitors of Class I HMGR, they have also 
been found to inhibit the activity of Class II HMGR of Pseudomonas mevalonii (24), 
Enterococcus faecalis (21) and Streptococcus pneumoniae (25), and have a weak 
effect on the HMGR of Listeria monocytogenes (26). Interestingly, statins also 
appear to have an inhibitory effect on bacteria which do not possess HMGR, such as 
E. coli and P. aeruginosa (5). 
In humans and other mammals, the mevalonate pathway is characterised by the 
presence of 5 key enzymes, including HMGR (described in Figure 1), and is 
dependent upon the synthesis of mevalonate, which is then phosphorylated, and 
converted to the isoprenoid intermediate isopentenyl-5-pyrophosphate (IPP). This 
compound is subsequently converted to the important intermediate compounds 
farnesyl-pyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP); these 
compounds are implicated in diverse physiological processes such as proliferation 
and inflammation due to their interaction with Rho GTPase family proteins (27, 28). 
Interestingly, an analogous mevalonate pathway to humans has also been identified 
in S. aureus, including the upstream HMG-CoA synthase, and the downstream 
mevalonate kinase, phosphomevalonate kinase and mevalonate diphosphate 
decarboxylase (29) (Figure 1).  The mevalonate pathway contributes to the synthesis 
of a family of lipid compounds termed isoprenoids (or terpenoids), which, in bacteria 
are involved in the synthesis of peptidoglycan and teichoic acid (30, 31) and electron 
transport (32). In humans, the intermediate compounds isopentenyl-pyrophosphate 
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(IPP), dimethylallyl-pyrophosphate (DMAPP) and the aforementioned FPP and GPP 
are produced as a result of mevalonate-dependent isoprenoid biosynthesis and 
analogues of the enzymes responsible for their production have been described in S. 
aureus isoprenoid biosynthesis (33). However, not all bacteria possess a mevalonate 
pathway, and in these species (and in plants) isoprenoid metabolism is mediated 
through the 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate 
(MEP-DOXP) pathway, which is mevalonate-independent (34, 35) (Figure 2). In this 
pathway, DOXP is synthesised and reduced to MEP, which is eventually converted 
to IPP and utilised in subsequent isoprenoid biosynthesis. 
The objectives of this study were as follows. Firstly, bioinformatic methodology was 
employed to investigate the prevalence of HMGR in respiratory bacteria, and 
examine the conservation and organisation of isoprenoid biosynthesis genes in 3 CF-
associated species – Staphylococcus aureus, Streptococcus pneumoniae and 
Burkholderia cenocepacia. The effect of statins on growth and virulence phenotypes 
of these species was then characterised using in vitro assays. Finally, the potential 





Figure 1: Comparison of the human and bacterial mevalonate pathways. The pathways 
are presented according to reference genomes for Homo sapiens and S. aureus. The core 
mevalonate pathway enzymes are functionally conserved between humans and bacteria. 
However, differences arise at the level of isoprenoid biosynthesis. In humans, 
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geranylgeranyl-pyrophosphate (GGPP) is synthesised as a product of farnesyl-
pyrophosphate (FPP) catabolism, but in bacteria, these intermediate isoprenoid compounds 
can be synthesised by the same protein (geranyltranstransferase). Furthermore, in bacteria, 




Figure 2: The MEP/DOXP (mevalonate-independent) pathway. This pathway is present 
in species which do not possess a mevalonate pathway, including plants and many bacterial 
species. 1-Deoxy-D-xylulose 5-phosphate (DOXP) is synthesised from pyruvate and 
glyceraldehyde-3-phosphate, following which it is reduced to 2-C-methylerythritol 4-
phosphate (MEP). 4-diphosphocytidyl-2-C-methylerythritol (CDP-ME) is synthesised from 
MEP, and is subsequently phosphorylated (MEcPP) and converted to (E)-4-Hydroxy-3-
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methyl-but-2-enyl pyrophosphate (HMB-PP). This compound is then reduced to the 




Materials and methods 
Bacterial strains and growth conditions 
Staphylococcus aureus NCDO949 (Shinfield, U. K.) and Burkholderia cenocepacia 
J2315 (BCCM) were cultured in LB broth (tryptone: 10 g/L, yeast extract: 5 g/L, 
sodium chloride: 5 g/L) at 37 ºC, and Streptococcus pneumoniae TIGR4 (ATCC) 
was cultured in Brain-Heart Infusion (BHI; Sigma-Aldrich, U.K.) at 37 ºC and 5 % 
CO2, unless otherwise stated. Simvastatin (Sigma-Aldrich) was resuspended in 
DMSO at a concentration of 20 mg/ml and stored at 4 ºC. Gentamicin sulphate 
(Sigma-Aldrich) was resuspended in water at 50 mg/ml. Stock solutions of 
gentamicin were stored at – 20 ºC and working solutions were stored at 4 ºC. 
 
Bioinformatic analysis 
Protein sequences of bacterial HMGR were obtained from NCBI Protein Database 
(http://www.ncbi.nlm.nih.gov/protein), and were imported into MEGA 5.2.1 (36). 
Sequences were aligned using ClustalW alignment (37), and the tree-building 
function of MEGA 5.2.1. was utilised to construct a maximum likelihood tree, using 
1000 Bootstrap replications. Mevalonate pathway proteins were defined according to 
those present in the Kyoto Encyclopedia of Genes and Genomics (KEGG) (38) 
pathway entry M00095. Homologues of these proteins were identified in S. 
pneumoniae and B. cenocepacia using the NCBI BLASTP algorithm, with an E-
value cut-off of 1. Genomic organisation of the mevalonate pathway was compared 
using WebACT (39). The Integrated Microbial Genomes (IMG) Database (40), 
Prokaryotic Operon Database (ProOpDB) (41) and Search Tool for the Retrieval of 
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Interacting Genes/Proteins (STRING) Database (42) were all employed in the 
examination of B. cenocepacia HMGR.  
 
Analysis of bacterial growth 
S. aureus and B. cenocepacia were cultured shaking overnight at 37 ºC, following 
which overnight cultures were centrifuged at 3220 x g, and washed twice in 
phosphate-buffered saline (PBS). Pelleted bacteria were then resuspended in 
Mueller-Hinton broth (Oxoid) and the absorbance at 600 nm (OD600nm) was 
measured using a Beckman-Coulter UD530 spectrophotometer. Bacteria were then 
inoculated into a 100 well honeycomb plate (Oy Growth Curves Ab Ltd) at an 
OD600nm of 0.01, containing 200 µL of Mueller-Hinton with either simvastatin (1 
mM, 500 µM, 100 µM, 50 µM, 25 µM, 10 µM and 1 µM) or DMSO (2.09 % (v/v)), 
or medium only. Plates were then incubated for 24 hours at 37 ºC on a Bioscreen-C 
automated growth curve system, and the OD600nm of each well was measured at 15 
minute intervals for 24 hours. Five technical replicates of each condition were 
utilised. 
For S. pneumoniae, bacteria were incubated static in BHI broth at 37 ºC and 5 % 
CO2 overnight. The OD600nm of the overnight culture was measured and bacteria 
were inoculated into a 100 ml conical flask containing 20 ml of BHI supplemented 
with simvastatin (1 mM, 500 µM, 100 µM, 50 µM, 25 µM, 10 µM and 1 µM) or an 
equivalent volume of DMSO (2.09 % (v/v)) at an OD600nm of 0.01. A BHI only flask 
was also prepared in this manner. Bacteria were incubated static at 37 ºC and 5 % 
CO2 for 24 hours, after which bacterial growth was examined by measuring the 
OD600nm of each flask on a Beckman-Coulter UD530 spectrophotometer.  
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Gentamicin potentiation analysis of B. cenocepacia was carried out using 50 µg/ml 
gentamicin and 50 µM simvastatin. This assay was carried out using the Bioscreen-C 
system and medium and growth conditions as described above.  
 
Motility assays  
Swarming motility of B. cenocepacia was analysed using 0.6 % (w/v) Eiken agar (6 
g/L Eiken agar, 8 g/L Eiken broth (both from Eiken Chemical, Japan)), 
supplemented with 0.5 % (w/v) glucose (Sigma-Aldrich). Swimming motility was 
analysed using 0.4 % (w/v) agar, containing 5 g/L peptone, 5 g/L yeast extract and 2 
% (v/v) glycerol. Colony spreading motility of S. aureus was examined using 0.24 % 
(w/v) tryptic soy broth in accordance with the protocol described in (43).  All plates 
were incubated at 37 ºC in an upright position for 24 hours, following which they 
were photographed with an Epson v750 scanner. 
  
Analysis of bacterial attachment 
Bacteria were cultured overnight at 37 ºC. The OD600nm of overnight cultures was 
measured, and bacteria were inoculated into a 24 well plate containing 1 ml LB broth 
(S. aureus and B. cenocepacia) or BHI broth (S. pneumoniae) supplemented with 
simvastatin or DMSO where appropriate, at an OD600nm of 0.1. Plates were incubated 
static at 37 ºC for 8 hours (S. aureus) or 24 hours (B. cenocepacia and S. 
pneumoniae), after which medium was removed. Wells were washed 3 times using 
LB broth or BHI broth as appropriate, and attached bacteria were stained using 
crystal violet (0.1 % w/v) for 15 minutes. Excess dye was removed by washing wells 
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5 times with water, and remaining dye was solubilised using 96 % ethanol for 15 
minutes. 100 µL of solubilised dye was transferred to a 96 well plate, and attachment 
was measured by quantifying the OD570nm using a SpectraMax Plus 384 96 well plate 
reader (Molecular Devices). 
 
Statistical analysis 







Distribution of HMGR in respiratory bacterial and fungal pathogens 
The objective in this study was to test the effects of statins on a selection of CF-
associated bacterial species. In order to identify target organisms for this 
investigation, the prevalence of the rate-limiting mevalonate pathway enzyme 
HMGR in respiratory bacterial and fungal pathogens was analysed. Statins inhibit 
HMGR function, and it was hypothesised that bacteria possessing an analogue of this 
enzyme would be susceptible to statin treatment. The NCBI Protein Database 
(http://www.ncbi.nlm.nih.gov/protein) was mined to determine which respiratory 
bacteria possessed HMGR. Protein sequences were aligned using ClustalW and 
aligned data was used to construct a Neighbour-joining phylogenetic tree (Figure 3). 
The sequence of HMGR from Pseudomonas mevalonii was also inputted into this 
analysis, because the HMGR of this species has been found to be inhibited by statins 
binding to its active site in a manner similar to human HMGR (24), and it was 
therefore hypothesised that bacteria possessing HMGR with closely conserved 
sequences to that of P. mevalonii may be inhibited by statins.  
According to this analysis, the respiratory pathogen with the closest conserved 
HMGR to that of P. mevalonii was that of Burkholderia cenocepacia. Interestingly, 
4 other species of the genus Burkholderia were tested, and these were grouped 
together, but this cluster did not include B. cenocepacia. HMGR was highly 
conserved within this cluster of Burkholderia strains, suggesting that B. cenocepacia 
has a distinctive HMGR sequence and structure compared to other members of its 
genus, and thus it may be more susceptible to statin treatment. The HMGR enzymes 
of staphylococci and streptococci were found to form 2 clusters; however, 
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examination of adjacent nodes suggested that the HMGR of Enterococcus faecalis 
was related to staphylococcal HMGR, while the HMGR of the Gram negative rod 
Leptotrichia buccalis was grouped with streptococcal HMGR. The HMGR of 
Nocardiopsis alba (Gram positive) and Bordetella petrii (Gram negative) were also 
present on another node, thus suggesting that there is no significant sequential 
difference between the HMGR of Gram positive and Gram negative bacteria. Three 
other nodes were noted – fungal species, Legionella species, and Coxiella burnetti 
and Nocardia brasiliensis. The significance of this analysis lies in examining the 
proximity of putative and uncharacterised HMGR to those that are known to be 
functional. For instance, the adjacent locations of the N. alba/B. petrii node and the 
P. mevalonii/B. cenocepacia node suggests that statins may be able to efficiently 





Figure 3: Neighbour-joining phylogenetic tree of HMGR protein sequences from 
bacterial and fungal respiratory pathogens. The HMGR sequences of respiratory 
pathogens were acquired using the NCBI protein database and aligned using a neighbour-
joining algorithm and 1000 Bootstrap replications. The evolutionary distances observed in 
this tree demonstrate that a high level of conservation is generally exhibited amongst 





Phylogenetic analysis also demonstrated the notable absence of HMGR in several 
significant respiratory bacteria, amongst them Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia and Bordetella pertussis. The KEGG Pathway 
Database (http://www.kegg.jp/kegg/pathway.html) was employed to examine 
whether respiratory bacteria favoured mevalonate-dependent or mevalonate-
independent metabolism, yielding some interesting information (Table 1). Firstly, it 
appeared that Gram positive respiratory pathogens mostly possess a mevalonate 
pathway, but Gram negative bacteria tend to favour mevalonate-independent 
isoprenoid metabolism. However, some species which do not possess a mevalonate 
pathway but utilise the MEP/DOXP pathway – B. petrii, B. cenocepacia, and N. alba 
– were also found to possess HMGR. The role of mevalonate in these organisms is 
currently unclear; it has been suggested that the HMGR of Aspergillus fumigatus 
(which possesses a complete mevalonate pathway) is linked to siderophore 
production (44), and it is possible that the “orphan” HMGR of these species could 
play a similar role. Finally, despite the fact that the mevalonate and MEP/DOXP 
pathways generally appeared to be mutually exclusive, Nocardia brasiliensis was 
found to possess homologues of both pathway genes, suggesting that statins may not 




Table 1: Isoprenoid metabolism of respiratory bacterial pathogens. The KEGG database 
was mined to examine the mechanisms of isoprenoid biosynthesis present in respiratory 






Conservation and genomic organisation of the mevalonate pathway in CF-
associated pathogens 
Based on phylogenetic analysis, it appeared that HMGR was present in a number of 
pathogens which cause chronic respiratory infection in individuals with the recessive 
genetic disorder cystic fibrosis (CF). From this subset of CF-associated pathogens, 3 
respiratory bacterial pathogens were chosen for further analysis – Staphylococcus 
aureus, Streptococcus pneumoniae and Burkholderia cenocepacia. All 3 of these 
species are prominent causes of opportunistic and nosocomial infections in cystic 
fibrosis (CF) patients (45–47). It was hypothesised that statins could potentially be 
used as a novel treatment against these bacteria, and the potential impact of statins 
on these micro-organisms was initially examined by exploiting bioinformatic 
methodologies. 
Initially, the sequence conservation of HMGR in the test strains was analysed and 
compared to the sequence of the 428 amino acid (aa) P. mevalonii HMGR. Protein 
sequences of HMGR were obtained from the NCBI protein database 
(http://www.ncbi.nlm.nih.gov/protein), and were aligned using the ClustalW 
algorithm. This analysis demonstrated that there was a high degree of homology 
between the HMGR protein sequences, with 103 aa being present in the same 
predicted locations in all 4 sequences. Class II HMGR are known to have at least 3 
regions which are essential for their catalytic function (48, 49). In P. mevalonii, these 
catalytic domains are present as follows: ENVIG (starting at aa position 52), 
DAMGAN (starting at aa 183) and GLVGG (starting at aa 326). S. aureus HMGR is 
also known to possess these catalytic domains (18), and the sequence conservation of 
HMGR in S. pneumoniae and B. cenocepacia was examined to determine whether 
these essential domains were conserved within these sequences. This analysis 
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revealed that regions with high homology to the 3 conserved catalytic domains of S. 
aureus and P. mevalonii were also present in the HMGRs of S. pneumoniae and B. 
cenocepacia (Figure 4). The sequences of the putative catalytic domains of B. 
cenocepacia HMGR were identical to those of P. mevalonii, and were located in the 
same aa position within the sequences. The 3 putative catalytic domains of S. 
pneumoniae HMGR were altered by at least 1 aa change compared to both S. aureus 
and P. mevalonii. The first domain observed was ENVVG, compared to ENVIA of 
S. aureus and ENVIG of P. mevalonii. The DAMGAN domain present in the other 
test strains was altered to EAMGAN in S. pneumoniae and the third S. pneumoniae 
domain (ATKGG) differed by 2 aa from those identified in S. aureus (AIVGG) and 
P. mevalonii/B. cenocepacia (GLVGG), but was present at the same aa position 
(324) as the third S. aureus domain. As well as the catalytic domains, a high degree 
of homology was observed between the HMGR protein sequences, with 24 % of aa 
(103 aa) being present in the same predicted locations in all 4 sequences. In addition, 
conserved long motifs at positions 81-92 and 255-275, and shorter conserved regions 
were also present towards the C-terminus region of the sequences were also 
identified. Significantly, it was noted that the HMGR of B. cenocepacia had a high 
degree of homology to that of P. mevalonii (72 %), while the HMGR of S. 
pneumoniae had much lower, but approximately equal levels of identity to those of 
S. aureus (43 %) and P. mevalonii (42 %). Given that 42 % sequence identity exists 
between S. aureus and P. mevalonii HMGR, and that statins can inhibit the HMGR 
of both P. mevalonii and S. pneumoniae (24, 25), it was thus proposed that statins 





Figure 4: Conservation of catalytic domains and amino acid residues of bacterial 
HMGR. The HMGR enzymes of P. mevalonii and S. aureus contain 3 conserved domains 
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which are essential for their catalytic activity. These residues are also conserved in the 
HMGR of S. pneumoniae and B. cenocepacia. Key to colours: red = catalytic domains, blue 
= conserved residue in all 4 sequences, yellow = conserved residue in 3 sequences, orange 
and green = conserved residue in 2 sequences. * indicates conserved aa in all 4 sequences.  
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The conservation of mevalonate pathway proteins in the selected species was 
subsequently examined. Several mevalonate pathway and isoprenoid biosynthesis 
genes have previously been characterised in S. aureus and S. pneumoniae (29, 33). 
However, the pathway of B. cenocepacia has not yet been studied, and sequence 
information is not available on the P. mevalonii mevalonate pathway. The NCBI 
BLASTP algorithm was used to identify homologues of S. aureus mevalonate 
pathway proteins from the reference genome NCTC 8325 in S. pneumoniae TIGR4 
and B. cenocepacia J2315. The proteins involved in the mevalonate pathway were 
defined according to those listed in the KEGG Reference pathway M00095 and by 
Balibar et al., (33); in total 8 proteins were analysed including HMGR. The results of 
this analysis are detailed in Table 2. S. pneumoniae was found to possess 
homologues of all 8 S. aureus mevalonate pathway and isoprenoid biosynthesis 
proteins. Examination of B. cenocepacia did not yield any obvious mevalonate 
pathway homologues; however, interestingly, this species was found to possess 
homologues of the isoprenoid biosynthesis proteins geranyltranstransferase and 
undecaprenyl-pyrophosphate synthase. The mevalonate pathway was previously 
found to be absent in B. cenocepacia (Table 1), and it is likely that the B. 
cenocepacia isoprenoid biosynthesis homologues metabolise the products of the 




Table 2: Homology of mevalonate pathway genes in S. pneumoniae and B. cenocepacia. 
The 8 mevalonate pathway genes of S. aureus were tested against the genomes of S. 
pneumoniae and B. cenocepacia using BLASTP, and the top hit for each gene is detailed 




Genomic localisation and organisation of the genes involved in the mevalonate 
pathway in S. aureus, S. pneumoniae and B. cenocepacia were compared using the 
genomic comparison tool WebACT. This analysis (detailed in Figure 5) yielded 
some surprising information, in that the relative genomic organisation of mevalonate 
pathway and isoprenoid biosynthesis genes differed between S. pneumoniae and S. 
aureus, despite their sequential similarities. Mevalonate synthase (mvaS) and HMGR 
(mvaA) were located furthest downstream in both species, but while these genes 
appeared to be present in an operon on the complement strand of the S. pneumoniae 
genome, in S. aureus they did not appear to be co-regulated, and were divergently 
expressed. A striking similarity between both species was that mevalonate kinase 
(mvaK1), phosphomevalonate kinase (mvaK2) and mevalonate diphosphate 
decarboxylase (mvaD) were present in predicted operons on the positive strand in 
both species. However, a key difference was that the S. pneumoniae operon 
contained a fourth gene, isopentenyl-diphosphate isomerase (fni), whereas this gene 
was located upstream of mvaA (by 217288 base pairs (bp)), and was present in the 
opposite orientation to the predicted mvaK operon in S. aureus. A difference was 
also observed in the relative locations of fni and farnesyl-pyrophosphate synthase 
(ipsA) – in S. aureus, fni was present in the same orientation as ipsA with a large 
distance (868753 bp) separating them; however in S. pneumoniae these genes were 
present in opposite orientations (ipsA on the complement strand) 773003 bp apart.  
The final isoprenoid gene studied, undecaprenyl pyrophosphate synthase (uppS) was 
was located 127178 bp upstream of the mvaK1 operon of S. pneumoniae, but was 
located 601974 bp downstream of the S. aureus mvaK1 operon. For B. cenocepacia, 
the 3 homologous proteins identified in Table 2 were present on 2 different 
chromosomes. uppS was located on Chromosome 1, whereas mvaA and ispA were 
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located 410011 bp apart on the positive strand on Chromosome 2. This correlated 
with the S. pneumoniae mvaA and ipsA homologues, which were separated by a 
similar distance (490800 bp). The differences in relative genomic locations of 
mevalonate pathway and isoprenoid biosynthesis genes suggested that the expression 
of these genes was differentially regulated between each species, which in turn 
suggested that each species might have a different susceptibility to any effects 






Figure 5: Genomic organisation of mevalonate pathway genes in S. aureus, S. 
pneumoniae and B. cenocepacia. The mevalonate pathway in S. aureus is composed of 1 
operon and 4 downstream genes which appear to be under their own regulatory systems. S. 
pneumoniae possesses 2 mevalonate pathway operons, and 1 distally-located upstream gene. 
The 3 mevalonate pathway homologues of B. cenocepacia are located in different 




As B. cenocepacia possesses an “orphan” HMGR (without other mevalonate 
pathway genes), further tools were utilised in an attempt to elucidate the function of 
HMGR and mevalonate in this organism. Firstly, the Gene Neighbourhood function 
of the IMG database was used to examine the chromosomal area surrounding the B. 
cenocepacia mvaA gene (BCAM0531) (Figure 6A). BCAM0531 lies in close 
proximity to 2 downstream hypothetical proteins (BCAM0532 and BCAM0533), 
while the upstream adjacent protein (BCAM0530) is a GntR-type regulator. 
BCAM0532 has no predicted products, whereas BCAM0533 has homology to a 
tricarboxylate transporter protein. The ProOpDB tool has predicted that BCAM0531 
is not part of an operon with any of its neighbouring genes.  
The STRING database was utilised to examine putative interaction networks of B. 
cenocepacia mvaA. This analysis yielded a number of potential functional partners of 
BCAM0531, the results of which are detailed in Figure 6B. The top 10 predicted 
partners were identified based on their proximity to BCAM0531 (neighbourhood) 
and textmining (the co-occurrence of protein names in literature). This algorithm 
predicted that BCAM0531 was part of a circuit with its neighbouring genes 
BCAM0530, BCAM0532 and BCAM0533. BCAM0531 was also predicted to be 
part of 2 tripartite regulatory loops. The first of these was with HisB and HisD, 2 
proteins which are involved in the biosynthesis of histidine, while the second 
encompassed PheA (responsible for phenylalanine biosynthesis) and the ribosomal 
protein RplT. Other predicted partners of BCAM0531 were the gluconate reductase 
DkgB, the tRNA synthase BCAL2169, and BCAM1883, of which the function is 
unknown. These putative interactions seem to illustrate a metabolic role for 





Figure 6: Analysis of the B. cenocepacia HMGR BCAM0531. (A) BCAM0531 is present 
on Chromosome 2 of J2315, where it is surrounded by mostly hypothetical or metabolic 
genes. (B) STRING database demonstrated putative interactions of mvaA (BCAM0531) with 
its neighbouring genes BCAM0530, BCAM0532 and BCAM0533, as well as several 
metabolic proteins (notably PheA, HisB, HisD and DkgB).   
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Simvastatin has distinct effects on bacterial growth levels and kinetics 
Based on bioinformatic analysis of the mevalonate pathway in B. cenocepacia, S. 
aureus and S. pneumoniae, it was hypothesised that statins may have differing 
effects on the growth of these species. Therefore, the effect of simvastatin on 
bacterial growth was analysed by culturing bacteria in the presence of varying 
simvastatin concentrations (1 mM, 500 µM, 100 µM, 50 µM, 25 µM, 10 µM and 1 
µM) for 24 hours, and comparing their growth to that of bacteria cultured in the 
presence of an equivalent DMSO vehicle control, and in medium alone. The first 
observation made in this study was that DMSO (2.09 % (v/v)) reduced the growth of 
B. cenocepacia (Figure 7A), S. aureus (Figure 8A) and S. pneumoniae (Figure 9A) 
compared to levels observed in medium alone. After 24 hours of growth, this 
difference was statistically significant for B. cenocepacia (P = 0.015), but a 
significant difference was not detected for S. aureus and S. pneumoniae.  
The growth of B. cenocepacia was inhibited by 1 mM, 500 µM and 100 µM 
simvastatin, but this effect was not bactericidal. 1 mM simvastatin inhibited B. 
cenocepacia growth at 8 hours post inoculation (hpi) and all subsequent timepoints, 
with statistically significant effects exerted at 16 hpi (P = 0.004) and 24 hpi (P 
=0.043) (Figure 7B). Simvastatin was still effective against B. cenocepacia at half of 
this concentration (500 µM), which reduced bacterial growth at 12 hpi and 
subsequent timepoints, and similarly to 1 mM simvastatin, a significant effect was 
exhibited by 500 µM at 16 hpi (P = 0.01) (Figure 7C). 100 µM simvastatin was also 
capable of significantly decreasing B. cenocepacia at 16 hpi (P = 0.03), and also 
caused moderate but not significant decreases in growth at 12, 20 and 24 hpi (Figure 
7D). 50 µM and lower simvastatin concentrations had no statistically significant 
effect on the kinetics of B. cenocepacia growth (Figure 7E-H). 25 µM simvastatin 
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had a slight bacteriostatic effect at 12, 16, 20 and 24 hpi, but this effect was not 
statistically significant and was less reproducible than the effects achieved at higher 
concentrations (Figure 7F). These data demonstrated that high statin concentrations 
were required to achieve significant inhibition of B. cenocepacia growth, and that 
inhibitory concentrations of simvastatin appeared to be most effective against B. 





Figure 7: Effect of simvastatin on growth of B. cenocepacia. (A) Effect of vehicle on 
bacterial growth. Bacteria were cultured in Muller-Hinton only, or were treated with a 
DMSO volume (2.09 % (v/v)) which was equivalent to that of 1 mM simvastatin. (B) to (H) 
Bacteria were cultured in the presence of 1 mM, 500 µM, 100 µM, 50 µM, 25 µM, 10 µM 
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and 1 µM simvastatin and the level of growth achieved at 4 hour intervals was compared to 
that of bacteria treated with the vehicle. Data presented are the average and standard 





Simvastatin also reduced the growth of S. aureus, although the kinetic pattern seen 
here was different to that of B. cenocepacia. 1 mM simvastatin significantly 
inhibited the growth of S. aureus compared to the DMSO control at 4 hpi, (P = 
0.047) and 8 hpi (P = 0.04), and non-significantly reduced growth at 12 hpi, 16 hpi 
and 20 hpi; however, no change was observed at 24 hpi (Figure 8B). An interesting 
trend was observed in the presence of 500 µM simvastatin – at this concentration, 
significant inhibitory effects were observed at 4 hpi (P = 0.016) and 8 hpi (P = 
0.013) and a non-significant reduction was observed at 12 hpi, but no change was 
observed at 16 hpi, and at subsequent intervals statin-treated bacteria actually grew 
to marginally greater – albeit non-significant – levels than vehicle-treated bacteria 
(Figure 8C). The same trend was noted in bacteria cultured with 100 µM simvastatin, 
but in this instance a significant inhibitory effect was observed at 4 hpi only (P = 
0.018) (Figure 8D). These data suggested that simvastatin could inhibit the 
progression of the exponential phase of S. aureus growth in a dose-dependent 
manner.  
Another striking alteration in S. aureus growth kinetics was observed in the presence 
of 50 µM and 25 µM simvastatin. At these concentrations, the growth of S. aureus 
appeared to be enhanced by simvastatin compared to the vehicle (Figure 8E and 8F). 
From 8 hpi onwards, a noticeable and significant increase in growth was observed in 
bacteria treated with 50 µM simvastatin. An increase was also observed with 25 µM 
simvastatin at 12 hpi and subsequent timepoints, but a significant increase was 
present at 12 hpi (P = 0.036) and 16 hpi (P = 0.024) only. Finally, 10 µM and 1 µM 
simvastatin had no significant effect on the kinetics of S. aureus growth (Figure 8G 
and 8H). Taken together, these data demonstrated that, as opposed to having a 
bacteriocidal effect on S. aureus, simvastatin instead appeared to delay the 
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progression of bacterial growth into exponential phase at high concentrations (1 mM, 
500 µM and 100 µM), but certain sub-inhibitory simvastatin concentrations (50 µM 






Figure 8: Effect of simvastatin on growth of S. aureus. (A) Effect of vehicle on bacterial 
growth. Bacteria were cultured in Muller-Hinton only, or were treated with a DMSO volume 
(2.09 % (v/v)) which was equivalent to that of 1 mM simvastatin. (B) to (H) Bacteria were 
cultured in the presence of 1 mM, 500 µM, 100 µM, 50 µM, 25 µM, 10 µM and 1 µM 
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simvastatin and the level of growth achieved at 4 hour intervals was compared to that of 
bacteria treated with the vehicle. Data presented are the average and standard deviation of 3 




The third organism tested in this study was S. pneumoniae. Interestingly, simvastatin 
was found to have a much greater antibacterial effect on this pathogen than on B. 
cenocepacia and S. aureus. In fact, after 24 hours of incubation, simvastatin 
concentrations of 1 mM, 500 µM, 100 µM and 50 µM had a significant bacteriocidal 
effect on the growth of S. pneumoniae (Figure 9B), with p-values of 0.005 (1 mM), 
0.008 (500 µM), 0.004 (100 µM) and 0.0045 (50 µM). 25 µM and 10 µM doses of 
simvastatin also reduced the growth of S. pneumoniae compared to the DMSO 
control, although these effects were not statistically significant. 1 µM simvastatin did 
not affect bacterial growth compared to the vehicle control. The inhibition of 
pneumococcal growth observed in this study was at lower concentrations than have 
been previously reported. 
These data indicated that statins could reduce the growth of all 3 test strains, but 
demonstrated a markedly increased effect on S. pneumoniae compared to B. 
cenocepacia and S. aureus. Furthermore, the statin effects appeared to be 





Figure 9: Effect of simvastatin on growth of S. pneumoniae. Bacteria were cultured for 
24 hours in media alone, in the presence of 1 mM, 500 µM, 100 µM, 50 µM, 25 µM, 10 µM 
and 1 µM simvastatin or an equivalent vehicle control (2.09 % (v/v) DMSO). (A) DMSO 
did not influence the growth of S. pneumoniae. (B) 1 mM, 500 µM, 100 µM, and 50 µM 
simvastatin had a significant bacteriocidal effect on S. pneumoniae compared to the vehicle. 
25 µM and 10 µM were capable of reducing bacterial growth, while 1 µM had no effect. 




Effect of simvastatin on bacterial motility  
It is well-known that certain compounds can influence the behaviour of bacteria at 
sub-inhibitory concentrations. For instance, the induction of quorum sensing by sub-
inhibitory concentrations of the peptide colistin has previously been demonstrated 
(50). Therefore, the effect of simvastatin on the virulence phenotypes of the chosen 
species was investigated, beginning with the examination of motility of B. 
cenocepacia and S. aureus. S. pneumoniae motility was not examined as the strain 
utilised in this study was non-motile. B. cenocepacia displays 2 types of in vitro 
motility; swimming, which is mediated through the polar flagellum of the bacteria 
(51), and swarming, which is linked to several factors including quorum sensing and 
biofilm formation as well as flagellar activity (52). Both of these motility phenotypes 
were tested at the sub-inhibitory simvastatin concentrations of 10 µM and 25 µM. 
Neither type of motility was inhibited by simvastatin compared to the vehicle control 
(Figure 10A). To further elucidate whether statins could affect B. cenocepacia 
motility, assays were also carried out in the presence of 100 µM and 50 µM 
simvastatin. None of these statin concentrations impacted on the motility of B. 
cenocepacia, indisputably demonstrating that simvastatin does not influence this 
phenotype. 
S. aureus, while strictly non-motile in situ, displays an in vitro colony spreading 
motility phenotype which is associated with techoic acid production (43). Colony 
spreading was tested in the presence of 50 µM, 25 µM and 10 µM simvastatin, 
which were all found to be sub-inhibitory during growth analysis. 50 µM simvastatin 
caused a reduction in spreading motility (Figure 10B). However, 25 µM and 10 µM 
simvastatin did not affect motility, demonstrating that its statin-mediated attenuation 




Figure 10: Effect of simvastatin on bacteria motility. B. cenocepacia and S. aureus were 
cultured on soft agar in the presence of inhibitory and sub-inhibitory concentrations of 
simvastatin. (A) Swimming and swarming motility of B. cenocepacia were not affected by 
any concentration of simvastatin. (B) 50 µM simvastatin reduced spreading motility of S. 
aureus; however lower concentrations were not effective. Data are representative of 3 




Simvastatin influences biofilm production of CF-associated bacteria 
Biofilm is another key virulence factor of B. cenocepacia, S. aureus and S. 
pneumoniae, which contributes to bacterial persistence in CF (recently reviewed in 
(53)). The effect of simvastatin on biofilm formation was investigated by examining 
attachment of the 3 test strains in the presence of sub-inhibitory simvastatin 
concentration compared to an appropriate DMSO vehicle control. In order to fully 
realise the anti-bacterial potential of simvastatin, its effect on biofilms was tested in 
accordance with the optimal incubation lengths observed in growth kinetic analysis; 
these data showed that simvastatin exerted its greatest anti-Staphylococcus effect at 
the beginning of log phase, but had a greater impact on B. cenocepacia at late log 
phase, and impacted S. pneumoniae at 24 hours. Therefore, S. aureus biofilm 
formation was tested after 8 hours, while B. cenocepacia and S. pneumoniae biofilms 
were cultured for 24 hours. After these periods of incubation attached bacteria were 
stained using crystal violet, which was resuspended in ethanol in order to quantify 
the magnitude of attachment. 100 µM simvastatin reduced the attachment of B. 
cenocepacia relative to the vehicle, although this effect was not statistically 
significant (P = 0.065) (Figure 11A). 50 µM did not decrease biofilm formation, and 
actually appeared to slightly increase attachment compared to the vehicle, but again 
this effect was not significant. Given that 100 µM simvastatin could also non-
significantly reduce the growth of B. cenocepacia, the reduction in biofilm at this 
concentration may have been a result of the growth inhibitory effect of simvastatin. 
However, the effects observed on S. aureus attachment in the presence of simvastatin 
appeared to occur independently of growth. 100 µM simvastatin (a growth-inhibitory 
concentration) caused an approximate 5-fold decrease in attachment compared to the 
vehicle (P = 0.0077) (Figure 11B). However, 50 µM simvastatin (sub-inhibitory) 
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also had an inhibitory, albeit non-statistically significant, effect on S. aureus biofilm. 
25 µM and 10 µM simvastatin were used in the analysis of S. pneumoniae 
attachment, given that these were the highest statin concentrations which did not 
obliterate bacterial growth. 25 µM simvastatin significantly attenuated the 
attachment of S. pneumoniae (P = 0.001), while 10 µM had a slight inhibitory effect 
(Figure 11C). However, as these concentrations had a bacteriostatic effect on S. 
pneumoniae growth, the anti-biofilm effect may be attributed to attenuation of 
growth. Taken together, these data demonstrated that statins had a dose-dependent 
effect on biofilm formation of CF-associated pathogens, but that sub-inhibitory 





Figure 11: Impact of simvastatin on attachment of CF-associated bacteria. Attachment 
of A) S. aureus, B) B. cenocepacia and C) S. pneumoniae was measured by crystal violet 
staining after 8 hours (S. aureus) or 24 hours (B. cenocepacia, S. pneumoniae) of incubation 
with simvastatin or vehicle control (0.209 % (v/v) DMSO for B. cenocepacia and S. aureus, 
0.052 % (v/v) for S. pneumoniae). (A) 100 µM reduced B. cenocepacia attachment, while 50 
µM had no inhibitory effect. (B) S. aureus attachment was reduced by both 100 µM and 50 
µM simvastatin. 100 µM had a significant effect (P = 0.0077). (C) 25 µM simvastatin 
significantly reduced S. pneumoniae attachment (P = 0.001), and 10 µM caused a slight, 




Simvastatin potentiates the effect of gentamicin against B. cenocepacia 
Given that statins caused the reduction of bacterial growth and virulence, it was 
hypothesised that statins could potentially increase the inhibitory effect of antibiotic 
treatment. The aminoglycoside antibiotic gentamicin was selected for this analysis, 
as this and other aminoglycosides are commonly used to treat infections and 
exacerbations in CF patients (54). B. cenocepacia was selected for this experiment, 
as clinical isolates of Burkholderia have been found to have a particularly high level 
of resistance against aminoglycosides (55). Furthermore, not only was this organism 
affected the least by simvastatin in this study (Figure 7), but preliminary analysis 
demonstrated that gentamicin had a markedly reduced effect against B. cenocepacia 
J2315 compared to S. aureus NCDO949, on which a largely bacteriocidal effect was 
exerted (Appendix Figure A1). Therefore, B. cenocepacia J2315 was cultured in the 
presence of sub-inhibitory concentrations of gentamicin (50 µg/ml) and simvastatin 
(50 µM) individually, and a combination of gentamicin + simvastatin. Bacteria were 
also cultured under control conditions of the vehicle (DMSO), and a combination of 
DMSO and gentamicin was also utilised to ensure that any effect observed was not 
due to cross-reaction between DMSO and gentamicin. Throughout early exponential 
phase (between 4 hpi and 8 hpi), no difference was observed in the growth of B. 
cenocepacia under different treatment conditions (Figure 12). However, by 12 hpi, 
the growth of bacteria treated with both simvastatin and gentamicin was modestly 
decreased compared to other conditions. When growth progressed from late log to 
early stationary phase (16, 20 and 24 hpi), a significant difference was observed in 
the growth of bacteria cultured with simvastatin and gentamicin combined compared 
to those cultured with the vehicle (16 hpi: P = 0.01, 20 hpi: P = 0.015, 24 hpi: P = 
0.008). Furthermore, at 20 and 24 hpi, the growth of bacteria treated with simvastatin 
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+ gentamicin was markedly decreased compared to all other conditions, and was 
significantly less than the growth of bacteria + simvastatin (20 hpi: P = 0.008, 24 
hpi: P = 0.004). These novel and exciting data demonstrated that simvastatin could 
significantly increase the inhibitory effect exerted by gentamicin on B. cenocepacia 
during log phase growth, suggesting that there could be potential for the use of these 





Figure 12: Effect of statins on the inhibitory potential of gentamicin. B. cenocepacia was 
treated with vehicle (black square markers), 50 µM simvastatin (green triangles), 50 µg/ml 
gentamicin (blue diamonds), vehicle + 50 µg/ml gentamicin (red crosses) and 50 µM 
simvastatin + 50 µg/ml gentamicin (grey circles). Simvastatin and gentamicin combined 
reduced the bacterial growth compared to all other conditions. Data are representative of the 




 Discussion  
Inhibition of bacterial growth and reduced inflammation, morbidity and mortality of 
patients with bacterial infections are key pleiotropic effects of statins. Therefore, it 
was hypothesised that statins could have an impact on bacterial pathogens associated 
with RTIs of people with CF, a condition characterised by chronic inflammation and 
infection. The first step in the identification of target organisms with possible 
susceptibility to statins was to search for the presence of HMGR, the enzyme which 
statins inhibit, in RTI-associated bacterial species. Here, it was observed that 10 out 
of 16 bacterial species examined possess a homologue of the enzyme that statins 
inhibit, HMGR, but only 7 of these organisms possess other mevalonate pathway 
genes. From the organisms surveyed, it generally appeared that Gram positive 
organisms tend to possess a mevalonate pathway, whereas Gram negative bacteria 
appear to predominantly utilise mevalonate-independent isoprenoid biosynthesis. It 
has been proposed that the mevalonate pathway was present in a common ancestor 
of prokaryotes, eukaryotes and archaea, but was subsequently replaced in most 
bacterial phyla by the MEP/DOXP pathway (56), and this may explain the higher 
occurrence of mevalonate pathway genes in Gram negative bacteria observed in this 
study.  
In B. cenocepacia, a HMGR homologue with no corresponding mevalonate pathway 
genes was identified. It is currently unknown whether this protein is functional in 
this species but given its close conservation to the functional HMGR of P. mevalonii 
(Figure 4) it was proposed that not only may B. cenocepacia HMGR be functional, 
but it may also be inhibited by statins. However, this still begs the question of the 
role of mevalonate in an organism where MEP/DOXP genes are present. 
Bioinformatic prediction of interactions suggested that the HMGR of B. cenocepacia 
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(BCAM0531) may have a metabolic role. Two proteins in the predicted BCAM0531 
network – PheA and HisB/HisD – may be of particular importance. PheA is 
responsible for biosynthesis of phenylalanine, which is known to inhibit Class I 
HMGR function (57), and therefore PheA may be part of a negative regulatory loop 
of BCAM0531 activity. Conversely, histidine has been found to increase mevalonate 
production (58), and as HisB and HisD are involved in biosynthesis of histidine, 
there may be a positive interaction between these and BCAM0531. Further work is 
needed to elucidate the role of HMGR in B. cenocepacia, and in other species 
lacking a mevalonate pathway. 
Although the effects of statins on bacterial growth and virulence were tested in a 
comparable manner between B. cenocepacia, S. aureus and S. pneumoniae, the 
magnitude of the effects observed was variable between the 3 species. Simvastatin 
reduced the growth of all 3 species, but much higher concentrations were required 
for the reduction of growth of B. cenocepacia and S. aureus than S. pneumoniae. It is 
possible that the differences observed in inhibitory statin concentrations may be 
linked to the differential organisation and regulation of the mevalonate pathway in 
these species. As the S. pneumoniae fni gene, which produces the Fni protein 
responsible for synthesis of the intermediate DMAPP, is located within the predicted 
mvaK1 operon, this strain may be more susceptible to statins than S. aureus, where 
fni appears to be independently regulated. An intriguing prospect uncovered in this 
study was that the growth of S. aureus was enhanced compared to the vehicle at 50 
µM and 25 µM simvastatin (Figure 8E and 8F). Biofilm formation and motility of S. 
aureus were decreased at 50 µM and 25 µM respectively. Therefore, it appears that 
simvastatin was effective against S. aureus at sub-inhibitory concentrations. As the 
enhancement of S. aureus growth is a novel statin effect, further studies are 
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warranted to investigate the metabolic consequences of simvastatin treatment on S. 
aureus. B. cenocepacia may exhibit reduced susceptibility to simvastatin compared 
to S. aureus and S. pneumoniae as this species undergoes mevalonate-independent 
isoprenoid metabolism. Species possessing a MEP/DOXP pathway may be affected 
to a lesser extent than those where mevalonate-dependent metabolism is used, as 
statins most likely do not inhibit the production of intermediate compounds by the 
mevalonate-independent pathway. 
An abundance of information is available regarding the effect of statins on bacterial 
growth, but to date, there is relatively little information available regarding the effect 
of statins on individual virulence factors of bacteria. The information currently 
available suggests that statins only target certain virulence phenotypes. Statins have 
been found to attenuate both the in vivo attachment of  S. pneumoniae (7) and  the 
epithelial translocation of P. aeruginosa (6), but did not impact on the production of 
quorum sensing compounds and protease by B. cenocepacia (59), or toxin 
production by S. pneumoniae (7). Motility and biofilm formation were focused on in 
this study and the effects of simvastatin on these phenotypes varied in a 
concentration-dependent manner. Simvastatin reduced attachment of all 3 test strains 
in an in vitro model, but only S. aureus was affected by sub-inhibitory 
concentrations. Furthermore, simvastatin had disparate effects on bacterial motility – 
it did not influence the motility of B. cenocepacia, but it reduced spreading motility 
of S. aureus at sub-inhibitory concentrations. Attachment and motility of S. aureus 
are both associated with the production of teichoic acid (43, 60). As teichoic acid and 
peptidoglycan production is dependent on isoprenoid metabolism (30, 31), it could 
be hypothesised that simvastatin-mediated inhibition of S. aureus HMGR may 
inhibit virulence phenotypes by reducing isoprenoid biosynthesis, thus disrupting the 
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structural integrity of the bacterial cell wall. The disruption of teichoic acid 
production may also contribute to the inhibitory effect of simvastatin on S. 
pneumoniae biofilm. However, given the substantial inhibitory effect of simvastatin 
on the growth of S. pneumoniae, it appears that the inhibition of streptococcal 
biofilm formation by simvastatin may occur as a result of growth inhibition rather 
than attenuation of biofilm-related factors. The reduced effectiveness of simvastatin 
against B. cenocepacia biofilm and motility suggests that the production of 
mevalonate by this species does not appear to be associated with the production of 
flagella and pili, and may not influence motility-associated quorum sensing. Unlike 
the MvaA of S. aureus, BCAM0531 does not appear to be associated with terpenoid 
backbone metabolism. Therefore, it can be hypothesised that simvastatin does not 
have an effect on the cell wall integrity of B. cenocepacia. 
One limitation of the use of statins as antimicrobial compounds is that the statin 
effects in this study were not observed at current physiologically relevant statin 
concentrations. The maximum plasma concentration of simvastatin in individuals 
who take a daily dosage is 20-34 ng/ml (61) which equates to roughly 48-81 nM, 
about 1000 times lower than the lowest effective concentration observed in this 
study. However, if statins were to be used to treat respiratory infections, an 
inhalation-based delivery route would need to be established, which could 
potentially increase localised statin concentrations. In addition, there is potential for 
the use of statins in combination therapy with other antimicrobial compounds. It was 
observed that simvastatin potentiated the effects of the aminoglycoside antibiotic 
gentamicin against B. cenocepacia. These results were extremely promising, as the 
individual effects of simvastatin and gentamicin were only exerted at high 
concentrations, but the combined effects of gentamicin and simvastatin reduced 
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bacterial growth at a physiologically relevant gentamicin concentration (50 µg/ml) – 
this was comparable with sputum levels achieved in a pilot study using nebulised 
gentamicin (62). Further studies examining the combined antimicrobial potential of 
statins and antibiotics may help to uncover a method to increase the efficacy of 
aminoglycosides against antibiotic resistant bacteria. Previous studies involving the 
effects of a combination of statins and anti-microbial compounds have had mixed 
success. Farmer and colleagues noted that statins do not potentiate the inhibitory 
effect of various antibiotics against several Gram negative pathogens (63), but 
simvastatin has been found to potentiate the effect of penicillin towards S. 
pneumoniae (4). Increased efficacy has also been reported using statins in 
combination with anti-fungal and anti-malarial drugs (64–66). Further studies 
examining the combined antimicrobial potential of statins and antibiotics may help 
to uncover a method to increase the efficacy of aminoglycosides against antibiotic 
resistant bacteria. Another area for future considerations is the elucidation of the 
mechanism by which the combined antimicrobial effect of statins and antibiotics is 
exerted. Aminoglycosides exert their anti-microbial potential by inhibiting protein 
synthesis (67), and the increased potency of simvastatin plus gentamicin may be due 
to the combined inhibitory effects on lipid metabolism and protein synthesis. Further 
studies examining the combined antimicrobial potential of statins and antibiotics 
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Cholesterol-lowering statin drugs have been shown to affect the growth of some 
microbial pathogens. However, little is known about the effect of statins on bacterial 
virulence factor production/expression. The objective in this study was to investigate 
whether statins could modulate virulence factor behaviour in the human nosocomial 
and cystic fibrosis-associated pathogen Pseudomonas aeruginosa. Here it was 
demonstrated that although statins did not have a significant effect on the growth of 
P. aeruginosa, they were capable of modulating 2 key P. aeruginosa virulence 
factors – swarming motility and biofilm formation. Swimming and twitching 
motility, chemotaxis, type 3 toxin expression and quorum sensing were also tested in 
the presence of statins, and were found to be unaffected. Moreover, transcriptome 
analysis revealed that statin treatment did not significantly impact gene transcription 
of P. aeruginosa. However, phenotypic screening of a P. aeruginosa mutant bank 
identified the PvrR regulator and fimbrial biogenesis genes as playing a role in the 
attenuation of attachment by simvastatin. Furthermore, global proteomic analysis 
revealed that the reduction/modulation of swarming by simvastatin appeared to be 







In Chapter 2, it was demonstrated that the cholesterol-lowering statin drug 
simvastatin was capable of modulating growth and virulence behaviour of 
respiratory tract infection-associated bacterial pathogens. The effect that sub-
inhibitory concentrations of statins have on virulence suggests that statins can 
influence processes other than metabolism, as these effects appear to be growth-
independent. The bacteria studied in Chapter 2 possess homologues of the enzyme 
that statins inhibit, 3-hydroxy-3-methylglutaryl-CoenzymeA reductase (HMGR). A 
point for consideration is whether statins can have the same influence on growth and 
virulence of bacteria which do not possess HMGR homologues. Many bacterial 
species do not possess HMGR, but instead synthesise isoprenoids via the 2-C-
methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate (MEP/DOXP) 
pathway. An example of a respiratory pathogen which lacks mevalonate-dependent 
isoprenoid biosynthesis is Pseudomonas aeruginosa.  
P. aeruginosa is a significant opportunistic pathogen, which causes chronic 
infections in 80 % of people with the genetic disease cystic fibrosis (CF) (1), and 
also causes pneumonia and corneal and wound infections. P. aeruginosa is an ideal 
model organism as it has a range of well-characterised virulence factors which can 
be studied using phenotypic and molecular assays. These virulence factors are 
essential in determining the outcome and persistence of P. aeruginosa infection. 
When P. aeruginosa first encounters the host, it attacks by way of an acute infection, 
causing cytotoxicity via type 3 secreted toxins. P. aeruginosa produces 4 type 3 
toxins – the bi-functional ExoS and ExoT which have ADP-ribosyltransferase and 
GTPase-activating domains (2–5); ExoY, which acts as an adenylate cyclase (6); and 




types of flagella-associated motility, swimming (8) and swarming (9). P. aeruginosa 
motility is also dependent on other factors including, but not limited to, 
lipopolysaccharide (LPS) synthesis (10) and surfactant production (11).  
Cell density-dependent cell-cell communication in P. aeruginosa is mediated 
through the quorum sensing (QS) signalling system. When a sufficiently large 
bacterial population has been established, the perception of QS signals by the 
bacteria crosses an essential threshold, leading to the co-ordinated regulation of gene 
expression and resulting behaviour associated with the chronic phase of infection. P. 
aeruginosa QS signals fall into 2 broad classes: acylated homoserine lactones 
(AHLs) and quinolones. AHL-mediated quorum sensing is regulated via the LasI/R 
and RhlI/R sensor-regulator 2 component systems (12–17), while the Pseudomonas 
quinolone signal (PQS) is produced by the pqsABCDE, pqsH and phnAB genes (18, 
19) and can cross-talk with RhlI/R quorum sensing (20). As a result of QS, bacteria 
begin attaching to host cell tissue and flagella-associated motility is inhibited (21–
24). Attachment is linked to a third type of P. aeruginosa motility – twitching 
motility – which is mediated through Type IV pili production (25), and is regulated 
by the LasI/R QS system (24). The chronic phase of infection is truly established 
when attached bacteria mature into a complete biofilm, by attaching irreversibly to 
the epithelial cell surface, descending into a sessile state and becoming surrounded 
by an extracellular matrix composed of polysaccharides, DNA and other components 
(24). P. aeruginosa can also produce a structure called a “microcolony” where 
bacteria attach to themselves and sputum components in response to limiting O2 
conditions (26). Biofilm maturation is regulated by RhlI/R QS (24). Once P. 
aeruginosa is in this state, it becomes extremely resilient when confronted with 




aeruginosa infections are further abrogated by antibiotic resistance mechanisms 
possessed by the bacteria.  
The objective in this study was to examine the effects of statins on a CF-associated 
bacterial species which did not possess a HMGR homologue. Three statins were 
used in this study in order to investigate whether the effects observed in Chapter 2 
were specific to simvastatin. The growth of P. aeruginosa was assessed in the 
presence of statins, and phenotypic analysis was carried out to examine if statins 
could influence P. aeruginosa virulence behaviour. As the mechanism by which 
statins could be influencing P. aeruginosa was unknown, transcriptomic, proteomic 
and mutant screening approaches were employed in an attempt to uncover how 





Materials and methods 
Bacterial strains and growth conditions 
All bacterial strains used in this study are listed in Table 1. P. aeruginosa strains 
were grown in Luria Bertani broth (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, 
15 g/L agar) unless otherwise stated.  
 
Statins  
Simvastatin (Sigma-Aldrich, U. K.) and mevastatin (Calbiochem, Germany) were 
resuspended in DMSO (Sigma-Aldrich) at concentrations of 20 mg/ml. Lovastatin 
(Sigma-Aldrich) was resuspended in DMSO at 10 mg/ml. All statins and DMSO 
vehicle controls were filter sterilised and stored at 4 ºC. To prepare hydrolysed forms 
of statins, lactone ring hydrolysis was carried out by firstly dissolving statins in 96 % 
ethanol at the following concentrations: simvastatin: 40 mg/ml; mevastatin: 25 
mg/ml; lovastatin: 25 mg/ml. 1.5 volumes of 0.1 N NaOH was added to dissolved 
statin, and this mixture was heated at 50 ºC for 2 hours. The pH of the mixture was 
adjusted to 7 using HCl, and the volume was adjusted to 1 ml using the 





Table 1: Bacterial strains used in this study. 
Strain Description Reference 
Pseudomonas aeruginosa   
PAO1 Wild type (27) 
PA14 Wild type (28) 
PAO1 exoS::lacZ exoS reporter strain (29) 
PA14 pqsA::lacZ pqsA reporter strain (30) 
CF194 Clinical isolate from Irish CF patient (31) 
TY5010 Clinical isolate from Turkish non-CF 
patient 
(32) 
PA14 ΔpvrR Transposon mutant in pvrR (28) 
PA14 ΔwspF Transposon mutant in wspF (28) 
PA14  ΔcupA1 Transposon mutant in cupA1 (28) 
PA14  ΔcupA2 Transposon mutant in cupA2 (28) 
PA14  ΔcupA3 Transposon mutant in cupA3 (28) 
PA14  ΔcupD1 Transposon mutant in cupD1 (28) 
PA14  ΔcupD2 Transposon mutant in cupD2 (28) 
PA14  ΔcupD4 Transposon mutant in cupD4 (28) 
PA14  ΔcupD5 Transposon mutant in cupD5 (28) 
PA14  ΔlptD Transposon mutant in lptD (28) 
PA14  Δpnp Transposon mutant in pnp (28) 
PA14  ΔdnaK Transposon mutant in dnaK (28) 
   
Other strains   






Measurement of bacterial growth 
Bacterial growth was measured according to the protocol described in Welsh et al., 
2009 (34). Briefly, bacteria were cultured shaking at 37 ºC for 16-18 hours. Cultures 
were centrifuged at 2330 x g for 10 minutes. Bacterial pellets were washed twice 
with phosphate buffered saline (PBS; Sigma-Aldrich) and resuspended in Muller-
Hinton broth (Oxoid) and the absorbance at 600 nm (OD600nm) was measured using a 
Beckmann-Coulter spectrometer. Bacteria were inoculated into Muller-Hinton broth 
(Oxoid) containing 1 mM, 100 µM, 10 µM, 1 µM, 100 nM and 10 nM of statins, or 
an equivalent DMSO vehicle control, at an OD600nm of 0.0005. 200 µl volumes of 
bacteria were inoculated into a 96 well microtitre plate, which was incubated static at 
37 ºC for 24 hours, following which bacterial growth was measured by quantifying 
OD600nm using a SpectraMax Plus 384 96 well plate reader (Molecular Devices).  
 
Motility assays 
Motility of P. aeruginosa was tested using 3 different agars. Swarming agar was 
composed of 6 g/L Eiken agar (Eiken Chemical), 8 g/L Eiken broth (Eiken 
Chemical), and 0.5 % (w/v) glucose (Sigma-Aldrich). Swimming and twitching 
agars consisted of 5 g/L peptone (Merck), 3 g/L yeast extract (Difco), 2 % (v/v) 
glycerol (Sigma-Aldrich), and 0.3 % (w/v) and 1 % (w/v) agar respectively. Plates 
were dried at room temperature overnight, and were inoculated with a single colony 
of P. aeruginosa from a freshly cultured plate. All plates were incubated in an 
upright position at 37 ºC – swarming for 12-18 hours, swimming for 24 hours, and 
twitching for 45 hours. Swarming and swimming assays were photographed directly 




removed from plates, and attached bacteria were stained using Coomassie Blue. 
Excess dye was removed using a destain solution (10 % (v/v) methanol, 10 % (v/v) 
acetic acid in H2O), following which plates were photographed. 
 
Measurement of attachment 
For analysis of early attachment, P. aeruginosa was cultured overnight in LB broth 
at 37 ºC, and inoculated into 100 ml conical flasks containing 20 ml LB broth 
supplemented with simvastatin or a DMSO vehicle control (0.209 % (v/v)) at 
OD600nm 0.05. After 3 hours of growth shaking at 37 ºC, bacteria were inoculated into 
24 well plates containing 1 ml of LB broth supplemented with simvastatin or vehicle 
at OD600nm 0.25, and incubated static at 37 ºC for 2 hours. Media was removed, and 
wells were washed 3 times with LB broth. Attached bacteria were stained with 0.1 % 
(w/v) crystal violet for 10 minutes at room temperature, and excess dye was removed 
by washing wells 5 times with water. Remaining dye was resuspended in 96 % 
ethanol, and the OD570nm of resuspended crystal violet was measured on a 
SpectraMax Plus 384 96 well plate reader. For analysis of mutant library strains, 
bacteria were inoculated at OD600nm 0.25 into 96 well plates containing 135 µl of LB. 
For determination of the effect of statins on attached bacteria, P. aeruginosa was 
inoculated into LB broth in a 96 well plate at OD600nm 1 at a volume of 200 µl per 
well, and incubated static at 37 ºC for 8 hours. Medium containing unattached 
bacteria was removed, and 200 µl LB broth containing either statin or DMSO was 
added to each well. This was incubated static at 37 ºC for 12 hours, following which 





Analysis of tight microcolony formation 
Tight microcolony formation of P. aeruginosa was measured according to Sriramulu  
et al., 2005 (35). Briefly, bacteria were cultured in LB broth overnight, and the 
OD600nm was measured. Bacteria were inoculated into 24 well plates where each well 
contained 1 ml of Artificial Sputum Media (ASM) (5 g/L mucin from porcine 
stomach muscosa (Sigma-Aldrich, U.K.), 4 g/L salmon sperm DNA (Fluka), 5.9 
mg/L diethylene triamine pentaacetic acid (DTPA), 5 g/L NaCl, 2.2 g/L KCl, 5 g/L 
amino acids and 0.5 % (v/v) egg yolk emulsion (Oxoid), pH 7) at OD600nm 0.05., 
supplemented with statins or vehicle where appropriate. Plates were incubated 
shaking at 37 ºC for 72 hours, and photographed using an Epson v750 scanner. 
 
Measurement of extracellular DNA production 
Extracellular DNA production by P. aeruginosa was measured according to the 
protocol described in Allesen-Holm et al., 2006 (36). Briefly, bacteria were cultured 
overnight in AB medium (2 g/L (NH4)2SO4, 6 g/L Na2HPO4, 3 g/L KH2PO4, 3 g/L 
NaCl, 0.1 M CaCl2, 0.1 M MgCl2, 3 mM FeCl3) supplemented with 0.5 % (w/v) 
glucose. The OD600nm of overnight cultures was measured, and bacteria were 
inoculated at OD600nm 0.001 into 96 well plates containing AB medium 
supplemented with 0.5 % (w/v) glucose and 50 µM propidium iodide (Fluka). Plates 
were incubated static at 37 ºC for 24 hours. The OD600nm (growth) and OD480nm 
(DNA) of each well were measured using a SpectraMax Plus 384 96 well plate 





Analysis of β-galactosidase production by lacZ promoter fusions 
P. aeruginosa exoS-lacZ and pqsA-lacZ reporter fusion strains (detailed in Table 1) 
were cultured shaking for 16-20 hours at 37 ºC. The OD600nm of overnight cultures 
were measured, and bacteria were inoculated into sterile 100 ml conical flasks 
containing LB broth supplemented with statins or DMSO where appropriate at 
OD600nm 0.05. LB containing 10 mM nitrilotriacetic acid (NTA) was used as a 
positive control to induce exoS promoter expression. Cultures were incubated 
shaking at 37 ºC until they reached OD600nm 1.5 (for exoS) or 1.2 (pqsA). β-
galactosidase activity was measured as described by Miller (37). Briefly, 1 ml of 
culture was removed and centrifuged at 16100 x g for 1 minute and pelleted bacteria 
were resuspended in 1 ml of LacZ buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 
mM KCl, 1 mM MgSO4, 2.7 ml/L β-mercaptoethanol; pH 7). 100 µl of LacZ buffer 
was added to 500 µl of cells, following which 20 µl 0.05 % (w/v) SDS and 20 µl 
CHCl3 were added to cells. This was mixed and incubated at 30 ºC for 10 minutes. 
100 µl of ONPG (4 mg/ml; freshly prepared in LacZ buffer) was added to cells, 
which were incubated until they turned a yellow colour. 260 µl of Na2CO3 was 
added to stop the reaction, and cells were centrifuged at 16100 x g for 1 minute. The 
OD420nm and OD550nm values of supernatant were measured, and the Miller units 
(representing β-galactosidase activity) were calculated using the following formula: 
Miller Units = ((OD420nm - (1.75 x OD550nm))/(Volume of cells used (ml) x Time (mins) x 







Quorum sensing indicator strain assays 
A single colony of the indicator strain Chromobacterium violaceum CV026 was used 
to make a linear streak on an LB plate which was supplemented with 100 µM of 
statin or a DMSO vehicle control. PAO1 and PA14 were cross-streaked at both a 90 
º angle and parallel to CV026 and plates were incubated at 30 ºC in an upright 
position for 24 hours. Plates were photographed using an Epson v750 scanner. 
 
RNA microarray analysis  
P. aeruginosa PA14 was inoculated into LB broth, containing either 100 µM 
simvastatin or an equivalent volume of DMSO, at a starting inoculum of OD600nm of 
0.01. Cultures were incubated at 37 ºC shaking at 180 rpm until bacteria reached an 
OD600nm of 0.8 ± 0.5, following which cells were harvested for RNA isolation. RNA 
protect was used according to manufacturer’s recommendations (QIAGEN, 
Germany). Total RNA was isolated from each cell pellet using a QIAGEN RNeasy® 
Mini kit. Residual genomic DNA was eliminated using Ambion Turbo DNA-free™ 
kit treatment according to manufacturer’s recommendations. RNA quantity was 
assessed using ND-1000 Spectrophotometer (NanoDrop Technologies, USA). 10 μg 
of DNA-free RNA was sent to DNAVision, Belgium where it was converted to 
cDNA, and hybridised to an Affymetrix™ GeneChip® specific for P. aeruginosa. 
Analysis of gene expression was carried out using GeneSpring GX software (Agilent 
Technologies, USA). Data were normalised using the Robust Multi-array Average 
(RMA) method and subsequently compared using an unpaired T-Test. Genes were 
considered differentially regulated if the relative change was ≥ 1.5 and the P value 




Quantitative RT-PCR (qRT-PCR) analysis of gene expression 
PA14 was cultured with either 100 µM simvastatin or DMSO, and RNA was isolated 
as previously described. 500 ng of DNA-free RNA was converted to cDNA, using 
AMV Reverse Transcriptase (Promega) according to manufacturer’s specifications. 
qRT-PCR analysis was carried out using the Roche Universal ProbeLibrary system, 






Table 2: Primers and probes used in qRT-PCR analysis. The annealing temperature of 
each primer set is 60 ºC. 
Gene Product Length (bp) Sequence Probe No. 
PA14_06700 103 Forward: acgaagtgctggaacaggtc 22 
  Reverse: atggcgttggcggtatag  
PA14_06710 124 Forward: accgctacaacctgtggttc 149 
  Reverse: cagtaggcttcctgcatcg  
PA14_06720 60 Forward: gacccacgaagtgatcgaa 162 
  Reverse: ctgaattccatgtgcagtacg  
PA14_06770 75 Forward: cggctaccagaacctgctc 107 
  Reverse: gggtagtcgaagcgcaac  
PA14_06790 70 Forward: gagtgctctactggcacatgg 150 
  Reverse: cattgcaggacgtagaccag  
ProC 79 Forward: cttcgaagcactggtggag 20 






Analysis of bacterial chemotaxis 
Chemotaxis was analysed using a modified version of the protocol described in 
Moulton & Montie, 1979 (38). Briefly, bacteria were cultured overnight at shaking 
in LB broth at 37 ºC. 1 ml of culture was pelleted and resuspended in mineral salt 
medium (MSM) (7 g/L K2HPO4, 3 g/L KH2PO4, 1 g/L (NH4)2SO4, 0.05 g/L 
MgSO4.dH2O, 0.025 g/L FeCl3.6H2O). The OD600nm of the culture was measured, 
and bacteria were inoculated into 1 ml of MSM supplemented with 100 µM 
simvastatin, or an equivalent amount of DMSO at a density of 1 x 10
7 
cfu/ml. One 
hundred microlitres of this was aliquoted into a clear 96 well plate (Sarstedt). 
Microcapillary pipettes with a 1-5 µL capacity (Sigma-Aldrich) were filled with 
MSM containing 10 mM of arginine, serine or glycine (all Sigma-Aldrich), and were 
placed in wells containing bacteria. Plates were incubated static at 37 ºC for 1 hour. 
The content of each capillary was eluted onto sterile Whatman paper, and diluted 
with 0.5 ml LB broth. Samples were then diluted ten-fold, and plated on LB agar 
plates in duplicate. Plates were incubated overnight at 37 ºC, following which 
colonies were counted. 
 
Protein isolation 
PA14 was inoculated onto 0.6 % Eiken agar plates (prepared as previously 
described) containing either 100 µM simvastatin or an equivalent volume of DMSO. 
Plates were incubated at 37 ºC for 16 hours. The outermost 1 cm of bacteria was 
removed from the plate using a sterile cotton swab and was transferred into a sterile 
tube containing 5 ml of wash buffer (50 mM Trizma Base, 100 mM 




by centrifugation in a Sorvall SS-34 rotor in a Sorvall RC-5B centrifuge at 12000 X 
g for 20 minutes. The pellet was resuspended in 5 ml of wash buffer and washed 
twice more under the same conditions as above. After 3 washes, cells were 
resuspended in wash buffer and were subjected to 3 cycles of incubation at -70 ºC 
for 10 minutes, followed by 37 ºC for 5 minutes. Cells were then lysed by sonication 
(amplitude 10,000 micron, On/30 seconds, Off/30 seconds for 12 minutes). 
Cytosolic proteins were removed by centrifugation (13000 x g, 20 minutes at 4 ºC). 
Proteins were quantified using a BCA assay kit according to manufacturer’s 
recommendations (Thermo Scientific) and precipitated using acetone. 
 
2-dimensional gel electrophoresis (2-DGE) 
Samples were resuspended in rehydration buffer (5 M urea, 2 M thiourea, 380 mg/L 
amberlite, 100 mg/L CHAPS, 100 mg/L SB 3-10, 10.8 mg/L DTT, 1.43 mg/L TCEP 
and 5 µl/L IPG buffer) and quantified using a Bio-rad assay (Bio-Rad). Proteins 
were rehydrated at a rate of 1 mg/ml. Two hundred micrograms of protein was 
loaded by in-gel hydration on 11 cm pH 3-7 immobilised pH gradient (IPG) strips 
(Bio-rad). Isoelectric focusing was carried out using the following protocol: 
Voltage Gradient µAmp Time Unit 
250 V Rapid 50 1:00 hh:mm 
500 V Rapid 50 1:00 hh:mm 
8000 V Gradual 50 1:30 hh:mm 
8000 V Rapid 50 35000 Volt hour 





IPG strips were equilibrated and electrophoresis in the second dimension was carried 
out at 500 V and 40 mA until samples reached the end of the gel. 
Gels were fixed in 50 % (v/v) methanol, 5 % (v/v) acetic acid for 20 minutes. They 
were then stained using 0.1 % silver nitrate for 20 minutes, and developed in 0.04 % 
(v/v) formalin 2 % (w/v) sodium carbonate. Protein spots were excised and washed 
in 25 mM ammonium bicarbonate 50 % (v/v) acetonitrile for 30 minutes, followed 
by 25 mM ammonium bicarbonate for 30 minutes, twice. They were then dehydrated 
in 100 % (v/v) acetonitrile and dried using a SpeedVac (Savant Instruments, USA) 
for 5 minutes at room temperature. Samples were then washed with 7 % (v/v) 
hydrogen peroxide and 100 % (v/v) acetonitrile and stored at – 20 ºC. 
 
Tandem mass spectrometry 
Samples were dried and desalted using Zip Tip C18 (Millipore) and peptides were 
then dissolved in 0.1 % (v/v) formic acid. All experiments were done on a LTQ-
Orbitrap Elite (Thermo Scientific) coupled with an Easy nLC II system (Thermo 
Scientific). The mass spectrometer was operated in positive ionization mode with a 
capillary voltage and a source temperature set at 1.5 kV and 275 °C, respectively. 
Three µL of sample was injected onto an enrichment column (C18 PepMap100, 
Thermo Scientific). Separation was achieved with an analytical column needle 
(NTCC-360/100-5-153, NikkyoTechnos, Japan). The mobile phase consisted of 
H2O/0.1 % (v/v) formic acid (buffer A) and 0.1 % (v/v) acetonitrile/formic acid 
(buffer B). Peptides were eluted at a flow rate of 300 nL/min from 2 to 55 % B over 
15 min. The samples were analysed using the CID (collision induced dissociation) 




(R=60,000) with the mass range m/z 400-2000. Then, the 20 most intense ions were 
selected for MS
2
 experiments. All measurements in the Orbitrap analyzer were 




Raw data files were processed using Proteome Discoverer 1.3 software (Thermo 
Scientific). Peak lists were searched using the MASCOT search engine (Matrix 
Science) against the database Pseudomonas aeruginosa PA14 containing 5,892 
protein sequences (http://www.pseudomonas.com/downloads/sequences). Database 
searches were performed with the following parameters: 1 missed trypsin cleavage 
sites allowed; variable modifications: carbamidomethylation of cysteine, and 
oxidation of methionine. 
 
Statistical analysis 







Statins do not affect the growth of P. aeruginosa 
It has previously been reported that growth of the P. aeruginosa reference strain 
ATCC 27853 was inhibited by 2 statins (34). In this study, rosuvastatin and 
atorvastatin had a bacteriostatic effect against ATCC 27853 at respective 
concentrations of 208 mM and 447.5 mM. The effect of statins on the lab reference 
P. aeruginosa strains PAO1 and PA14 was consequently tested in the same manner. 
PAO1 and PA14 were cultured in the presence of a 10-fold dilution series of statins 
(from 1 mM to 10 nM), as well as an appropriate DMSO vehicle control. Lovastatin, 
mevastatin and simvastatin were tested in this study. Addition of DMSO to the 
growth medium was found to reduce growth of both strains. However, no reduction 
in growth was observed between vehicle- and statin-treated cells, at any 
concentration of statins (Figure 1).  
The impact of statins on the growth of P. aeruginosa ATCC 27853 was also tested, 
under the same statin concentrations and growth conditions as PAO1 and PA14. 
Statins did not influence the growth of this strain – the growth levels obtained 
against each statin and the vehicle control were comparable to those achieved for 
PAO1 and PA14. It was therefore concluded that statins do not have a significant 






Figure 1: Effect of statins on growth of P. aeruginosa. The P. aeruginosa strains PAO1, 
PA14 and ATCC 27853 were cultured in Muller-Hinton broth containing a 10-fold dilution 
series of (A) lovastatin (B) mevastatin or (C) simvastatin, as well as DMSO (vehicle) (2.09 
% (v/v)) and media only (LB) controls, for 24 hours. OD600nm was measured to determine 




The Type III secretion system of P. aeruginosa is not affected by statins 
It has been demonstrated that virulence behaviour of P. aeruginosa can be 
influenced by sub-inhibitory concentrations of drugs such as colistin (30). It was 
questioned if statins could have this effect on P. aeruginosa, despite their lack of 
influence on the growth of this species, and this hypothesis was tested by examining 
the effects of statins on Type III secretion (TTSS) of P. aeruginosa, which is crucial 
for the acute phase of infection (39). The transcriptional expression of exoS 
(PA3841) was examined using a PAO1exoS::lacZ reporter strain, cultured in LB 
supplemented with 10 mM NTA in order to induce the TTSS. The expression of 
exoS was analysed using beta-galactosidase assays in the presence of 100 µM, 10 
µM and 1 µM concentrations of simvastatin, lovastatin and mevastatin, which were 
compared to controls of LB NTA, and a DMSO vehicle control (Figure 2). It was 
noted that, unlike growth, the vehicle had no influence on exoS expression. 
Furthermore, no statin concentration tested in this study altered the expression of 
exoS compared to the vehicle control, or TTSS-inducing conditions. It was thus 







Figure 2: Effect of statins on Type III secretion. P. aeruginosa exoS::lacZ was cultured in 
the presence of 100 µM, 10 µM and 1 µM (A) lovastatin, (B) mevastatin or (C) simvastatin 
in addition to DMSO and inducing conditions (LB NTA). Expression of exoS was analysed 
at OD600nm using Miller assay and was compared to the expression observed under inducing 






Statins influence swarming motility of P. aeruginosa 
In order to further examine whether statins had an influence on the acute infection 
virulence behaviour of P. aeruginosa, their potency was tested against bacterial 
motility. This is not only an important factor in the acute phase of infection, but is 
also implicated in the switch between the acute and chronic phases of infection. P. 
aeruginosa displays 3 in vitro motility phenotypes. Swarming and swimming 
motility are linked to flagellar motion of the bacterium (as well as several other 
factors), while twitching motility is associated with the production of Type IV pili. 
The effect of statins on the motility of P. aeruginosa was assessed using lovastatin, 
mevastatin, and simvastatin. Swarming motility was reduced by 100 µM of all 3 
statins (Figure 3A). As this effect was comparable between PAO1 and PA14, the 
influence of statins on clinically-relevant P. aeruginosa strains was assessed, by 
testing the effect of 100 µM simvastatin, lovastatin and mevastatin against the 
motility of 2 clinical isolates. CF194 was originally isolated from an Irish CF patient, 
while TY5010 was recovered from a Turkish non-CF patient. The swarming motility 
of both these strains was attenuated by all 3 statins tested (Figure 3B).  
Each of the statins tested in this study was used in an “inactive” form, which is 
characterised by an intact lactone ring to which a decalin structure and a butaryl side 
chain are attached. However, in situ, statins are converted to an active form via 
hydrolysis of the lactone ring, and it is the hydrolysed statin form which binds to 
HMGR. Therefore, it was decided to examine whether lactone ring hydrolysis was a 
determining factor in the effects that statins had on P. aeruginosa virulence. The 
lactone rings of lovastatin, mevastatin and simvastatin were hydrolysed using 
sodium hydroxide/ethanol treatment, and 100 µM of hydrolysed statin was added to 




(0.209 % (v/v)) was used. The hydrolysed forms of lovastatin and mevastatin did not 
decrease motility, or alter the appearance of projections compared to the solvent 
control (Figure 3C). However, the hydrolysed form of simvastatin caused decreased 
swarming compared to the vehicle control, in a similar manner to the reduction 
caused by the unhydrolysed form. These results were consistent between PAO1 and 
PA14, and appear to indicate that an intact lactone ring is essential for the effect of 
lovastatin and mevastatin on virulence, but is not required by simvastatin. This 
suggests that the butaryl side chain of simvastatin may be responsible for its effects 
on P. aeruginsosa virulence. 
The effect of statins on swimming and twitching motility of P. aeruginosa were also 
analysed, using 100 µM simvastatin. Despite the effects observed on swarming 
motility, statins were not capable of influencing P. aeruginosa swimming and 
twitching motility (Figure 3D and E). Both PAO1 and PA14 behaved in a similar 
manner in the presence of each statin as they did in the presence of the vehicle. 
Altogether, these data suggested that statins have a specific effect on P. aeruginosa 







Figure 3: Influence of statins on P. aeruginosa swarming motility. Bacteria were cultured 
on 0.6 % (w/v) Eiken agar. (A) Swarming motility of PAO1 and PA14 was reduced by 100 
µM simvastatin, mevastatin and lovastatin. (B) The clinical isolates CF194 and TY5010 




concentrations. (C) The lactone ring of simvastatin, lovastatin and mevastatin was 
hydrolysed by NaOH and heat treatment, to determine whether the activated form of statins 
yielded the same effect as the inactive form with the intact lactone ring.  Hydrolysed 
lovastatin and mevastatin were no longer capable of attenuating swarming compared to the 
vehicle; however, 100 µM of hydrolysed simvastatin reduced swarming of PAO1 and PA14 
to a comparable extent. (D) and (E) Swimming and twitching motility of PAO1 and PA14 
were measured using 0.3 % and 1 % (w/v) agars respectively. 100 µM simvastatin did not 





Statins reduce early attachment, but not biofilm maturation 
Biofilm formation is a key virulence factor involved in the establishment and 
persistence of P. aeruginosa chronic infections. As an association has been found 
between reduced swarming motility and attenuated biofilm formation (40), the effect 
of statins on this phenomenon of was tested. At this point in the study, it was decided 
to continue using simvastatin only, as it appeared that all the inactive forms of all 3 
statins tested were having a similar effect on P. aeruginosa.  
The first phenotype tested was initial attachment, which is the first stage of biofilm 
formation and associated with the switch from acute to chronic infections. Bacteria 
were incubated with 100 µM simvastatin for 2 hours, following which attached 
bacteria were stained with crystal violet. It was found that 100 µM simvastatin was 
capable of significantly reducing attachment of PA14 (Figure 4A). A reduction was 
also observed in response to 10 µM simvastatin, but this was not statistically 
significant. However, unlike the effect observed on swarming motility, this 
phenotype was strain-specific. A reduction in attachment was not observed with 
PAO1 – even 100 µM of simvastatin did not influence the attachment of this strain 
compared to the DMSO control (Figure 4B). Furthermore, 100 µM simvastatin also 
failed to reduce the attachment of the clinical isolates CF194 (Figure 4C) and 
TY5010 (Figure 4D). 
Based on these results, the effect of statins on bacteria which had established 
attachment was examined. PA14 was allowed to attach to a surface for 8 hours, after 
which time bacteria were treated with 100 µM simvastatin to assess whether statins 
could disrupt established attachment. After 12 hours of statin treatment, crystal violet 




this time, simvastatin did not alter the numbers of attached bacteria relative to those 
treated with vehicle (Figure 4E). 
The effect of statins on biofilm maturation was also examined by using assays to 
measure extracellular DNA (eDNA) production and tight microcolony formation. 
Both of these phenotypes were tested in the presence of 100 µM simvastatin. Neither 
eDNA production nor tight microcolony formation was significantly altered in the 
presence of statins when compared to vehicle-treated bacteria (Figure 4F and 4G). 
Taken together, the results of this section of the study indicated that statins have a 
specific effect on the initial stage of P. aeruginosa biofilm formation, but are not 






Figure 4: Biofilm-related phenotypes of P. aeruginosa in the presence of statins. The 
effect of statins on bacterial attachment was tested by crystal violet staining after 2 hours of 
incubation with 100 µM simvastatin. (A) Attachment of PA14 was significantly decreased 
by 100 µM simvastatin, and a non-significant reduction was observed with 10 µM 




and TY5010. (E) Crystal violet staining was also used to investigate whether statin treatment 
of attached bacteria could result in their removal. 100 µM simvastatin did not significantly 
influence PA14 which had previously attached to a plastic surface. (F) The effect of statins 
on eDNA production by PA14 was examined using propidium iodide staining. There was no 
change in eDNA levels in 100 µM simvastatin-treated cells compared to DMSO-treated 
cells. (G) PA14 was cultured in artificial sputum media in the presence of 100 µM 
simvastatin to determine whether statin treatment could affect tight microcolony formation. 
This phenotype (visible as a solid structure in the centre of the well) was not altered by 






P. aeruginosa quorum sensing is not altered by statins 
As swarming motility and attachment are linked to quorum sensing, the effect of 
statins on this phenomenon was examined. P. aeruginosa produces several types of 
AHL quorum sensing molecules, and the Pseudomonas quinolone signal (PQS) and 
its precursor molecule 2-heptyl-4-quinolone (HHQ). PQS-dependent signalling has 
been found to be responsible for decreased swarming motility (22) and increased 
biofilm formation (41) and it was hypothesised that a statin-mediated alteration in 
quorum sensing may be responsible for the inhibition of swarming motility by 
statins. PQS and HHQ are synthesised via the pqsABCDE operon (42) and therefore 
the effect of statins on the first gene in this operon, pqsA, was analysed. A PA14 
strain containing a pqsA-lacZ reporter construct was cultured in the presence of 100 
µM simvastatin and pqsA expression was examined using a Miller assay. The 
expression of pqsA in statin-treated bacteria was equivalent to its expression in 
vehicle-treated bacteria, demonstrating that statins did not have an effect on pqsA 
expression (Figure 6A). It can be hence inferred that statins did not influence the 
regulation of the pqsABCDE operon.  
The impact of statins on AHL-mediated QS was investigated by utilising a well-
characterised indicator strain, Chromobacterium violaceum CV026. C. violaceum 
wildtype produces a purple pigment called violacein in an AHL-dependent manner. 
However, CV026 possesses a Tn5 insertional mutation in the region responsible for 
AHL synthesis (a luxI homologue), meaning that this strain cannot produce violacein 
unless it is exposed to exogenous sources of AHLs. Therefore, CV026 can be used 
as a biosensor to measure AHL activity. The effect of statins on AHLs was tested by 
cross-streaking CV026 with P. aeruginosa PAO1 and PA14, in the presence of 100 




levels in statin-treated bacteria and in controls, indicating that statins did not alter 
AHL production (Figure 6B). It should be noted that CV026 biosensor activity is 
optimal for AHLs which have C8 acyl chains (C8-HSL). However, given that AHL 
production in P. aeruginosa is mediated through the LasI/LasR system (43, 44), it 
can be inferred that from the observations made in this study that statins do not affect 






Figure 5: Effect of simvastatin on quorum sensing of P. aeruginosa. (A) A pqsA reporter 
strain was utilised to examine if statins influenced quinolone production. 100 µM 
simvastatin did not influence the expression of pqsA compared to the DMSO control. (B) 
The effect of statins on AHL production was tested using the indicator strain 
Chromobacterium violaceum CV026. PAO1 and PA14 were cross-streaked with CV026 in 
the presence of 100 µM simvastatin. There was no change in pigment production by CV026 
treated with simvastatin compared to that treated with DMSO, indicating that statin 





Transcriptomic analysis of the effect of simvastatin on P. aeruginosa 
The results of phenotypic analysis indicated that the effect of statins on P. 
aeruginosa was targeted towards 2 particular types of virulence behaviour, swarming 
motility and early attachment. These virulence factors are united in that they are both 
regulated by complex yet well-defined genetic pathways. Therefore, the effect of 
statins on gene expression of P. aeruginosa was examined using a global 
transcriptomic approach. P. aeruginosa PA14 was cultured with either 100 µM 
simvastatin or an equivalent volume of DMSO, and cells were harvested at OD600nm 
of 0.8 ± 0.05 for microarray analysis. Following statistical analysis under the least 
stringent conditions, a total of 47 genes with a fold change of ≥ 1.5 were identified 
(Table 3) (Appendix A5). It was immediately noted that, according to heat map 
analysis, total gene expression was at a similar level between statin-treated and 
vehicle-treated cells (Figure 6A). Furthermore, the normalised intensity values of 
genes in biological replicate 1 of statin-treated cells appeared to cluster differently 
than those of biological reps 2 and 3, indicating that some disparity was present in 
gene regulation between the replicates (Figure 6B). This was reflected in the average 
fold changes of genes, many of which had large standard deviations due to 
incongruent gene expression between each biological replicate of statin-treated 
bacteria. Altered genes fell into 7 functional categories, with the majority of altered 
genes classified as having either metabolic or hypothetical functions (Figure 6C). 
Other altered functional clusters were chemotaxis, transport, ribosomal, regulation 
and secretion. No genes typically associated with motility or biofilm were found to 
be altered. 
Five candidate genes were chosen to validate the array - PA0514 (PA14_6700), 




PA0521 (PA14_06790). These genes were chosen as they appear to have a common 
function in that they are present in a cluster responsible for the production of nitrite 
reductase (45). Furthermore, these genes are part of 2 operons – PA0514-516 are 
predicted to be part of the nirSMCFDLGHJEN  cluster, and PA0520 and PA0521 are 
part of the predicted nirQ operon (46). qRT-PCR analysis of these genes was carried 
out in statin-treated PA14 cells compared to vehicle-treated bacteria (Figure 6D). No 
effect was noted on PA0514 and PA0515 – the fold changes of these genes 
compared to vehicle were 1.19 and 1.14 respectively. The fold changes of these 
genes in the microarray analysis were -3.28 and -1.54. Meanwhile, PA0516 and 
PA0520 were increased to a greater extent by simvastatin, with non-statistically 
significant fold changes of 1.64 and 1.7, compared to relative fold changes of -0.67 
and 114.22 in the microarray. PA0521 was increased almost 3 fold by simvastatin, 
compared to an overall fold increase of 6.56 in microarray data. Given that the fold 
changes of 4 out 5 genes tested in this experiment differed from those observed in 
the microarray, and taking the variation in microarray expression levels into 
consideration, it was concluded that statins do not have a significant or reproducible 





Table 3: Microarray analysis of differentially-regulated PA14 genes altered in the 
presence of simvastatin. Fold change (FC) is the average of 3 biological replicates and 
STDEV is the standard deviation of the fold change. P-value is based on an unpaired 
Student’s T-Test. 
PA No. Name FC STDEV p-value Function 
PA0025 aroE -0.88 0.20 0.00 Shikimate 5-dehydrogenase 
PA0028  0.90 0.70 0.03 Hypothetical protein 
PA0047  4.71 8.69 0.01 Hypothetical protein 
PA0171  5.76 9.50 0.04 Hypothetical protein 
PA0179  -1.61 1.76 0.02 Probable 2 component response 
regulator/chemotaxis response regulator 
PA0271  1.50 1.49 0.01 Hypothetical protein 
PA0437 codA 2.66 3.13 0.01 Cytosine deaminase/chitinase 
PA0514 nirL -3.28 4.19 0.04 Heme biosynthesis 
PA0515  -1.54 1.77 0.03 Probable transcriptional regulator 
PA0516 nirF -0.67 0.95 0.01 Heme d1 biosynthesis 
PA0520 nirQ 114.22 198.41 0.02 Regulatory protein 
PA0521 nirO 6.56 12.11 0.05 Probable cytochrome c oxidase subunit 
PA0656  1.99 4.05 0.02 Probable HIT family protein 
PA0835 pta -1.18 0.52 0.02 Phosphate acetyltransferase 
PA1523 xdhB 0.57 0.37 0.01 Xanthine dehydrogenase 
PA1664 orfX -2.02 2.96 0.03 Putative protein secretion/export 
apparatus 
PA2567  17.34 29.04 0.00 Hypothetical protein (predicted c-di-
GMP phosphodiesterase) 




PA2788  -2.31 3.63 0.04 Probable chemotaxis transducer 
PA3049 rmf 10.09 18.13 0.03 Ribosome modulation factor 
PA3054  -1.28 2.90 0.05 Hypothetical protein (predicted 
carboxypeptidase) 
PA3179  -2.19 3.00 0.03 Hypothetical protein (predicted 
pseudouridine synthase activity) 
PA3418 ldh 2.66 3.85 0.00 leucine dehydrogenase 
PA3452 mqoA 0.56 0.37 0.04 Malate:quinone oxidoreductase 
(pyruvate metabolism) 
PA3609 potC 1.85 1.83 0.03 Polyamine transport protein 
PA3615  -0.38 1.21 0.00 Hypothetical protein 
PA3641  -50.27 94.05 0.01 Probable amino acid permease 
PA3651 cdsA -1.65 1.39 0.03 phosphatidate cytidylyltransferase 
PA3741  -1.05 0.09 0.01 Hypothetical protein 
PA3820 secF 0.46 0.33 0.02 Secretion protein 
PA3821 secD 1.03 0.74 0.01 Secretion protein 
PA3882  2.37 2.86 0.04 Hypothetical protein 
PA4349  1.67 0.92 0.02 Hypothetical protein (putative acyl-coA 
dehydrogenase) 
PA4351 olsA 1.57 0.23 0.00 1-acyl-sn-glycerol-3-phosphate 
acyltransferase 
PA4357  1.58 0.77 0.04 Conserved hypothetical protein 
(provisional ferrous iron transport 
protein) 
PA4358  1.36 0.92 0.00 Probable ferrous iron transport protein 
PA4432 rpsI 0.98 1.02 0.03 30S ribosomal protein S9 
PA4673  -0.65 0.19 0.00 Hypothetical protein (predicted GTPase) 




PA4916  -1.76 1.29 0.05 Hypothetical protein (putative ADP-
ribose pyrophosphate) 
PA4919 pncB1 2.44 1.27 0.02 Nicotinate phosphoribosyltransferase 
PA4920 nadE -1.57 0.93 0.01 NH3-dependent NAD synthetase 
PA4933  1.23 0.82 0.00 Hypothetical protein 
PA4934 rpsR 0.62 0.17 0.01 30S ribosomal protein S18 
PA4935 rpsF -0.73 0.75 0.03 30S ribosomal protein S6 
PA5025 metY -0.51 0.34 0.01 Homocysteine synthase 







Figure 6: Analysis and validation of microarray data. (A) Heat mapping demonstrated 
that the overall gene expression levels were comparable between vehicle-treated and statin-
treated cells. (B) Intensity values of expressed genes were similar in vehicle-treated cells, 
but 1 biological replicate of statin-treated cells appeared to be out-lying. (C) Functional 
grouping of statin-regulated genes in P. aeruginosa demonstrated that the majority of altered 
transcripts had either hypothetical or metabolic functions. (D) Expression of PA0514, 
PA0515, PA0516, PA0520 and PA0521 in the presence of 100 µM simvastatin. Fold change 






Analysis of the effect of statins on P. aeruginosa chemotaxis 
As the expression of swarming and attachment-associated genes was not altered in 
microarray analysis, it was hypothesised that the effect of statins on these 
phenotypes may be mediated through post-translational modification of proteins, 
alteration of protein-protein interactions or direct interactions between statins and 
proteins. Chemotaxis is one phenotype which is linked to both motility and 
attachment (47), and therefore the effect of statins on this phenomenon was 
examined. Firstly, experimental optimisation was undertaken by investigating the 
chemo-attractive capability of the amino acids arginine, glycine and serine towards 
P. aeruginosa PA14 in order to find the strongest chemoattractant. It was determined 
that arginine was more chemoattractive to P. aeruginosa than either glycine or serine 
(Figure 7A).  
The impact of statin treatment on this effect was subsequently examined. Bacteria 
were inoculated into media containing 100 µM simvastatin or an equal volume of 
DMSO, and were exposed to capillaries containing media supplemented with 10 mM 
arginine. Bacteria cultured in all conditions were capable of significant chemotaxis 
towards arginine (p-values were 0.009 for un-treated bacteria, 0.023 for vehicle-
treated bacteria and 0.002 for statin-treated bacteria), suggesting that statin-treated 
bacteria were equally capable of movement towards arginine compared to controls 
(Figure 7B). Therefore, it appeared that chemotaxis towards arginine was not 





Figure 7: P. aeruginosa chemotaxis and statins. (A) Medium containing arginine, glycine 
and serine was aspirated into capillaries, and the movement of P. aeruginosa PA14 towards 
the amino acids was observed. Arginine proved to have the strongest chemo-attractant effect 
on PA14. (B) PA14 was equally capable of chemotaxis towards arginine under all treatment 





The effect of simvastatin on P. aeruginosa attachment is mediated through the 
PvrR response regulator 
P. aeruginosa PA14 possesses over 140 environmental sensors and response 
regulators  (46). In order to determine whether any of these proteins were involved in 
the attenuation of swarming and attachment by simvastatin, the PA14 transposon 
library constructed by Liberati et al. (28)  was employed. Mutants in each of the 
PA14 sensory and regulatory proteins were screened for swarming and attachment 
phenotypes in the presence of 100 µM simvastatin. It was not possible to elucidate 
the role of these proteins in the effect of simvastatin on motility, as many of the 
mutant strains were found to be non-motile. However, 27 mutant strains screened 
were found to display restored or increased attachment in the presence of 
simvastatin. Of these, 1 strain – a mutant in the pvrR gene (ΔpvrR), which encodes 
the PvrR regulatory protein – reproducibly demonstrated increased attachment in the 
presence of simvastatin compared to WT PA14 (P = 0.02) (Figure 8A). 
PvrR negatively regulates the expression of the cupA and cupD gene clusters which 
are involved in fimbriae production (48, 49). Furthermore, PvrR possesses an EAL 
domain, meaning that it functions catabolically as a cyclic-di-GMP (c-di-GMP) 
phosphodiesterase (50, 51). The c-di-GMP signalling molecule is known to promote 
biofilm production and inhibit swarming motility of P. aeruginosa (52, 53). In 
addition, the ectopic expression of PvrR was found to restore virulence to an 
attenuated mutant of the WspF methylesterase, suggesting that PvrR and WspF may 
interact (54). Therefore, the effect of simvastatin on the attachment of mutants in the 
cupA and cupD operons, as well as on a wspF mutant, was examined in order to 
determine whether these gene products played a role in the attenuation of P. 




ΔcupA1 mutants was significantly increased by simvastatin compared to the WT (P 
= 0.017 and 0.019 respectively). In addition, non-significant increases were 
observed in ΔcupA2 and ΔcupD1 compared to WT. This suggested that simvastatin 
may inhibit fimbriae production in P. aeruginosa. WspF is involved in P. aeruginosa 
motility, as the swarming phenotype of a wspF mutant strain was found to be 
attenuated (54). As simvastatin increased attachment in a ΔwspF background, it was 
questioned whether statin treatment could also restore the swarming phenotype of a 
wspF mutant. ΔwspF was cultured in the presence of 100 µM simvastatin, but 






Figure 8: The role of pvrR, wspF and fimbriae-associated cup genes in the effect of 
simvastatin on P. aeruginosa. Bacterial attachment in the presence of 100 µM simvastatin 
was tested by crystal violet staining after 2 hours of incubation. (A) Simvastatin increased 
attachment in a PvrR mutant. (B) Attachment of the PvrR regulatory targets WspF, CupA1, 
CupA2 and CupD1 was increased by simvastatin. (C) Simvastatin did not restore motility to 





Regulation of the P. aeruginosa proteome by simvastatin 
A role for PvrR, CupA1, CupA2 and CupD1 in the impact of simvastatin on P. 
aeruginosa PA14 had previously been identified. The transcriptomic expression of 
these proteins was not found to be altered in microarray analysis, and it therefore 
appeared that simvastatin may be influencing P. aeruginosa at the proteomic level. 
This hypothesis was subsequently examined by isolating protein expression at the 
swarm tip of P. aeruginosa PA14 cultured in the presence and absence of 
simvastatin. Total protein was harvested from the outermost 1 cm of the swarm tip, 
and samples were separated by 2-DGE. Altered proteins were identified using mass 
spectrometry (Appendix A6 and A7). This analysis demonstrated that 6 proteins 
were reproducibly induced by simvastatin treatment (Table 4). Two of these proteins 
appear to play a role in virulence. LptD is an outer membrane protein which 
transports LPS to the outer membrane (55), whereas AcnB is a metabolic protein 
which may repress expression of Exotoxin A (ExoA) (56). Of the remaining 
proteins, 2 are involved in translation (FusA1 and RpsA) (57, 58), while Pnp is 
involved in transcription (59). Finally, DnaK acts as a chaperone during 
chromosomal DNA replication and is involved in the heat shock response (60). 
Interestingly, 5 of the altered proteins were also found to be post-translationally 
modified by simvastatin. 
In order to verify that the altered proteins were involved in the attenuation of 
swarming by simvastatin, swarming assays were carried out on PA14 transposon 
mutant strains in 3 target proteins – Δlptd, Δpnp and ΔdnaK (Figure 9). Δlptd was 
motile to a comparable extent as the wild type, and the motility of this strain was 
attenuated by simvastatin in a similar manner to that of the wild type. However, 










Table 4: Upregulated PA14 swarm front proteins in the presence of simvastatin. 
Results are based on 2 biological replicates. 
Accession PA No. Name Function Post-translational modification 
    Oxidation Carbamidomethylation 
PA14_07770 PA0595 LptD/ 
OstA 
Organic solvent 
tolerance protein  
+ + 
PA14_08820 PA4266 FusA1 Elongation factor G + + 
PA14_23330 PA3162 RpsA 30S ribosomal protein - - 
PA14_41470 PA1787 AcnB Aconitate hydratase + + 
PA14_62710 PA4740 pnp Polyadenylase + + 






Figure 9: Swarming motility of mutants in altered P. aeruginosa proteins. Mutant 
strains in lptD, pnp and dnaK were analysed in the presence of 100 µM simvastatin or an 
equivalent amount of vehicle. Simvastatin inhibited swarming motility of ΔlptD, and 
reduced the limited motility of Δpnp. ΔdnaK was non-motile regardless of treatment. Data 






It has previously been demonstrated that growth and virulence behaviour of bacterial 
species can be altered by simvastatin (Chapter 2). However, all of the species 
investigated possessed a homologue of HMGR, and at least one other mevalonate 
pathway protein homologue. It was thus questioned whether statins were effective 
against these bacteria because of their metabolic capabilities, and sought to 
investigate further by testing the effects of statins on a bacterial species which does 
not possess HMGR. P. aeruginosa was chosen for this analysis because it is a 
virulent CF-associated pathogen. Unlike the other bacterial species tested, statins did 
not influence the growth of P. aeruginosa. This may be due to the mevalonate-
independent isoprenoid metabolism in this species. Previous studies have reported 
that both Type 1 and Type 2 statins decreased the growth of P. aeruginosa (34, 61). 
These studies used the strains ATCC 27853 and ATCC 9027. However, it was 
demonstrated that statins did not impact the growth of ATCC 27853 in this study. 
One possible explanation for this is that the highest statin concentration used in this 
study was lower than those used in previous reports. The highest concentration that 
was tested was 1 mM, whereas Welsh et al. reported MICs equating to 447.5 mM 
(atorvastatin) and 208 mM (rosuvastatin) (34). Although statins did not affect the 
growth of P. aeruginosa, it appears that they have different efficacies against 
different strains. This hypothesis is support by the effects of simvastatin on P. 
aeruginosa biofilm formation observed in this work. Simvastatin had no effect on 
the attachment of PAO1 and the clinical isolates CF194 and TY5010, suggesting that 
its effect on PA14 was mediated through PA14-specific genes or proteins. 
Statins did not affect the promoter expression of the TTSS toxin ExoS. This 




treatment did not influence the secretion of the Streptococcus pneumoniae toxin 
pneumolysin (62). Statins were able to reduce swarming, but not swimming, 
twitching or chemotaxis, suggesting that they did not influence the production and 
activity of flagella or pili, but instead targeted physiological capabilities of the 
bacteria. Over 200 genes are involved in swarming motility, and these are involved 
in processes as diverse as RNA and protein synthesis, metabolism and transport (63). 
It therefore appeared that simvastatin may influence some of these processes. The 
results obtained in 2-DGE analysis of the P. aeruginosa swarm tip appeared to 
confirm this, as simvastatin altered expression of proteins responsible for RNA and 
protein synthesis, as well as transport of LPS. 
Several biofilm-related phenotypes were tested in the presence of simvastatin, but 
only 1 of these (early attachment) was attenuated, suggesting that statins impact the 
beginning of biofilm production, but not biofilm maturation. The alteration of 
attachment suggested that statins may also be altering P. aeruginosa quorum 
sensing, as biofilm formation is regulated by PQS- and AHL-mediated signalling 
(24, 64). In particular, LasI/R-mediated signalling typically occurs when bacteria 
become irreversibly attached to surfaces (24). Neither type of signalling was altered 
in the presence of simvastatin. Overall, the phenotypic data obtained suggested that 
the effect of statins on P. aeruginosa was specifically directed towards early biofilm 
formation.  
A reproducible statin effect on the P. aeruginosa transcriptome was not observed in 
this study. The genomic contents of PAO1 and PA14 are similar, but the PA14 
genome is larger than that of PAO1, due to the presence of 2 pathogenicity islands 
(65) and PA14 is known to possess almost 500 genes which are not present in PAO1 




gene chip specific for PAO1, as a PA14 chip is not currently available. This issue 
was addressed by examining the effect of simvastatin on PA14 sensor and regulator 
proteins. It was identified that the PvrR regulatory protein appeared to be involved in 
the effects of simvastatin on P. aeruginosa. Furthermore, CupA1, CupA2 and 
CupD1 expression also appears to be altered by simvastatin treatment. CupA1 and 
CupD1 both encode fimbrial subunits, while CupA2 acts as a chaperone protein (49, 
67). Both pvrR and the cupD operon are encoded by the PAPI-1 pathogenicity island 
(65), meaning that they are absent in PAO1. This may account for the inability of 
simvastatin to reduce the attachment of this strain. This could also suggest that the 
clinical isolates CF194 and TY5010 lack a PvrR homologue. The genomes of CF194 
and TY5010 have not yet been sequenced, but it is possible that they do not possess 
orthologues of PAPI-1 and PAPI-2. The WspF methylesterase was also found to be 
associated with the impact of simvastatin on P. aeruginosa attachment. WspF 
expression is associated with decreased biofilm formation (68), and it therefore 
appears that simvastatin may increase the expression or post-translational activity of 
this protein. Furthermore, it appears that simvastatin may attenuate the virulence of 
P. aeruginosa by reducing intercellular c-di-GMP levels, as both PvrR and WspF are 
associated with decreased c-di-GMP (48, 68).  
The P. aeruginosa proteome was modified by simvastatin. This analysis confirmed 
the hypothesis that the effect of simvastatin on P. aeruginosa was extremely specific, 
as only 6 proteins were increased by statin treatment. In addition, this may be the 
first study to demonstrate post-translational modification of bacterial proteins by 
statins. It appears that the most promising candidate proteins from this work were 
LptD and AcnB, due to their roles in virulence. Simvastatin attenuated swarming 




not essential for reduction of motility. However, as LPS is required for P. 
aeruginosa motility (10), it is possible that simvastatin may decrease motility by 
alteration of LPS synthesis or transport. It was not feasible to examine the swarming 
phenotype of an acnB-deficient strain. Therefore, future studies should be conducted 
to elucidate the essentiality of AcnB in the repression of swarming by simvastatin, 
and to examine impact of simvastatin on LPS and ExoA production.  
One interesting observation from this study was that the effects observed for the 
three statins tested – lovastatin, mevastatin and simvastatin – were comparable. 
These 3 statins are type 1 statins, meaning that they are lipophilic and are composed 
of a conserved central lactone ring, to which a distinct butaryl side chain and decalin 
ring are attached (69). The relative structural similarity of the statins tested could 
give reason to the comparable effects exerted on bacterial virulence. However, in situ 
these statins are hydrolysed by hepatocytes to give an “active” form where the 
lactone ring is cleaved (70). Therefore, an in vitro hydrolysis of the statins was 
performed to determine whether the active form of the statins still yielded the same 
inhibitory effects. Activated lovastatin and mevastatin no longer had an inhibitory 
effect on swarming motility, but activated simvastatin still had a modulatory effect, 
suggesting that the side chain of simvastatin has some impact in the exertion of its 
effects. Simvastatin differs from lovastatin and mevastatin by way of 2 methyl 
groups in the secondary carbon position in its side chain (C-2), and the inhibition of 
swarming motility by hydrolysed simvastatin suggests that this functional group may 
play a role in mediating the anti-virulence effects of simvastatin. It is unclear from 
the current literature whether statins are metabolised or altered by P. aeruginosa. In 
the liver, statins are converted to their active form by esterase activity, or can be 




cytochrome P450 orthologues, the results of this study seem to indicate that statins 
are not hydrolysed by the bacteria in the same manner that they are by hepatocytes. 
Based on the data accumulated in this study, it is evident that P. aeruginosa is 
affected by statins. It may be thus inferred that P. aeruginosa has some mechanism 
whereby it perceives statins and its behaviour is altered accordingly. The results 
obtained in this study indicate that statins could potentially be used as a novel anti-
microbial agent against P. aeruginosa, but they would not be suitable for use as a 
sole anti-microbial agent, due to their extremely specific and limited anti-virulence 
effects, and the fact that the concentrations used in this study were much higher than 
the levels typically found in blood. However, as it has been demonstrated that 
inhalation of the antibiotic tobramycin increased its levels in the lungs (71, 72), there 
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  Abstract 
The statin family of cholesterol-lowering drugs is known to have pleiotropic 
properties which include anti-inflammatory and immunomodulatory effects. Statins 
exert their pleiotropic effects by altering expression of human immune regulators 
including pro-inflammatory cytokines. Previously it was found that statins modulate 
virulence phenotypes of the human pathogen Pseudomonas aeruginosa, and 
therefore it was investigated whether simvastatin could alter the host response to this 
organism in lung epithelial cells. Simvastatin increased the expression of the P. 
aeruginosa target genes KLF2, KLF6, IL-8 and CCL20, demonstrating the novel 
induction of KLF6 and a novel pro-inflammatory effect of statins on lung cells. 
Furthermore, both simvastatin and P. aeruginosa induced alternative splicing of 
KLF6. P. aeruginosa was also capable of inducing KLF6 alternative splicing in a 
cystic fibrosis model. The impact of P. aeruginosa on KLF6 alternative splicing was 
found to be mediated through the bacterial ExoS toxin. In addition, the novel effect 
of simvastatin on wtKLF6 expression was found to be responsible for induction of 
the KLF6-regulated genes CCL20 and iNOS, which have roles in the immune 
response. Simvastatin also increased the adhesion of P. aeruginosa to host cells, 
without altering invasion or cytotoxicity. Taken together, these results demonstrated 





The key function of the statin family of drugs is inhibition of cholesterol 
biosynthesis. However, these compounds are also known to have cholesterol-
independent pleiotropic effects. One of the many pleiotropic effects of statins is the 
attenuation of bacterial infections. It has previously been demonstrated that statins 
improved survival in patients who had sepsis and pneumonia (1–6). This can be 
attributed in part to the inhibition of anti-inflammatory pathways. For instance, 
statins can reduce activation of the pro-inflammatory cytokine Interleukin-8 (IL-8) 
by bacterial and fungal surface antigens in ex vivo blood cells (7). Production of 
another infection-induced chemokine, Chemokine (C-C motif) ligand 20 (CCL20; 
also known as macrophage-inhibitory protein 3α (MIP-3α)), is also reduced by statin 
treatment of keratinocytes (8). As well as inhibiting pro-inflammatory components, 
statins also increase the expression of anti-inflammatory components, such as 
endothelial nitric oxide synthase (eNOS) (9) and thrombomodulin (10). The anti-
inflammatory and immunomodulatory effects of statins are mediated through the 
alteration of expression of transcription factors such as NFκB (11).  
One group of transcriptional regulators that is now emerging as both a key group of 
immune and inflammatory regulators and a target of statin treatment is the Kruppel-
like Factors (KLFs). These are a family of transcription factors characterised by the 
presence of 3 conserved zinc fingers (12). Two KLF family members, KLF2 and 
KLF6, have previously been found to be increased in an in vitro Pseudomonas 
aeruginosa infection model (13). P. aeruginosa is an important human pathogen that 
causes serious infections in immunocompromised individuals and is the main 
pathogen associated with chronic refractory pulmonary infections in cystic fibrosis 
(CF) patients. The pathogenesis of P. aeruginosa can be attributed to a plethora of 
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virulence associated phenotypes including the production and secretion of toxins via 
the Type 3 secretion system (TTSS). Previously, the exotoxins ExoS and ExoY 
secreted by the TTSS were shown to be required for P. aeruginosa induction of 
KLF2 and KLF6 in CF airway epithelial cells (13). KLF2 is mainly characterised as 
an anti-inflammatory regulator which can control the activation of monocytes and 
macrophages (14, 15), and has been found to be induced by toxin activity of 
Staphylococcus aureus (16), Yersinia enterocolitica (17) and Clostridium botulinum 
(18). Furthermore, statins can also induce the expression of KLF2 (18, 19). 
The role of KLF6 in infections is currently less clear than that of KLF2. KLF6 is 
most widely-recognised as a tumour suppressor protein which inhibits proliferation 
(20) and induces apoptosis (21). However, KLF6 is known to be alternatively spliced 
into a full-length transcript (wtKLF6) and 3 truncated variants (SV1, SV2, SV3) 
(22). In contrast to the tumour-suppressive action of wtKLF6, the splice variants of 
KLF6, particularly SV1, have been found to have oncogenic properties and have 
been implicated in several types of cancer including lung, liver, ovarian and prostate 
(22–25). Given that they do not possess the 3 zinc fingers of wtKLF6 it is believed 
the splice variants cannot exert their biologic effects through direct binding of DNA 
but instead must interact with other proteins (26). For example, SV1 has been shown 
to bind directly to wtKLF6 accelerating its degradation and thus antagonising its 
tumour suppressor function (27).  
While to date, it has not been characterised, it is likely that KLF6 does play a role in 
bacterial infections, as it is upregulated by S. aureus (16) and P. aeruginosa (13), 
and can promote the apoptosis of cells infected with respiratory syncytial virus (28) 
and influenza A (29). Furthermore, some regulatory targets of KLF6 are known to 
have roles in the immune response to infections. KLF6 directly activates promoter 
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expression of ASAH1 (acid ceramidase) (30) and iNOS (inducible nitric oxide 
synthase; NOS2) (31), 2 proteins that regulate the production of signalling molecules 
with roles in the inflammatory response. ASAH1 negatively regulates the production 
of ceramide, which is upregulated as part of the host response to P. aeruginosa (32), 
leading to increased inflammation (33). iNOS is responsible for the production of 
nitric oxide (NO), a signalling molecule which is responsible for increased 
inflammation, lung damage and bacterial killing during infections (34, 35). In 
addition, KLF6 also induces the expression of the pro-inflammatory chemokine 
CCL20 (MIP-3α). It has been proposed that this effect is indirect, mediated through 
the KLF6-dependent inhibition of another transcription factor called Peroxisome 
Proliferator-Activated Receptor γ (PPARγ) in kidney cells (36). 
In this study, it was sought to investigate the effect of simvastatin on the expression 
of P. aeruginosa-responsive immune modulators, including KLF6 splice variants, in 
a lung epithelial cell model. In addition to KLF2 and KLF6, P. aeruginosa has been 
shown to alter the expression of several modulators of the host immune response 
including IL-8 (37), CCL20 (38) and TLR5 (Toll-like Receptor 5) (39), which 
activates NFκB-dependent inflammation in response to bacterial cell surface 
component flagellin (40, 41). It was demonstrated that simvastatin induces pro-
inflammatory modulators of the immune response and that both P. aeruginosa and 
simvastatin induce KLF6 splice variants in A549 epithelial cells, with the wtKLF6 
being the dominant variant. Thus, it was observed that simvastatin could alter the 
genetic and physiological immune response in lung cells and KLF6 was identified as 
a novel target of statins and an important transcriptional regulator in the lung.  
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Materials and methods 
Mammalian cells and bacterial strains 
All cell lines and bacterial strains used in this study are detailed in Table 1. A549 
cells were grown in minimal Eagle’s medium (MEM) (Sigma-Aldrich, U. K.) 
supplemented with 10 % foetal bovine serum (FBS), 50 units/ml pen-strep and 2 
mM L-glutamine. Phoenix packaging cells were utilised for the production of 
recombinant retroviruses and were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10 % FBS, 50 units/ml pen-strep and 2 mM L-glutamine. IB3-1 cells 
were cultured on plastic coated with bovine serum albumin (BSA)-collagen-
fibronectin using LHC-8 medium supplemented with 10% FBS and 50 units/ml of 
penicillin-streptomycin. Infection assays were carried out using co-culture medium 
(LHC-8 or MEM minus pen-strep), and cells that were used in the determination of 
cytotoxicity were cultured in serum-free medium. All medium components were 
obtained from Gibco unless stated otherwise. Cells were incubated at 37 °C in a 
humidified 5% CO2 atmosphere.  
All P. aeruginosa strains were cultured in Luria-Bertani broth (10 g/L tryptone, 5 
g/L yeast extract, 5 g/L NaCl) and were subcultured for infection assays in co-culture 
medium. A complete list of cell lines and strains used in this study is detailed in 
Table 1.  
 
Generation of stable cell lines 
wtKLF6 and SV1-specific cDNA fragments were cloned into the pSUPER retroviral 
si-RNA vector (Oligoengine) between the HindIII and BglII sites (described in Narla 
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et al., 2005a and Narla et al., 2005b (22, 42)). Phoenix cells were co-transfected with 
4 µg of each pSUPER-wtKLF6, pSUPER-luc (vector control) and a pAMPHO viral 
vector (Clontech) using the X-tremeGENE reagent (Roche). Transfection was 
performed as per the manufacturer’s recommendations. Fresh medium was added to 
cells at 8 hours post transfection, and virus was collected 12 hours after this. Virus 
was collected by removing medium from cells, and passing it through a 0.45 µm 
filter. Following the first collection, virus was collected twice more at successive 12 
hour timepoints. All collected viruses were stored at 4 ºC. 
A549 cells were seeded in 10 cm diameter plates at a density of 8000 cells/cm
2
, and 
allowed to grow for 16-20 hours. Medium was aspirated, and 6 ml of virus 
containing 10 µg/ml polybrene (Sigma) was added to each dish. Cells and virus were 
co-incubated for 12 hours at 37 ºC and 5 % CO2 for 12 hours, after which medium 
was aspirated and 2 successive infections were carried out in the same manner. 
Following this, medium was aspirated and replaced with fresh medium containing 
0.5 µg/ml puromycin (Sigma). Medium was replaced every 2-3 days and cells were 
cultured until 80-90 % confluency was achieved, following which they were 
trypsinised and passaged as previously described. All pSUPER-cells were 
maintained in medium supplemented with 0.5 µg/ml puromycin throughout the 




Table 1: Cell lines and bacterial strains used in this study 
 Type Reference 
Mammalian cell line   
A549 Wild type squamous alveolar epithelia ATCC 
A549 pSUPER-wtKLF6 si-RNA-mediated knockdown of 
wtKLF6 
This study 
A549 pSUPER-Retro Luc Vector Control This study 
IB3-1 Bronchial epithelial cell line derived 
from a CF patient with CFTR ΔF508 
ATCC 
Phoenix HEK 293T transfected with gag, pol and 
env constructs for retrovirus production 
(43) 
   
Bacterial strain   
P. aeruginosa PAO1 Wild type (44) 
P. aeruginosa ΔexoS Mutant in exoS (45) 
P. aeruginosa ΔexoY Mutant in exoY (45) 
P. aeruginosa ΔexoSΔexoY Double mutant in exoS and exoY (45) 




Statin treatment and infection of cells  
Simvastatin (Sigma-Aldrich) was resuspended in DMSO at a concentration of 20 
mg/ml, filter sterilised and stored at 4 °C. A549 cells were washed twice with PBS, 





were then incubated until they achieved 80 % confluency, following which they 
were treated with either 10 µM simvastatin or an equivalent volume of DMSO. Cells 
were treated with simvastatin for 24 hours. 
Bacteria were cultured shaking at 37 °C at 16-18 hours in LB broth, following which 
they were sub-cultured in infection medium shaking at 37 °C for 3 hours. 
Subsequently, the culture was centrifuged (2330 x g; 10 minutes), and washed twice 
with PBS, following which the bacterial densities were adjusted so as to infect cells 
at a multiplicity of infection (MOI) of 50:1. 
 
RNA isolation and quantitative real-time PCR (qRT-PCR) 
RNA isolation was carried out using an RNeasy mini kit (QIAGEN, Germany) for 
A549 cells or an RNeasy Plus mini kit (QIAGEN) for IB3-1 cells according to 
manufacturer’s specifications, and was quantified using a ND-1000 
Spectrophotometer (NanoDrop Technologies, USA). Genomic DNA was removed 
using Turbo DNA-free™ (Ambion), and samples were confirmed to be free of DNA 
by PCR. RNA was converted to cDNA using oligod(T) and AMV reverse 
transcriptase (both Promega). qRT-PCR was carried out using the Universal 
ProbeLibrary system (Roche) according to manufacturer’s specifications, and 
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samples were normalised to hypoxanthine phosphoribosyltransferase (HPRT). A full 




Table 2: Primers used for qRT-PCR analysis of host gene expression.  
Gene Product Length (bp) Sequence Probe No.* 
HPRT 102 Forward: tgaccttgatttattttgcatacc 73 
  Reverse: cgagcaagacgttcagtcct  
KLF2 67 Forward: cctcccaaactgtgactggt 115 
  Reverse: ctctgtagccacgctgtgc  
wtKLF6 70 Forward: aaagctcccacttgaaagca 2 
  Reverse: ccttcccatgagcatctgtaa  
SV1 109 Forward: ggcacttccgaaagcaca 24 
  Reverse: cctcagaggtgcctcttcat  
SV2 96 Forward: gggaaccttctcaactgtgg 24 
  Reverse: aaggcttttctcctggcttc  
SV3 96 Forward: acgcacacaggtgtttttcc 32 
  Reverse: ccttttagcctacaggatccac  
IL-8 77 Forward: gccaggatccacaagtcct 98 
  Reverse: tggtggctaatactttttccact  
CCL20 77 Forward: tggcttttctggaatggaat 117 
  Reverse: tgtgcaagtgaaacctccaa  
ASAH1 86 Forward: ttgacatttggggatctggt 10 
  Reverse: attcaacacccacgctgaa  
iNOS 68 Forward: ttccttacgaggcgaagaag 3 
  Reverse: tcagagcgctgacatctcc  
PPARγ 78 Forward: accagctgaatccagagtcc 81 
  Reverse: gcgggaaggactttatgtatga  
* The annealing temperature of all primer sets is 60 ºC.
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Determination of cytotoxicity  
Cytotoxicity of statin treatment and/or Pseudomonas aeruginosa PAO1 infection 
was measured using a LDH Cytotoxicity Detection Kit (Roche) according to 
manufacturer’s instructions. Infection and statin-treatment of A549 cells were set up 
as previously described, except that in this instance serum-free medium was used, as 
FBS has been found to cause high background in this assay. The OD492nm of samples 
was measured at 1.5, 3 and 6 hours post infection using a SpectraMax Plus 384 96 
well plate reader (Molecular Devices).  
 
Measurement of bacterial adhesion and invasion 
Adhesion and invasion of bacteria were quantified as described by Burns et al., 1996 
(46). Briefly, A549 cells were treated with simvastatin and infected with P. 
aeruginosa PAO1 as previously described. For determination of invasion, after 1 
hour of infection ceftazimide (1 mg/ml) and gentamicin (2 mg/ml) (both Sigma-
Aldrich) were added for a further 2 hours, following which cells were washed twice 
with PBS and lysed using 0.1 % Triton X-100. Intercellular bacteria were 
enumerated by serial dilutions and plate counts. To measure bacterial adherence, 
extracellular bacteria were removed from epithelial cells, which were lysed to 
provide a total and intercellular count following 3 hours of infection. The adherent 
count was determined by subtracting the number of intercellular and extracellular 
bacteria from the total bacterial count.  
 
Statistical analysis 




Simvastatin influences the gene expression of P. aeruginosa-responsive host 
immune modulators 
In order to investigate the effect of statins on the expression of infection-responsive 
and immunomodulatory genes, 5 genes previously shown to be induced during P. 
aeruginosa infection were selected for analysis: KLF2, KLF6, IL-8, CCL20 and 
TLR5 (13, 37–39). The expression of these candidate genes was analysed in A549 
squamous epithelial lung cells which were treated with 10 µM simvastatin or an 
equivalent volume of DMSO vehicle control for 24 hours, following which they 
were infected with P. aeruginosa PAO1 at an MOI of 50:1 for 3 hours. Gene 
expression was analysed using qRT-PCR. Simvastatin has been found to induce 
KLF2 in endothelial cells & human peripheral blood monocytes (18) and the results 
obtained in this study complied with these findings. KLF2 was significantly 
increased in statin-treated A549 cells compared to DMSO-treated cells (P = 0.012) 
(Figure 1A). Interestingly, P. aeruginosa also significantly induced KLF2 expression 
(P = 0.033) but to a much lesser degree than simvastatin alone and there was no 
additive effect in statin-treated infected cells (P = 0.008). Previous studies have 
shown that statins were ineffective against KLF6 expression (18), however here a 
significant induction of wtKLF6 by simvastatin treatment was demonstrated in A549 
lung epithelial cells (P = 0.005) (Figure 1B). P. aeruginosa also significantly 
induced KLF6 (P = 0.015), but to a greater extent than simvastatin (fold change), 
and this effect was sustained in simvastatin-treated infected cells (P = 0.0019). Thus, 




As expected, P. aeruginosa infection significantly induced IL-8 expression; 
transcript levels in infected cells were over 100 times higher than control cells 
(Figure 1C). Interestingly, in contrast to published reports (7) it was observed that 
simvastatin increased the expression of IL-8 by 14.75-fold compared to vehicle 
treated epithelial cells. However, when cells were pre-treated with simvastatin and 
subsequently infected with P. aeruginosa the level of IL-8 expression was not 
significantly different to untreated infected cells. Therefore, again there was no 
additive effect of simvastatin and P. aeruginosa on IL-8 expression. 
CCL20 expression was also significantly increased by P. aeruginosa compared to 
uninfected cells (P = 0.03) and it was increased to a lesser extent (14.5-fold; P = 
0.02) by simvastatin alone compared to vehicle-treated cells (Figure 1D). 
Interestingly however, in simvastatin-treated infected cells, a significant increase in 
CCL20 expression was observed (P = 0.02). This effect was greater than CCL20 
induction by simvastatin (P = 0.02) or P. aeruginosa (P = 0.054) individually, 
suggesting that CCL20 expression was synergistically induced by a combination of 
these factors. 
In contrast to IL-8 and CCL20, TLR5 expression was not significantly altered by 
simvastatin (Figure 1E). The expression of this gene was significantly increased by 
P. aeruginosa (P = 0.015) but interestingly, under combined statin treatment and 
infection expression levels were comparable to statin-treated uninfected cells 
suggesting that simvastatin may reduce P. aeruginosa-mediated induction of TLR5.




Figure 1: Effect of statin treatment on the host response to P. aeruginosa infection. 
A549 cells were treated with 10 µM simvastatin for 24 hours, and were subsequently 
infected with P. aeruginosa PAO1 for 3 hours at MOI 50:1. The effect of simvastatin, PAO1 
and simvastatin + PAO1 was examined on (A) KLF2 (B) KLF6 (C) IL-8 (D) CCL20 and 
(E) TLR5. *P, ≤ 0.05, **P, ≤ 0.01, ***P, ≤ 0.001.  
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Novel induction of KLF6 alternative splicing by P. aeruginosa and simvastatin 
While the results obtained here confirm P. aeruginosa induction of wtKLF6 
expression (13), the expression of KLF6 splice variants in the context of bacterial 
infections has never been characterised. Therefore, this study sought to examine 
whether P. aeruginosa could influence the alternative splicing of KLF6 in lung 
epithelial cells. For this analysis, A549 cells were infected with P. aeruginosa PAO1 
for 3 hours, at an MOI of 50:1, and the expression of KLF6 splice variants was 
analysed by qRT-PCR. 
In uninfected cells, a basal level of expression was observed for each splice variant; 
however, wtKLF6 was clearly the dominant variant (Figure 2A). P. aeruginosa 
induced the expression of all 3 KLF6 splice variants but to varying degrees. Of the 3 
variants, SV3 was increased to the greatest extent (P = 0.005), and SV2 was also 
significantly induced (P = 0.013). SV1 displayed the lowest level of induction of the 
3 variants and this did not reach significance. Interestingly, wtKLF6 was induced to 
the greatest magnitude by P. aeruginosa (P = 0.015). Thus, wtKLF6 was the 
dominant variant in A549 cancer lung epithelial cells under basal and P. aeruginosa 
infected conditions. 
Given the prominence of P. aeruginosa as an opportunistic pathogen in CF patients, 
it was subsequently examined whether P. aeruginosa could induce KLF6 alternative 
splicing in CFTR-deficient cells. For this analysis, IB3-1 cells were utilised. IB3-1 
cells are bronchial epithelial cells which possess the most common CFTR mutation, 
Δ508, which is present in approximately 70 % of CF patients (47). IB3-1 cells were 
infected with P. aeruginosa PAO1 for 3 hours and expression of the KLF6 splice 
variants was examined using qRT-PCR. Interestingly, it was observed that the 
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pattern of basal splice variant expression differed between IB3-1 and A549 cells. In 
IB3-1 cells (Figure 2B), wtKLF6 was expressed at a slightly lower level than in 
A549 cells. Furthermore, SV3 expression was extremely low in IB3-1 cells, 
compared to both its expression in A549 cells, and the expression of the other 
transcripts. In contrast, SV1 and SV2 were present at higher levels in IB3-1 cells 
than in A549 cells, and also appeared to be more abundantly expressed than 
wtKLF6. P. aeruginosa induced all splice variants in CF cells, but the pattern of 
expression varied compared to that of A549 cells. P. aeruginosa-induced wtKLF6 
expression was lower in IB3-1 cells than in A549 cells, although the fold increase of 
wtKLF6 was comparable between both cell types. Similarly, SV1 expression was 
increased by P. aeruginosa in CF cells in a comparable manner to A549 cells, but 
unlike wtKLF6, its corresponding transcript levels were higher in CF cells. SV2 was 
significantly increased by P. aeruginosa in IB3-1 cells (P = 0.02), but the extent of 
this increase was lower than in A549 cells. SV3 was also significantly induced by P. 
aeruginosa in CF cells (P = 0.03), but both the fold change and transcript expression 
were lower here than in non-CF cells. It therefore appears that CFTR deficiency may 
influence the expression levels and P. aeruginosa-mediated induction of KLF6 
splice variants. 
The mechanism behind the induction of KLF6 alternative splicing by P. aeruginosa 
was subsequently investigated. KLF2 and KLF6 were previously found to be 
induced by the ExoS and ExoY toxins from the P. aeruginosa Type 3 secretion 
system (TTSS) (13), and therefore this study examined whether these toxins were 
also responsible for induction of KLF6 alternative splicing. A549 cells were infected 
with P. aeruginosa PAO1 single mutants in exoS (ΔexoS) and exoY (ΔexoY), a 
double exoSexoY mutant (ΔexoSΔexoY), and an isogenic PAO1 WT strain (RP289), 
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for 3 hours. qRT-PCR was used to test the expression of wtKLF6, SV1, SV2 and 
SV3 in infected cells relative to uninfected cells. As expected, WT PAO1 
significantly increased the expression of all variants: wtKLF6 (P = 0.005), SV1 (P = 
0.008), SV2 (P = 0.0007) and SV3 (P = 0.01) (Figure 2C). In cells infected with 
ΔexoS, no significant change was observed in any of the transcripts tested. This was 
also the case for cells that were infected with ΔexoSΔexoY. However, when cells 
were infected with ΔexoY, expression of all variants was induced to a comparable 
level to those of cells infected with the WT strain. These data indicated that ExoS 
was responsible for the P. aeruginosa-mediated induction of KLF6 and its splice 





Figure 2: The effect of P. aeruginosa on KLF6 alternative splicing.  Cells were infected 
with P. aeruginosa PAO1 for 3 hours at MOI 50:1 and expression of wtKLF6, SV1, SV2 
and SV3 was examined using qRT-PCR. (A) P. aeruginosa PAO1 induced KLF6 alternative 
splicing in A549 lung cells. (B) The expression of KLF6 splice variants was examined in 
CFTR-deficient cells (IB3-1). All variants were upregulated in response to PAO1, but the 
fold changes of SV2 and SV3 were lower than those of cells with a non-CF phenotype. (C)  
The P. aeruginosa ExoS toxin is required for the induction of KLF6 splice variants. *P, ≤ 




As both statins and P. aeruginosa had significant effects on the RNA level of 
expression of wtKLF6, and P. aeruginosa could induce KLF6 alternative splicing, 
the expression of KLF6 splice variants in response to simvastatin alone and in 
combination with P. aeruginosa infection in lung epithelial cells was subsequently 
examined. As before, A549 cells were pre-treated with 10 µM simvastatin for 24 
hours and subsequently infected with P. aeruginosa PAO1 for 3 hours and splice 
variant expression was analysed using qRT-PCR. Simvastatin increased the 
expression of SV1 (Figure 3A), SV2 (Figure 3B) and SV3 (Figure 3C), with SV3 
levels reaching significance (P = 0.01). As with wtKLF6, P. aeruginosa had a 
greater effect on the expression of all 3 splice variants than simvastatin and there was 
a slight but not significant additive effect on SV1 and SV3 in simvastatin pre-treated 
infected cells. Of particular note was that the transcript levels of wtKLF6 were 
higher than those of SV1, SV2 and SV3 under all conditions, suggesting that 
wtKLF6 was the dominantly expressed variant in A549 cells and in response to 





Figure 3: Induction of KLF6 splice variants by simvastatin. A549 cells were treated with 
10 µM simvastatin for 24 hours, following which they were infected with P. aeruginosa 
PAO1 for 3 hours at MOI 50:1. The expression of (A) SV1, (B) SV2 and (C) SV3 was 
examined using qRT-PCR. *P, ≤ 0.05, **P, ≤ 0.01. 
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Elucidating the downstream effect of statin-mediated KLF6 induction 
In order to further examine the influence and impact of the induction of KLF6 splice 
variants by P. aeruginosa and statins, stable knockdown cell lines were generated for 
wtKLF6 and SV1 (respectively designated si-wtKLF6 and si-SV1). A549 cells were 
transfected with pSUPER retroviral vectors containing fragments of wtKLF6 and 
SV1 cDNA, and positive clones were selected using puromycin. To verify that si-
cells were displaying reduced expression of wtKLF6 and SV1, they were harvested 
for RNA isolation, and the expression of wtKLF6 and SV1 was examined by qRT-
PCR. It was demonstrated that in cells containing pSUPER-wtKLF6, wtKLF6 
expression was significantly reduced by 47.2 % compared to the cells containing the 
vector control (designated si-luc) (P = 0.008) (Figure 4A). However, in cells 
containing pSUPER-SV1, SV1 was expressed at a comparable level to cells 
containing the vector control (Figure 4A), demonstrating that the si-SV1 vector was 
not functioning as expected. 
To examine the role of wtKLF6 and SV1 in P. aeruginosa infection,  si-wtKLF6, si-
SV1 and vector control cell lines were infected with P. aeruginosa PAO1 for 3 hours 
at MOI 50:1 (Figure 4B). wtKLF6 and SV1 were induced to a similar extent by P. 
aeruginosa infection in their respective si-cell lines as in the si-luc cells. This 
analysis correlated with the previously-observed technical issues with the pSUPER-
SV1 vector, but it also indicated that the effect of P. aeruginosa on wtKLF6 
expression was able to override the inhibitory effects of the pSUPER-wtKLF6 
vector. Therefore, the si-wtKLF6 cell line was found to be unsuitable for the analysis 





Figure 4: Validation of stable knockdown cell lines. (A) wtKLF6 mRNA expression was 
reduced by 47.2 % in si-wtKLF6 cells compared to vector control cells (P = 0.008) but SV1 
expression was not altered between si-SV1 cells and vector control cells. (B) Both wtKLF6 




To investigate the consequences of KLF6 knockdown in lung cells, expression 
analysis was carried out on 4 KLF6 regulatory target genes: ASAH1, CCL20, iNOS 
and PPARγ. In si-wtKLF6 cells, the expression of 3 target genes was attenuated 
(Figure 5A); ASAH1, CCL20 and iNOS expression was decreased by an average of 
30.3 % (non-significant), 51.5 % (P = 0.012) and, 72.9 % (P = 0.047) respectively in 
si-wtKLF6 cells compared to vector control cells. However, the expression of 
PPARγ was comparable between si-wtKLF6 and si-luc cells, suggesting that the 
expression of PPARγ in the model used in this study was not dependent upon 
wtKLF6. This also suggests that KLF6 regulation of CCL20 was not dependent on 
PPARγ, although it may be possible that the level of wtKLF6 reduction obtained in 
si-cells may not be enough to inhibit PPARγ expression. 
Thus, wtKLF6 plays a key, multifaceted regulatory role in lung epithelia and the 
effect of simvastatin on wtKLF6 and its regulatory targets in si-wtKLF6 lung cells 
was subsequently examined. This analysis was carried out using qRT-PCR of 
transcripts isolated from pSUPER-wtKLF6 cells and vector control cells which had 
been treated with 10 µM simvastatin for 24 hours. Firstly, transcript expression of 
wtKLF6 in pSUPER-wtKLF6 cells was examined to determine whether this model 
was suitable for use with statin treatment, given the technical issues which arose 
when they were subjected to infection experiments. After 24 hours of treatment, 
wtKLF6 was significantly increased by simvastatin in both vector control (P = 
0.015) and pSUPER-wtKLF6 (P = 0.004) cell lines. However, despite this increase, 
wtKLF6 was still decreased by 33 % in si-wtKLF6 cells compared to vector control 
cells in the presence of simvastatin (P = 0.02) compared to a 46 % decrease between 
vehicle-treated si-wtKLF6 and vector control cells (Figure 5B). Based on these 
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results, it was concluded that wtKLF6 was sufficiently reduced in knockdown cells 
to allow the examination of statin-related phenotypes. 
The effect of simvastatin treatment was subsequently examined on KLF6 regulatory 
target genes, in order to investigate the downstream effects of statin-mediated KLF6 
induction. A simvastatin-mediated increase in the expression of ASAH1 in vector 
control and si-wtKLF6 cells was observed (Figure 5C). While ASAH1 was 
decreased in DMSO (vehicle)-treated si-wtKLF6 cells, its expression in statin-treated 
si-wtKLF6 cells was equivalent to that of statin treated si-luc cells, signifying that 
the induction of ASAH1 by simvastatin did not appear to be mediated through 
wtKLF6. 
The wtKLF6-dependent decrease in CCL20 that was observed in untreated si-cells 
was maintained in vehicle-treated si-cells (P = 0.04) (Figure 5D).  However, in the 
presence of simvastatin CCL20 expression was decreased in vector control cells, 
implying that the selective marker itself may have been interfering with its 
expression. Nevertheless, in si-wtKLF6 cells, the expression of CCL20 was 
equivalent between simvastatin-treated and DMSO-treated cells, suggesting that the 
novel CCL20 induction observed in statin-treated wild type A549 cells may be 
wtKLF6-dependent. 
The third KLF6 target gene examined was iNOS. Interestingly, in contrast to 
CCL20, simvastatin treatment reduced iNOS expression in vector control cells 
(Figure 5E). However, in si-wtKLF6 cells, this reduction in iNOS expression by 
simvastatin was not observed, and expression was at an equivalent level to that of 
vector control cells. This latter suggests that simvastatin may inhibit iNOS 
expression in a KLF6-dependent mechanism. 
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PPARγ (Figure 5F), was significantly reduced in si-wtKLF6 cells compared to 
vector control cells in the presence of the vehicle (P = 0.02). Simvastatin treatment 
increased the expression of PPARγ in both cell types to an equal but non-significant 
extent, regardless of the presence or absence of knockdown. Therefore, PPARγ 
appears to be a statin target in lung cells, albeit a target which is regulated 





Figure 5: wtKLF6 knockdown and simvastatin effects in the lung. (A) Expression of the 
wtKLF6 target genes ASAH1, CCL20, iNOS and PPARγ was examined by qRT-PCR in si-
wtKLF6 cells compared to si-luc cells. ASAH1, CCL20 and iNOS were inhibited in si-cells 
compared to vector control cells. (B) Simvastatin treatment did not override the effect of the 
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wtKLF6 knockdown vector. (C) wtKLF6 does not play a role in simvastatin-mediated 
ASAH1 expression. However, the effects of simvastatin on CCL20 (D) and iNOS (E) 
appeared to be regulated via wtKLF6. (F) PPARγ was also slightly increased by simvastatin 




The effect of simvastatin on cellular cytotoxicity and P. aeruginosa adhesion 
and invasion 
Having established that simvastatin treatment can alter the induction of host immune 
response genes, and having previously demonstrated the alteration of in vitro P. 
aeruginosa motility and early biofilm formation by statins (48) (Chapter 2),  the 
effect of statins on P. aeruginosa-related cytotoxicity, adhesion and invasion of 
A549 epithelial cells was investigated. The cytotoxic effect of P. aeruginosa is 
exerted via its TTSS toxins, in particular ExoS (49), which in turn is required for P. 
aeruginosa-mediated induction of KLF6 (13), suggesting that KLF6 induction may 
lead to P. aeruginosa-initiated cell death. Furthermore, the induction of IL-8 and 
CCL20 has previously been linked to bacterial adhesion and invasion (50–52) and 
therefore statins may have a regulatory impact on these phenotypes. To examine the 
effect of statins on these physiological outcomes, A549 cells were treated with 10 
µM simvastatin for 24 hours and subsequently infected with P. aeruginosa PAO1. 
Cytotoxicity was quantified by measuring lactate dehydrogenase (LDH) release from 
cells as a marker of tissue breakdown during statin treatment and P. aeruginosa 
infection (Figure 6A). LDH release was measured at 3 hours post infection (HPI), as 
this was the interval at which gene expression was measured, but LDH release was 
also evaluated at an early interval (1.5 HPI) and a late interval (6 HPI) to determine 
whether statins could influence the kinetics of P. aeruginosa infection as well as host 
response.  At 1.5 HPI, there was no significant effect on LDH release in any samples 
compared to untreated cells. At 3 HPI, very minimal effects on cytotoxicity were 
observed. Simvastatin-treated cells exhibited slightly increased but non-significant 
LDH release compared to vehicle-treated cells, which also displayed a very modest 
level of cytotoxicity. P. aeruginosa had a significant cytotoxic effect (P = 0.03) 
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compared to untreated cells, and statin treatment and P. aeruginosa combined caused 
a moderate, non-significant increase in LDH release compared to statins and P. 
aeruginosa individually.  
Interestingly, at 6 hours post infection, simvastatin alone had a low but significant 
cytotoxic effect compared to untreated and DMSO treated cells respectively (P = 
0.018, P = 0.04). While P. aeruginosa was significantly cytotoxic compared to 
untreated cells (P = 0.027) and statin-treated cells (P = 0.044), in simvastatin-treated 
cells P. aeruginosa infection was significantly more cytotoxic compared to untreated 
cells (P = 0.0003), vehicle-treated cells (P = 0.0006) and simvastatin-treated, 
uninfected cells (P = 0.0005). This increase in cytotoxicity between infected cells 
and statin-treated infected cells suggested that the presence of simvastatin may 
increase cell damage caused by P. aeruginosa.  
The role of wtKLF6 in inhibiting cell proliferation and inducing apoptosis has been 
extensively established (53); it was thus investigated whether the wtKLF6 played a 
role in the cytotoxic effects exerted by simvastatin on lung epithelial cells. si-
wtKLF6 cells and vector control cells were treated with either 10 µM simvastatin or 
DMSO vehicle for 24 hours in serum-free medium, and cytotoxicity was quantified 
by measuring LDH release. In comparison to untreated cells, simvastatin caused a 
significant but comparable increase in LDH release in both vector control (P = 0.04) 
and si-wtKLF6 (P = 0.005) cells (Figure 6B). This demonstrated that wtKLF6 does 
not play a role in statin-mediated cytotoxicity and cell death, thus suggesting that 
wtKLF6-induced CCL20 and iNOS do not regulate these processes.  
The effect of simvastatin on bacterial adhesion and invasion was also examined in 
A549 cells treated with 10 µM simvastatin for 24 hours and subsequently infected 
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with P. aeruginosa PAO1 for 3 hours. Simvastatin increased the adhesion of PAO1 
to A549 cells compared to those treated with vehicle, but, in contrast, statin 






Figure 6: Cellular responses to simvastatin treatment and infection. Cells were treated 
with 10 µM simvastatin for 24 hours (A, B, C), following which they were infected with P. 
aeruginosa PAO1 at MOI 50:1 (A, C). (A) Simvastatin did not attenuate P. aeruginosa-
mediated LDH release at 1.5, 3 or 6 hours post infection. (B) wtKLF6 was not implicated in 
simvastatin-mediated  cytotoxic effects on lung cells. (C) Simvastatin treatment increased 
bacterial adhesion to cells, but did not influence invasion at 3 hours of infection. *P ≤ 0.05, 





In this study, it was demonstrated that simvastatin can modulate the expression of 
genes involved in the host response to P. aeruginosa infections in lung epithelial 
cells. Previous studies have shown that attenuation of pro-inflammatory cytokine 
production is a key pleiotropic effect of statins in several tissue types (reviewed in 
(53) and (54)), including bronchial epithelial cells (55). However, Kiener and 
colleagues showed that statins could increase monocytic pro-inflammatory cytokine 
and chemokine production in a mevalonate-dependent manner, thus sensitising them 
to challenge by inflammatory agents (56). The latter of these studies correlates with 
the observation in this study whereby simvastatin treatment induced IL-8 and CCL20 
expression and that this was sustained and synergistically increased respectively 
upon infection with P. aeruginosa. The mechanism for this synergistic effect on 
CCL20 expression is unknown but it could be hypothesised that it may be partly due 
to the increase in bacterial adhesion in the presence of simvastatin, as CCL20 
expression in bacterial infections is linked to this phenotype (52). However, P. 
aeruginosa adherence has also been linked to the induction of IL-8 (52), which was 
not synergistically induced in this study. Therefore, other factors are likely to be 
involved in the additive induction of CCL20 by P. aeruginosa and simvastatin. 
Furthermore, P. aeruginosa-mediated IL-8 and CCL20 production has been shown to 
be TLR5-dependent (39, 52), but TLR5 does not appear to be involved in the 
simvastatin induction of these factors, as TLR5 expression was not altered by statin 
treatment. In this study, the novel alteration of ASAH1 and iNOS expression in 
response to simvastatin treatment was also observed. The induction of ASAH1 by 
simvastatin could potentially be beneficial, as it may decrease ceramide-mediated 
inflammation in people with CF and other inflammatory disorders. 
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The anti-inflammatory regulator KLF2 was also induced by simvastatin. These 
results correlate with previous reports of statin induction of KLF2 and it was 
demonstrated that simvastatin had a significantly greater affinity for KLF2 induction 
than P. aeruginosa. This is possibly because statins have been shown to directly 
induce KLF2 expression by binding to a MEF2 transcription factor site in the klf2 
promoter region (18), while the induction of KLF2 by P. aeruginosa is proposed to 
be indirectly regulated by Type 3 toxin-mediated inhibition of host protein (RhoA) 
activity (13, 57, 58). In contrast to KLF2, KLF6 has not previously been shown to be 
induced by statins. Here it was demonstrated for the first time that simvastatin did 
induce KLF6 in airway epithelial cells. Furthermore, as in silico prediction of 
binding sites in the KLF6 promoter region demonstrates that a putative MEF2A 
binding site is located 228 bp upstream of the klf6 start site (data not shown), it may 
be proposed that statins may induce klf6 transcription in a similar manner to klf2. 
However, this does not account for the induction of KLF6 alternative splicing by 
statins. Production of KLF6 splice variants is regulated by a signalling cascade 
which involves the Rho GTPase Ras and the downstream Akt and 
phosphatidylinositol 3-kinase (PI3-K) signalling proteins (24). Previous studies have 
demonstrated that statins can modulate the phosphorylation and activation of the Akt 
signalling molecule in the Ras pathway (59, 60), which may account for splice 
variant production by simvastatin. However, this may be balanced with the 
characteristic statin-mediated inhibition of Ras prenylation first described by 
Leonard et al. (61).  
The induction of KLF6 alternative splicing by P. aeruginosa was also identified for 
the first time. Previously it was reported that KLF6 is induced by P. aeruginosa 
TTSS toxins (13), and here it was demonstrated that the induction of KLF6 splice 
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variants by P. aeruginosa is dependent upon the ExoS toxin. The induction of KLF6 
splice variants by P. aeruginosa could thus be mediated through 2 TTSS-dependent 
mechanisms. Firstly, P. aeruginosa may induce KLF6 alternative splicing by 
modulating Ras signalling, as ExoS has been found to regulate activation of Ras 
(62). Secondly, the P. aeruginosa TTSS also induces the production of reactive 
oxygen species (ROS) during infection (63) and these compounds can induce KLF6 
alternative splicing (64). It was interesting to note that wtKLF6 was the dominant 
KLF6 variant in A549 lung epithelial cells both at basal level and in response to P. 
aeruginosa infection, in spite of them being a cancer cell line. Previously, increased 
SV1 has been linked to various cancers including that of the lung. Nevertheless these 
results clearly demonstrate a role for wtKLF6 in modulating the host response to 
infection.  
Interestingly, KLF6 alternative splicing may also play a role in CF, as wtKLF6 and 
its 3 variants were all induced by P. aeruginosa in CFTR-deficient bronchial 
epithelial cells (IB3-1 cells). However, it was particularly interesting that SV2 and 
SV3 levels were significantly lower in IB3-1 cells compared to A549 cells 
harbouring normal CFTR. The production of KLF6 splice variants is known to be 
regulated by the splice factors ASF/SF2 and SRp40 (22, 24). The expression of 
SRp40 and another splice factor – SRp20 – is known to be increased in macrophages 
by P. aeruginosa PQS (65). Therefore, the increased induction of these splice factors 
may pose a potential mechanism for the induction of KLF6 alternative splicing, 
although these data suggest that this is mediated through ExoS-regulated Ras 
modulation rather than by secreted compounds. Furthermore, although SRp40 
expression levels have been found not to vary between CF and non-CF cells (66), the 
ability of this protein to regulate alternative splicing is regulated by phosphorylation 
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(67), a process that can be differentially regulated between CF patients and healthy 
individuals (68). These results suggests that CFTR deficiency may alter the 
regulation of splice variant production, and indeed the alternative splicing of another 
infection-related protein – TLR4 – is known to be altered when CFTR is non-
functional (69). In addition, wild type (but not mutated) CFTR can act as a 
recognition molecule for P. aeruginosa (70), and altered binding of P. aeruginosa to 
CF cells may also alter ExoS production and thus influence Ras/Akt-mediated splice 
variant production. 
wtKLF6 was found to regulate the statin effects on CCL20 and iNOS but not 
ASAH1 in lung epithelial cells. Interestingly, the data in this study showed that 
wtKLF6 did not appear to regulate the expression of PPARγ in lung cells as it did in 
kidney cells (36), suggesting that this interaction and subsequent CCL20 induction 
may be tissue-specific. The regulation of statin-mediated CCL20 and iNOS 
induction by wtKLF6 affirms the role of this protein in the immune response, and 
suggests that wtKLF6 has a role as a regulator of immune signalling. However, 
wtKLF6-dependent ASAH1 induction suggests that, like statins, wtKLF6 may 
activate both pro- and anti-inflammatory responses, and may thus play a role in 
maintaining a balanced inflammatory response. Furthermore, KLF6 splice variants 
may also antagonise the pro-inflammatory effects of wtKLF6; SV1 has been found 
to have a negative regulatory effect on the pro-inflammatory cytokine TNFα, 
whereas wtKLF6 may induce this protein (64). 
Statins have been proposed as novel therapeutics in the fight against infections (5, 6) 
and this work demonstrates some potential effects simvastatin could have if used as 
an anti-microbial agent in respiratory infections. The manipulation of pro-
inflammatory cytokines and KLFs by simvastatin may lead to improved survival and 
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bacterial clearance mediated by IL-8 and CCL20, whereas statin-induced KLF2 may 
serve as a regulator to downplay other elements of the inflammatory response. The 
dominance of wtKLF6 compared to the other splice variants suggests that a general 
anti-proliferative effect is conferred on simvastatin-treated and P. aeruginosa 
infected cells. Further studies are needed to elucidate the mechanistic role of KLF6 
splice variants in the P. aeruginosa-host response, and to determine whether statins 
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Novel developments generated in this work 
The overall objective of this work was to examine the interaction between statins and 
bacterial pathogens individually and subsequently study their combined impact on 
the host response. In this work, novel statin effects were identified against the 
growth and virulence of cystic fibrosis (CF)-associated pathogens. Simvastatin was 
found to inhibit the growth of Burkholderia cenocepacia for the first time, and lower 
simvastatin concentrations than previously reported (1) were demonstrated to be 
effective against Streptococcus pneumoniae. This study also identified the novel 
statin-mediated reduction of both the in vitro motility of Staphylococcus aureus and 
Pseudomonas aeruginosa, and the in vitro biofilm formation of all 4 species tested. 
In addition, simvastatin was found to increase the anti-microbial potential of 
gentamicin against B. cenocepacia. Furthermore, several novel targets of simvastatin 
were identified in P. aeruginosa.  The PvrR and WspF regulators and several Cup 
fimbrial proteins were found to play a role in the attenuation of biofilm by 
simvastatin, while 6 proteins were upregulated by statin treatment in swarming cells. 
This study also identified novel statin effects in eukaryotic cells. Simvastatin was 
found to induce the expression of the pro-inflammatory cytokines IL-8 and CCL20 
in lung epithelial cells. In addition, this study not only demonstrated a novel 
induction of KLF6 by simvastatin, but also identified the induction of KLF6 splice 
variants by statins and P. aeruginosa for the first time. Furthermore, it was 
elucidated that P. aeruginosa regulated KLF6 alternative splicing by way of the 
ExoS toxin. A role for the statin-mediated induction of wtKLF6 was identified, as 
this protein was found to regulate CCL20 and iNOS expression in response to statin 
treatment. Simvastatin pre-treatment was also found to have a novel effect on 
adhesion of P. aeruginosa to host cells. 
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Overall significance of results 
Throughout the course of this work, statins have been demonstrated to have multi-
faceted effects in the context of infection and immunity. Four key areas where statins 
target bacteria were identified: growth, motility, biofilm and host interactions (Figure 
1). According to the data obtained in this study, statins appear to inhibit bacterial 
growth in a HMGR-dependent manner. Previous studies have demonstrated that 
bacteria which lacked a HMGR were inhibited by statin treatment (2, 3). However, 
these studies used statin concentrations which were much greater than those used in 
this work. It was elected to use comparably lower statin concentrations in this study 
in an attempt to observe inhibitory concentrations that were as close as possible to in 
situ plasma concentrations.  
The inhibition of motility and biofilm by statins occurred at both growth-inhibitory 
and sub-inhibitory statin concentrations. This may be the first study to demonstrate 
reduced bacterial motility in the presence of statins. In addition, the reduction of 
attachment observed here correlates with a previously-reported reduction of Candida 
albicans biofilm formation by sub-inhibitory simvastatin concentrations (4). It was 
also observed that statins can also alter the host response to bacterial infections, at a 
concentration that inhibited motility and biofilm but not growth. Interestingly, 
simvastatin treatment increased adhesion of P. aeruginosa to host cells, despite 
decreasing in vitro attachment. This may be a result of increased actin 
depolymerisation caused by statin treatment, as actin depolymerisation is associated 
with increased attachment to host cells in E. coli infections (5). It was found that 
simvastatin did not alter bacterial invasion, and these results correlated with those 





Figure 1: Methods of anti-bacterial effects of statins. This study identified 4 key areas of 
statin interaction with bacteria. Statins decreased bacterial growth in an apparently HMGR-
dependent mechanism. Motility and biofilm-related phenotypes were attenuated by statins at 
both inhibitory and sub-inhibitory concentrations. Finally, statins influenced the host 




It was demonstrated that statins attenuate the swarming motility and early attachment 
of P. aeruginosa. These phenotypes are associated with the switch from the motile 
sessile stage of acute infection to the beginning of biofilm formation, which is 
associated with chronic infection. Understanding the mechanism by which statins 
influence P. aeruginosa motility and biofilm formation is important for elucidating 
the overall value of statins as anti-microbial agents and how they would best be 
administered. Certain P. aeruginosa pathways that may be targeted by statins have 
been identified in this study, and a possible model for the interplay between statins 
and these pathways is proposed in Figure 2.  
It was observed that simvastatin increased attachment in a pvrR deletion mutant. 
PvrR negatively regulates biofilm formation by inhibiting expression of the cupA 
and cupD fimbrial gene clusters and degrading cyclic-di-GMP (c-di-GMP) (7–9). It 
was therefore proposed that simvastatin may increase PvrR activity, thus decreasing 
c-di-GMP and the expression of the PvrR regulatory targets CupA1, CupA2 and 
CupD1. This would consequently decrease fimbriae expression, thus decreasing 
bacterial attachment. However, a potential role was not identified for PvrS, the 
cognate sensor of PvrR, in the impact of simvastatin. In addition, the RcsB regulator 
can induce biofilm dispersal in a  PvrR-dependent manner (8), but it was observed 
that RcsB did not appear to be involved in the statin effects on attachment. 
A role for the methylesterase WspF in the effect of simvastatin on P. aeruginosa 
biofilm formation was also identified, as simvastatin increased attachment of a WspF 
mutant strain. WspF decreases intercellular c-di-GMP levels and exopolysaccharide 
production (10, 11), suggesting that modulation of these compounds by simvastatin 
may result in decreased attachment. However, low c-di-GMP levels are associated 
with increased swarming motility (12), meaning that reduction of c-di-GMP by PvrR 
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and WspF are most likely not associated with the statin-mediated reduction in 
swarming. Neither PvrS/R, RscB nor WspF appeared to be involved in the 
attenuation of swarming motility by simvastatin. It therefore appears that statins may 
modulate swarming in a c-di-GMP-independent manner. However, it is possible that 
the proposed reduction in fimbriae by simvastatin could contribute to decreased 
swarming motility, as microarray analysis and screening of transposon mutant banks 
have demonstrated that fimbrial proteins may be involved in swarming motility (13–
15). 
In order to elucidate the mechanism behind the attenuation of swarming by 
simvastatin, proteins were isolated from the swarm tip of statin-treated bacteria. This 
analysis revealed that simvastatin increased the expression of proteins involved in 
transcription, translation, LPS transport and metabolism. The LptD transport protein 
was increased by simvastatin. This protein is responsible for the transport of LPS to 
the outer membrane. As structurally correct LPS is required for motility (16), it was 
hypothesised that simvastatin may attenuate swarming motility by aberrantly 
regulating transport of LPS to the outer membrane by potentially increasing 
expression of or post-translationally modifying LptD. 
Another statin target of P. aeruginosa was the aconitase AcnB. Aconitase is part of 
the citric acid cycle, where it converts citrate to isocitrate. This enzyme requires iron 
to function, and is inactive under conditions of limiting iron (17). Conversely, 
increased iron concentrations cause the inhibition of swarming motility (18). To 
date, it is unknown whether statins can influence P. aeruginosa iron uptake and 
metabolism. However, microarray analysis has demonstrated that simvastatin 
induced the expression of genes associated with iron transport in S. pneumoniae (1). 
Therefore, further study may be warranted on the effects of statins on P. aeruginosa 
254 
 
iron metabolism. Furthermore, AcnB has been linked to reduced Exotoxin A (ToxA) 
production (17), and although the effects of simvastatin on ToxA were not examined 






Figure 2: Hypothesis examining the effects of simvastatin on P. aeruginosa. Simvastatin 
appears to have several key modes of action against P. aeruginosa. It may alter the activity 
of PvrR and WspF, thus reducing c-di-GMP and biofilm formation. In addition, simvastatin 
increased the expression of LptD and AcnB, which may alter LPS transport to the outer 
membrane, and exotoxin A production, respectively. Broken arrows represent hypotheses 




Three key simvastatin effects were observed on lung epithelial cells: altered 
expression of P. aeruginosa target genes, induction of KLF6 alternative splicing and 
increased adhesion of P. aeruginosa. A mechanistic model detailing total statin 
effects is proposed in Figure 3. In vitro attachment was decreased by simvastatin, but 
it was observed that simvastatin increased adhesion of P. aeruginosa to lung 
epithelial cells. This contrasts with a previous observation that simvastatin reduced 
adhesion of S. pneumoniae to human brain microvascular epithelial cells (1). One 
hypothesis for statin-mediated increased attachment to cells is that  P. aeruginosa 
uses actin to bind to host cells (19). Therefore, statin-mediated actin 
depolymerisation of human cells may therefore contribute to the increased 
attachment observed in this study. Another issue is that 100 µM simvastatin was 
required for a significant reduction in in vitro attachment, and the 10 µM 
concentration used in this study may not have been sufficient to reduce attachment to 
cells. 
A positive correlation has previously been observed between increased attachment 
and IL-8 expression (19), and therefore it is possible that statin-induced adhesion 
may contribute to the sustained IL-8 expression in infected cells. However, the 
mechanism of IL-8 induction by simvastatin is unclear. Previous studies have 
reported that statins reduced IL-8 expression (20). Kiener et al. reported that statin-
increased IL-8 in monocytes was reversed by the addition of mevalonate, but did not 
propose a cytokine-based regulatory mechanism (21). Furthermore, the data in this 
study demonstrated that the expression of CCL20 by simvastatin was mediated 
through wtKLF6. Both IL-8 and CCL20 are induced by the activation of TLR5 by P. 
aeruginosa flagellin (22) but TLR5 expression was not altered in this study, 
suggesting that IL-8 and CCL20 were induced by an alternative mechanism.  
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It is possible that ExoS may induce expression of KLF2 and KLF6 alternative 
splicing by targeting Rho GTPase signalling. KLF2 is induced when RhoA is 
inhibited (23), and ExoS inhibits RhoA activity (24). Furthermore, production of 
KLF6 splice variants is associated with Ras GTPase signalling, in particular the 
phosphorylation of phosphatidylinositol 3-kinase (PI3-K) and Akt (25). ExoS can 
inactivate Ras (26), and reduces downstream Ras signalling by inhibiting 
phosphorylation of these proteins (27). Inhibition of Ras signalling results in 
dominant production of wtKLF6, and a lower level of splice variant production (25). 
Therefore, it appears that the inhibition of Ras signalling by P. aeruginosa ExoS 
may be responsible for the dominant production of wtKLF6 in infected cells. The 
inhibition of Rho GTPase activity by statins is well-documented (28). However, 
statins can also inhibit PI3-K and Akt phosphorylation (29, 30), meaning that, like 
ExoS, simvastatin may also cause dominant expression of wtKLF6 in this manner. 
Furthermore, statins can directly induce KLF2 expression by binding to a MEF2A 
consensus sequence in its promoter (31), and transcription of KLF6 and its splice 
variants may be induced in the same manner. There was not a cumulative effect on 
KLF2 and KLF6 expression when statins and P. aeruginosa were combined, and this 
correlates with in vitro data demonstrating that statins did not influence expression of 
exoS. 
The novel induction of KLF6 and its variants by simvastatin treatment was 
demonstrated in this study. Previously, statins were not found to influence KLF6 in 
vascular endothelial cells (31), suggesting that statins may have a tissue-specific 
effect on KLF6 expression. The induction of wtKLF6 by statins was found to be 
responsible for the induction of CCL20 and repression of iNOS by simvastatin, 
suggesting that wtKLF6 has a role in the immune response. This concept correlates 
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with a recent report which suggested that wtKLF6 positively regulated TNFα 
expression (32). The induction of CCL20 by simvastatin may increase bacterial 
killing and clearance of infection as this compound has anti-microbial properties 
(33). Simvastatin and P. aeruginosa had a synergistic effect on CCL20 induction, 
and this could be a possible result of wtKLF6-dependent CCL20 activation by 
simvastatin and the induction of CCL20 by P. aeruginosa attaching to cells (22). 
Statin-induced KLF6 expression attenuated iNOS in this study, but it has previously 
been reported that KLF6 can activate iNOS transcription in fibroblasts and T cells 
(34). This again suggests that the observations in this work may occur as a result of 
tissue-specific statin effects. It is possible that the attenuation of iNOS by 
simvastatin may occur in order to suppress particular components of the immune 
response; a similar hypothesis has been proposed for the induction of KLF2 by 
bacterial toxins (23). Moreover, nitric oxide reduces attachment of P. aeruginosa to 
cells (35); therefore, it is possible that the statin-mediated repression of iNOS 
observed in this study may contribute to the increased attachment of P. aeruginosa 




Figure 3: Proposed model of statin activity against P. aeruginosa infections. The P. 
aeruginosa ExoS toxin induces KLF2 and KLF6 splice variant expression, and this may 
mediated through inhibitory effects on RhoA and Ras signalling, respectively. Inhibition of 
Ras signalling by simvastatin and P. aeruginosa may result in dominant expression of 
wtKLF6. Simvastatin can induce KLF2 expression by binding to a MEF2 promoter site, and 
it is possible that transcription of klf6 may also be induced in this manner by simvastatin. 
Furthermore, simvastatin may increase bacterial adhesion by altering the actin cytoskeleton. 
The mechanism by which simvastatin alters IL-8 expression is unclear. However, it was 
hypothesised that the additive effect observed on CCL20 may be a result of increased 
bacterial attachment, and induction via wtKLF6. iNOS was reduced by wtKLF6 in statin-
treated cells, and this may pose another mechanism whereby bacterial adhesion is induced. 
Broken arrows indicate mechanisms which require further elucidation.  
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Clinical significance of this study 
Susceptibility to statins – the bacterial mevalonate pathway 
In this study, it was demonstrated that statins had an impact on the growth of 
bacteria with HMGR homologues, but did not influence the growth of P. aeruginosa, 
which lacks HMGR. However, B. cenocepacia does not possess a canonical 
mevalonate pathway, and it was hypothesised that the HMGR of this species is not 
involved in isoprenoid metabolism. Based on the data acquired in this study, it was 
proposed that the level of efficacy of statins against bacterial pathogens depends on 
the presence of not only HMGR, but also the mechanism of terpenoid backbone 
biosynthesis used by the bacteria. The basis of this hypothesis is that, according to 
this study, statins appeared most effective against S. aureus and S. pneumoniae, both 
of which possess the 8 canonical mevalonate pathway and isoprenoid biosynthesis 
genes. Higher statin concentrations (100 µM) were required to attenuate the 
virulence (biofilm formation) of B. cenocepacia, which possesses mvaA and uppS 
only, although the growth of this species was reduced at similar statin concentrations 
to those that affected S. aureus. It was hypothesised that statins had a reduced impact 
against B. cenocepacia (and P. aeruginosa) due to the absence of a mevalonate 
pathway. In conclusion, if statins were to be used as antimicrobial agents, they may 
be most effective against bacterial species that undergo isoprenoid biosynthesis using 
the mevalonate pathway, but they could still be used against non-mevalonate 
pathway bacteria as part of combination therapy.  




Statins, bile and cholesterol: a potential benefit for CF patients? 
Cholesterol is the end product of the mevalonate pathway, but this compound has 
downstream applications of its own. Notably, following its formation in the liver, 
cholesterol can be oxidised to form the 2 primary bile acids cholic acid and 
chenodeoxycholic acid (36). Approximately half of all cholesterol synthesised daily 
– 500 mg – is metabolised into the primary bile acids (37). Bile acids are typically 
absorbed by the small intestine where their role is to emulsify and solubilise ingested 
lipids. However, bile acids have been found to be aspirated into the lungs of 
individuals with both respiratory disease and gastro-oesophageal reflux (GER), a 
condition where the contents of the stomach leak into the oesophagus (38–42). GER 
is a common complication in people with CF – the incidence of GER in CF patients 
is anywhere between 35 % to 80 %, and it is thought that up to 80 % of CF patients 
may have bile acids present in their lungs (38).  
Bile production in the context of CF is significant for 2 reasons. Firstly, bile was 
found to induce a chronic phenotype in CF-associated pathogens, by reducing 
motility and inducing biofilm formation (43). Secondly, the inhibition of mevalonate 
production by statins is known to decrease the formation and secretion of bile acids 
and salts (44, 45). The inhibition of cholesterol and bile salt production by statins 
may prove beneficial to CF patients with GER. If statins are taken via their 
conventional oral delivery route, the consequent inhibition of bile acid production 
may attenuate the aspiration of bile into the CF lung. This in turn may reduce the 
bile-regulated adaptation of bacteria from acute to chronic phase infections, 
especially given that this study demonstrated the statin-mediated inhibition of 




Pro-inflammatory effects of statins 
Statins are classically regarded as inhibitors of infection, and have previously been 
found to reduce expression of IL-8 and CCL20 (20, 46), 2 pro-inflammatory 
cytokines that were induced by simvastatin in this study. The results observed in this 
study are therefore novel and require further study. It is possible that the induction of 
inflammation by statins in this study may be a tissue-specific effect, and therefore 
the regulatory mechanism of statin-mediated inflammation in lung cells needs to be 
examined. Furthermore, the effect of statins on CF-affected lung cells also needs to 
be studied. IL-8 production is aberrantly increased in CF-patients (47), and therefore 
the impact of statins on IL-8 production in a CF background needs to be elucidated. 
The reduction of iNOS may also prove problematic, as NO production is decreased 
in CF patients (48). However, the induction of KLF2 in statin-treated infected cells is 
promising, as this protein confers anti-inflammatory effects on lung and endothelial 
tissue and macrophages (46, 49) and sustained expression of KLF2 may help to 
reduce the initial induction of inflammation by statins and P. aeruginosa. 
Furthermore, KLF2 expression is decreased in CF patients (50) and therefore the 
induction of KLF2 by statins may help to ameliorate CF-associated inflammation. A 
clinical trial has been proposed to examine the potential for the use of statins as 
therapeutic agents in CF (51), and the results of such studies may help to uncover the 
in situ effects of statins on pulmonary inflammation.  
  
Implications of the induction of KLF6 splice variants 
It was demonstrated that P. aeruginosa and statins were individually capable of 
inducing the expression of splice variants in lung cells. The expression of these 
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variants has typically been associated with cancer (52); however, they have also been 
found to be induced as a result of alcohol-induced oxidative stress (32), implying 
that KLF6 splice variants may be induced in non-cancer scenarios although to date 
their expression during microbial infection has not been elucidated. This study 
suggests that wtKLF6 is the dominant variant induced by both simvastatin and P. 
aeruginosa. This suggests that the net effect conferred on the cells will be apoptotic. 
ExoS induces apoptosis of infected cells (24), and it is possible that ExoS-mediated 
wtKLF6 production may act as a key mechanism of cell death during infection. 
However, statins may also influence apoptosis of infected cells, as a slightly 
increased level of cytotoxicity was observed when statins and P. aeruginosa were 
combined, compared to in untreated infected cells. This is in accordance with 
previous reports which demonstrated that statins can induce apoptosis of lung cells 
(53). However, this effect appears to occur independently of wtKLF6, as cytotoxicity 
was comparable between statin-treated si-wtKLF6 cells and vector control cells. 
 The results of this study demonstrate wtKLF6 to be a regulator of iNOS and CCL20 
in lung cells, both of which contribute to the innate immune response. This suggests 
that wtKLF6, like other members of the KLF family, may potentially have a greater 
role in regulation of immunity than previously thought. The role of the induction of 
KLF6 splice variants is unclear. As SV1 and SV2 have antagonistic functions 
towards wtKLF6 in cancer cells, it is possible that these compounds may act in an 
anti-inflammatory manner. An anti-inflammatory capacity of SV1 has been 






Potential further studies of RTI-associated pathogens 
Simvastatin reduced the growth of species which possess the mvaA gene, but do not 
impact the growth of P. aeruginosa (which lacks mvaA). This could be indicative 
that statins exert their inhibitory effect on strains which possess HMGR via 
inhibition of the mevalonate pathway. Therefore, examination of the effect of statins 
on the growth and virulence of an mvaA mutant strain needs to be carried out in 
order to verify this hypothesis. The most significant information could arguably be 
gained from the generation of a B. cenocepacia HMGR mutant strain. As a clear role 
has not yet been defined for this enzyme in B. cenocepacia, characterisation of the 
phenotypic behaviour of an mvaA-deficient strain in this species could potentially 
define the role of this gene in B. cenocepacia. Synergy between simvastatin and the 
antibiotic gentamicin was also identified against this species. This suggests that 
simvastatin could be used in combination therapy to treat antimicrobial infections. 
Further studies could focus on screening combinations of different antibiotics and 
varying simvastatin concentrations, to determine if they produce optimal 
bacteriocidal effects. In particular, the potential for the use of simvastatin in 
combination therapy against P. aeruginosa needs to be elucidated, as statins did not 
affect the growth of this species. 
Another point to consider is the effect of statins on fungi and viruses. Statins have 
been found to inhibit the growth of the several yeast species, including Candida and 
Cryptococcus species (54) and members of the class Zygomycetes (55). Sub-
inhibitiory simvastatin concentrations can reduce biofilm formation of Candida 
albicans, and this effect is attenuated by ergosterol, thus implying that the anti-
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biofilm effect of simvastatin is dependent on the mevalonate pathway (4). Statins 
also impact viral infections – the infectious potential of influenza A, hepatitis C and 
cytomegalovirus (CMV) is reduced by statins (56–58). Taking these studies into 
consideration, it appears that the effects that were observed in this work may not be 
just limited to RTI-associated bacteria, but may also reduce the efficacy of fungal 
and viral RTIs. 
 
Further examination of the interaction between simvastatin and P. aeruginosa 
In this study, PvrR and WspF were found to be involved in the effect of simvastatin 
on the attachment of P. aeruginosa. Intracellular levels of the signalling molecule c-
di-GMP are increased in mutants of these proteins (7, 11). Therefore, simvastatin 
may attenuate the biofilm formation of P. aeruginosa by decreasing c-di-GMP levels 
in a PvrR- and WspF-dependent manner. This hypothesis could be elaborated upon 
by quantifying the intracellular c-di-GMP levels in statin-treated cells using high-
performance liquid chromatography.  
The reproducible alteration of 6 P. aeruginosa proteins by simvastatin was also 
observed. However, only 3 of these proteins were examined further. Therefore, in 
order to fully elucidate the roles of AcnB, FusA1 and RpsA in the attenuation of 
swarming by simvastatin should be examined. This could be achieved by 
construction of single deletion mutants in these proteins, and examining their 
motility phenotype in the presence and absence of simvastatin. Furthermore, as LptD 
and AcnB have roles in regulating LPS and ExoA respectively (17, 59), the impact 
of simvastatin on production of LPS and ExoA should be elucidated. In addition, the 
impact of simvastatin on iron metabolism should be elucidated, given that AcnB is 
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induced under high iron concentrations. Finally, it appeared that 5 of the simvastatin-
altered proteins were post-translationally modified by either oxidation or 
carbamidomethylation. It is unclear how simvastatin treatment caused these 
modifications, and the mechanism behind these modifications could prove insightful 
as it could allow for further elucidation of pleiotropic statin effects on proteins. 
   
Development of statin analogues  
Elucidation of the bacterial response to statin treatment could allow for the 
development of statins analogues. These compounds could be tested against bacteria, 
with a view to developing a compound which could significantly inhibit bacterial 
growth and virulence at a physiologically relevant concentration and that would also 
be safe for human consumption. This approach has previously been taken with the P. 
aeruginosa signalling molecules PQS and HHQ – synthetic analogues of these 
compounds were developed and tested against several bacterial and fungal species 
(60, 61). In accordance with the results of this study, the 3 key criteria required for 
potential synthetic statin analogues would be inhibition of bacterial growth and 
behaviour, efficacy at physiologically relevant concentrations and minimal side 
effects. A potential benefit of hypothetical statin analogues is that they may have a 
reduced risk of side effects compared to statins. One key limitation of statins is that 
they pose several health risks, including liver damage and rhabdomyolysis, although 
these are extremely rare. However, a significant minority of the general population is 
intolerant to statins and develop myalgia and myopathy. The use of statin analogues 




Elucidation of the role of KLF6 splice variants in infection   
During the course of this work, a study of the downstream effects of P. aeruginosa-
induced KLF6 alternative splicing had been planned. However, the correct 
knockdown of SV1 in a si-RNA cell line could not be verified. In addition, infection 
of a si-wtKLF6 cell line with P. aeruginosa caused upregulation of wtKLF6 to such 
an extent that the effects of the knockdown vector were abrogated. Therefore, the 
downstream effects of the induction of KLF6 alternative splicing by P. aeruginosa 
could not be examined. Future work should focus on the elucidation of these effects 
and the mechanism behind them. This analysis could be carried out using a P. 
aeruginosa strain which produces lower amounts of ExoS than PAO1 or by 
transiently transfecting si-cells with a vector expressing the ExoS protein. By using 
either of these models, the downstream effects of ExoS-induced wtKLF6 and SV1 




This study identified several potential benefits of the prospective use of statins as 
anti-microbial agents. The results obtained here provide a case for the potential of 
statin use to treat CF-associated bacterial infections. In addition, the bacteria tested 
in this study can also cause other types of infections, including those of the urinary 
tract, cornea and wounds. Therefore, it is possible that statins may have multi-
species anti-microbial effects against many different types of localised infections. 
Furthermore, the multi-species effects of simvastatin against bacterial attachment 
would indicate that they may be effective against polymicrobial biofilms. Statins 
could also be potentially used in combination therapy with other anti-microbial 
agents to treat bacterial infections.  
This study also highlighted several limitations of using statins as anti-microbial 
compounds. One such limitation is that statins do not appear to have an effect on 
previously established biofilms, meaning that if statins were to be used to fight 
infections, they would probably be most effective as a prophylactic agent. However, 
simvastatin pre-treatment increased bacterial adhesion to lung cells, meaning that 
further study is required to determine whether the in vitro reduction of attachment by 
statins can be replicated in vivo and eventually in patients. Another potential 
limitation would be the delivery route of statins. These drugs are conventionally 
administered orally in tablet form, and typically have a low bioavailability (as low as 
5 % for lovastatin and simvastatin) and low plasma concentrations (10-20 ng/ml for 
lovastatin and 20-34 ng/ml for simvastatin) (62). Other antimicrobials, notably the 
aminoglycoside antibiotic tobramycin, have been found to be effective against 
respiratory infections when aerosolised and delivered via inhalation (63, 64). This 
delivery route also increases the local concentration of the antibiotic. Therefore, in 
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order to achieve the concentrations required to inhibit bacterial growth and virulence 
that were observed in this study, aerosolisation of statins may have to be considered, 
and any potential risk factors must be identified. 
Despite their limitations, statins have shown some promise as novel anti-microbial 
therapies, which are greatly needed. In September 2013, the Centres for Disease 
Control and Prevention (CDC) issued a sobering report which estimated that in the 
U.S.A. alone, antibiotic-resistant microorganisms cause approximately 2 million 
infections per year, and at least 23,000 people in the USA now die every year as a 
direct result of antibiotic-resistant infections (65). According to this report, 3 of the 
bacterial species studied in this work – P. aeruginosa, S. aureus and S. pneumoniae 
– are collectively responsible for over 30,000 deaths and over 4.1 million infections 
per year. Therefore, statins may present an opportunity to aid the eradication of 
antibiotic-resistant infections. However, the scope of the antimicrobial and anti-
virulence capacities of statins observed in this study is limited. Therefore, more 
research is needed, particularly in the areas of efficacy and safety, to determine 
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A1. Effect of gentamicin on the growth of S. aureus and B. cenocepacia 
 
Figure A1. Inhibition of the growth of S. aureus and B. cenocepacia by the 
aminoglycoside antibiotic gentamicin. S. aureus NCDO949 and B. cenocepacia J2315 
were cultured in the presence of Muller-Hinton broth containing a concentration gradient of 
gentamicin and incubated at 37 ºC for 24 hours, following which growth was measured by 
determination of OD600nm. Preliminary analysis (1 biological replicate with 3 technical 
replicates) demonstrated that S. aureus was more susceptible to lower gentamicin 
concentrations than B. cenocepacia.  
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A2. Effect of lovastatin and mevastatin on attached bacteria and extracellular 
DNA production 
 
Figure A2: Biofilm phenotypes of PA14 in the presence of lovastatin and mevastatin. 
(A) 100 µM of lovastatin and mevastatin did not influence detachment of previously 
attached PA14 cells. (B) Extracellular DNA production by PA14 was not affected by either 




A3. Effect of lovastatin and mevastatin on pqsA expression 
 
Figure A3: pqsA expression in the presence of lovastatin and mevastatin. 100 µM of 




A4. Effect of hydrolysed simvastatin on P. aeruginosa quorum sensing 
 
Figure A4: Production of homoserine lactones (HSLs) in the presence of hydrolysed 
simvastatin. The active form of simvastatin did not have any impact on HSL production of 






Table A5: Microarray data demonstrating the effect of simvastatin on PA14. The 
average fold change (AVG FC) and standard deviation (STDEV) was calculated from the 
fold change (FC) of each biological replicate. P-value is based on an unpaired Student’s T-
test. 
PA No. Symbol FC Rep 1 FC Rep 2 FC Rep 3 AVG FC STDEV p-value 
PA0025 aroE -0.67 -0.91 -1.07 -0.88 0.20 0.00 
PA0028 
 
1.39 1.21 0.10 0.90 0.70 0.03 
PA0047 
 
14.74 -0.48 -0.13 4.71 8.69 0.01 
PA0171 
 
16.71 0.92 -0.34 5.76 9.50 0.04 
PA0179 
 
-3.64 -0.71 -0.50 -1.61 1.76 0.02 
PA0271 
 
3.19 0.39 0.93 1.50 1.49 0.01 
PA0437 codA 5.71 2.83 -0.55 2.66 3.13 0.01 
PA0514 nirL -7.91 -2.18 0.25 -3.28 4.19 0.04 
PA0515 
 
-3.48 -1.13 -0.02 -1.54 1.77 0.03 
PA0516 nirF -1.77 -0.14 -0.11 -0.67 0.95 0.01 
PA0520 nirQ 343.32 -0.34 -0.33 114.22 198.41 0.02 
PA0521 nirO 20.54 -0.41 -0.44 6.56 12.11 0.05 
PA0656 
 
6.66 -0.40 -0.30 1.99 4.05 0.02 
PA0835 pta -1.17 -1.71 -0.67 -1.18 0.52 0.02 
282 
 
PA1523 xdhB 0.98 0.48 0.26 0.57 0.37 0.01 
PA1664 orfX -5.44 -0.27 -0.36 -2.02 2.96 0.03 
PA2567 
 
50.87 0.85 0.30 17.34 29.04 0.00 
PA2663 ppyR 1.62 0.49 0.08 0.73 0.80 0.03 
PA2788 
 
-6.50 -0.27 -0.15 -2.31 3.63 0.04 
PA3049 rmf 31.02 -0.45 -0.32 10.09 18.13 0.03 
PA3054 
 
-4.58 0.82 -0.07 -1.28 2.90 0.05 
PA3179 
 
-5.47 -1.50 0.40 -2.19 3.00 0.03 
PA3418 ldh 7.07 0.96 -0.05 2.66 3.85 0.00 
PA3452 mqoA 0.92 0.56 0.19 0.56 0.37 0.04 
PA3609 potC 3.92 1.18 0.44 1.85 1.83 0.03 
PA3615 
 
-1.74 0.55 0.05 -0.38 1.21 0.00 
PA3641 
 
-158.77 7.98 -0.02 -50.27 94.05 0.01 
PA3651 cdsA -2.61 -2.28 -0.06 -1.65 1.39 0.03 
PA3741 
 
-1.14 -0.98 -1.02 -1.05 0.09 0.01 
PA3820 secF 0.75 0.54 0.10 0.46 0.33 0.02 
PA3821 secD 1.83 0.89 0.38 1.03 0.74 0.01 
PA3882 
 
5.59 1.39 0.12 2.37 2.86 0.04 
PA4349 
 
2.73 1.13 1.15 1.67 0.92 0.02 
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PA4351 olsA 1.77 1.64 1.32 1.57 0.23 0.00 
PA4357 
 
2.10 0.70 1.94 1.58 0.77 0.04 
PA4358 
 
2.43 0.90 0.76 1.36 0.92 0.00 
PA4432 rpsI 2.16 0.32 0.46 0.98 1.02 0.03 
PA4673 
 
-0.84 -0.63 -0.46 -0.65 0.19 0.00 
PA4811 fdnH -2.64 -0.64 -0.90 -1.39 1.09 0.04 
PA4916 
 
-1.74 -0.48 -3.06 -1.76 1.29 0.05 
PA4919 pncB1 3.06 3.29 0.98 2.44 1.27 0.02 
PA4920 nadE -2.05 -2.17 -0.50 -1.57 0.93 0.01 
PA4933 
 
1.18 2.08 0.43 1.23 0.82 0.00 
PA4934 rpsR 0.68 0.75 0.42 0.62 0.17 0.01 
PA4935 rpsF -1.59 -0.34 -0.27 -0.73 0.75 0.03 
PA5025 metY -0.71 -0.11 -0.69 -0.51 0.34 0.01 
PA5207 
 
4.54 1.55 0.36 2.15 2.16 0.03 




Table A6: Biological replicate 1 of altered swarm tip proteins in the presence of 
simvastatin or DMSO. Proteins were identified using tandem mass spectrometry. Oxidation 




Accession Sample Description Ox. Carb. 
PA14_02220 Statin Putative chemotaxis transducer + - 
PA14_07760 DMSO Peptidyl-prolyl cis-trans isomerase SurA - - 
PA14_07770 Statin Organic solvent tolerance protein OstA 
precursor + + 
PA14_07910 DMSO Ribulose-phosphate 3-epimerase + - 
PA14_08680 DMSO Elongation factor Tu + + 
PA14_08710 Statin Transcription antitermination protein NusG + - 
PA14_08820 Statin Elongation factor G + + 
PA14_11130 DMSO Short chain dehydrogenase - - 
PA14_16630 DMSO Putative outer membrane protein, OmpA - - 
PA14_16950 Statin Tetrahydrodipicolinate succinylase + - 
PA14_17100 Statin Ribosome recycling factor + - 
PA14_17150 Statin Putative outer membrane antigen + - 
PA14_17270 DMSO Acetyl-CoA carboxylase carboxyltransferase 
subunit alpha - - 
PA14_23330 Statin 30S ribosomal protein S1 - - 
PA14_23370 DMSO Putative UDP-N-acetylglucosamine 2-
epimerase - + 
PA14_24270 Statin Aminopeptidase N + + 
PA14_29240 DMSO Putative hydrolase - - 
PA14_30370 DMSO Hypothetical protein - - 
PA14_33040 DMSO Glycine cleavage system protein T2 - + 
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PA14_34600 DMSO Putative glyceraldehyde-3-phosphate 
dehydrogenase - - 
PA14_38470 DMSO Gamma-carboxygeranoyl-CoA hydratase - - 
PA14_41470 Statin Bifunctional aconitate hydratase 2/2-
methylisocitrate dehydratase + + 
PA14_41570 DMSO Major porin and structural outer membrane 
porin OprF precursor - - 
PA14_41670 Statin Phosphoenolpyruvate synthase + + 
PA14_43940 DMSO Succinyl-CoA synthetase subunit alpha - + 
PA14_44120 DMSO Putative 3-hydroxyisobutyrate 
dehydrogenase - - 
PA14_51390 DMSO 3-oxoacyl-(acyl carrier protein) synthase III + - 
PA14_53250 DMSO Chitin-binding protein CbpD precursor + + 
PA14_57740 DMSO Hypothetical protein + + 
PA14_58180 DMSO Aspartyl/glutamyl-tRNA amidotransferase 
subunit A - - 
PA14_60330 DMSO 4-hydroxy-3-methylbut-2-enyl diphosphate 
reductase + + 
PA14_62710 Statin Polynucleotide phosphorylase/polyadenylase + + 
PA14_62970 Statin Molecular chaperone DnaK + - 
PA14_63020 DMSO Ferric uptake regulation protein + - 
PA14_64440 DMSO Hypothetical protein + + 
PA14_66770 DMSO ATP-dependent protease peptidase subunit + - 
PA14_67930 DMSO Imidazoleglycerol-phosphate dehydratase + + 
PA14_71620 DMSO Phosphoribosylaminoimidazole carboxylase, 
catalytic subunit + - 






Table A7: Biological replicate 2 of altered swarm tip proteins in the presence of 
simvastatin. Proteins were identified using tandem mass spectrometry. Oxidation (Ox) and 
carbamidomethylation (Carb) of proteins were also identified. 
   Post-translational modification 
Accession Sample Function Ox. Carb. 
PA14_06290 Statin Malate synthase G - - 
PA14_07770 Statin Organic solvent tolerance protein OstA 
precursor 
- - 
PA14_08820 Statin Elongation factor G + + 
PA14_09000 Statin 50S ribosomal protein L6 + - 
PA14_11690 Statin Inorganic pyrophosphatase - + 
PA14_13130 Statin Hypothetical protein - - 
PA14_18690 Statin Putative peroxidase + - 
PA14_23330 Statin 30S ribosomal protein S1 - - 
PA14_25830 Statin Hypothetical protein - - 
PA14_25880 Statin Electron transfer flavoprotein alpha-subunit - - 
PA14_34460 Statin Hypothetical protein - - 
PA14_41470 Statin Bifunctional aconitate hydratase 2/2-
methylisocitrate dehydratase 
+ + 
PA14_43850 Statin Heat shock protein 90 + - 
PA14_50270 Statin Flagellar capping protein FliD - - 
PA14_53820 Statin Hypothetical protein - - 
PA14_57010 Statin Chaperone GroEL - - 
PA14_58540 Statin Hypothetical protein - + 
PA14_61850 Statin Putative TonB-dependent receptor - - 
PA14_62710 Statin Polynucleotide phosphorylase/polyadenylase + + 
PA14_62970 Statin Molecular chaperone DnaK + - 
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PA14_64840 Statin Putative short-chain dehydrogenase - - 
PA14_66330 Statin Peptide methionine sulfoxide reductase + + 
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